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Abstract 
 
AMP-activated protein kinase (AMPK) serves as an energy-sensing protein that is activated by a 
variety of metabolic stresses. Recent studies suggest that AMPK is also regulated by hormones 
and by nutrients such as glucose and fatty acids. In skeletal muscle it was previously shown that 
AMPK activity was decreased with increasing glucose concentration. In the present study both the 
activity and the Threonine-172 phosphorylation of AMPK in incubated rat ventricular cardiac 
myocytes were found to be decreased by increasing glucose in the presence and absence of 
palmitate. Glucose also caused a decrease in the AMPK-driven phosphorylation of acetyl-CoA 
carboxylase. Measurements of the myocyte contents of ATP, ADP, AMP and glycogen showed 
that the effect of glucose on AMPK activity could not be secondary to changes in the levels of 
these metabolites. The decrease in AMPK activity with glucose was additive to and distinct from 
the effect of insulin which is mediated through protein kinase B (PKB). Increasing glucose 
concentration had no effect on the phosphorylation of Threonine-308 and Serine-473 in PKB. 
AICAR, a pharmacological activator of AMPK, had no effect on the ability of glucose to 
inactivate AMPK. The myocyte content of the pentose phosphate pathway (PPP) metabolite 
xylulose 5-phosphate (Xu5P), a known allosteric activator of PP2A, was increased with increasing 
glucose concentration such that AMPK activity was inversely related to  Xu5P content. The 
glucose 6-phosphate dehydrogenase inhibitor diehydroepiandeosterone (DHA) and thiamine, the 
precursor of the coenzyme for transketolase, both increased AMPK activity whereas the NADPH 
oxidant phenazine methosulphate (PMS) decreased AMPK activity. DHA and PMS respectively 
decreased and increased flux through the PPP. The findings suggest that inactivation of AMPK by 
glucose may be mediated by the activity of the PPP which sets the level of Xu5P. Two other 
findings were also made during the  course of this project. First, the activity of 
phosphofructokinase-2 (PFK-2) in the perfused heart was previously shown to be activated 
through phosphorylation by AMPK. It was therefore expected that increasing glucose   4 
concentration would decrease myocyte PFK-2 activity. However PFK-2 activity was found to be 
increased by glucose. Second, the phosphorylation of Threonine-308 in PKB in response to insulin 
was appreciably increased in the presence of AICAR suggesting that there may be crosstalk 
between AMPK and the insulin signalling pathway at the level of PKB.          
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  Chapter-1- General Introduction   23 
General Introduction 
 
The heart can utilize a variety of carbohydrate and lipid fuels to generate energy in the form 
of adenosine triphosphate (ATP) for contractile function. The rate of oxidation of these fuels 
depends on the demands of the heart. The increase in work rate increases ATP demand which 
leads to increases in oxidative phosphorylation and citric acid cycle activity. Under normal 
conditions, the myocardium takes its fuels from the bloodstream so that the energy stores of 
glycogen and triacylglycerol (TAG) are preserved. 
 The oxidation of fatty acids is a very effective source of energy compared to glucose. 
Normally, it provides 60-70% of the energy requirement of the myocardium. It has been well 
established that fatty acids inhibit  the utilization of carbohydrate in the heart through 
sequences of regulatory mechanisms known as the glucose/fatty acid cycle. A major regulator 
of fatty acid and glucose metabolism during stress is the AMP-activated protein kinase. It has 
also become increasingly clear that AMPK can be regulated by nutrients and hormones. 
Under a variety of pathological conditions, it has been proved that high levels of circulating 
fatty acids markedly decrease glucose utlization by the heart. The strict control of fuel 
selection in the heart is essential for efficient contractile functioning. The purpose of this 
study is to examine the effects of carbohydrates and insulin on AMPK activity in cardiac 
myocytes.  
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1.2 Cardiac Energy Metabolism 
The heart can produce energy from a wide range of substrates including dietary fatty acids and 
carbohydrates as well as from various molecules produced during their metabolism, such as 
lactate, pyruvate and ketone bodies. Carbohydrates are not the preferred myocardial fuel under 
normal conditions. Decreased perfusion during myocardial ischemia limits the delivery
 of oxygen 
and nutrients and decreases oxidative metabolism.
 Under these conditions, increased glycolytic 
ATP production
 becomes a critical energy source. Several mechanisms
 have been proposed to 
account for the increases in glucose uptake
 and glycolysis during myocardial ischemia. These 
include:  -adrenergic
 mechanisms, p38 activation, and more recently, the stimulation
 of AMP-
activated protein kinase (AMPK). 
1.3 AMPK 
AMPK is a member of a metabolite-sensing protein kinase family that is found in all eukaryotes 
(Hardie et al.; 1998). AMPK has been proposed to act as a cellular fuel sensor, which controls 
metabolism to balance energy supply and demand. A decreased cellular energy supply leads
 to an 
AMPK-mediated adaptation to allow cellular survival.  In
 doing so, AMPK acts as a cellular "fuel 
gauge" (Hardie et al.; 1998)..  
During stress, such as
 nutrient deprivation, AMPK will inhibit energy-consuming pathways
 while 
it promotes energy producing pathways, e.g., fatty acid
 oxidation and glycolysis. This simple 
principle is not only operative
 at the cellular level, because AMPK also governs whole body
 
energy metabolism by the regulation of food intake in the hypothalamus (Xue and Kahn 2006).  
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1.3.1   The role of AMPK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 1.1: The role of AMP-activated protein kinase (AMPK) on energy substrate 
utilization:  AMPK activates energy-generating pathways such as glycolysis  by increasing 
glucose uptake, phosphofructokinase-2 activity and fatty acid oxidation.  The later occurs via a 
number of mechanisms such as the increased uptake of fatty acids from the circulation through the 
recruitment of lipoprotein lipase to the endocardia surface as well as promoting the translocation 
and/or retention of the fatty acid transporter (CD36) at the plasma membrane. In addition, AMPK 
may inhibit energy-consuming pathways, such as protein and glycogen synthesis (Hardie et al.; 
2003). 
    26 
 1.3.2. AMPK Structure 
 
Mammalian AMPK is a trimeric enzyme comprising a catalytic α subunit (63 kDa) and non-
catalytic β and γ subunits (Figure 1.2). Multiple isoforms of each mammalian enzyme subunit 
exi st (α1, α2, β1, β2, γ 1–γ 3), each encoded by a different gene. The β subunits have a calculated 
molecular mass of 30 kDa, but migrate on SDS/PAGE with apparent masses of 38 kDa (β1) and 
34 kDa (β2), whereas the three γ isoforms have molecular masses of 37 kDa (γ 1), 63 kDa (γ 2) 
and 55 kDa (γ 3).  
The catalytic α subunit (Carling et al 1989) transfers ATP to serine or threonine residues 
in the consensus sequence (Φ(X,β)XXS/T*XXXΦ, where Φ and β indicate hydrophobic 
and basic residues, respectively; X indicates any amino acid; the order of the amino acids 
within the parenthesis is not important) (Weekes et al 1993; Dale et al 1994; Salt et al 
1998). However, a structural modelling of the interaction between the catalytic domain of 
AMPK and the region around Ser79 (AMPK phosphorylation site) of ACC1  has 
suggested that residues over a much longer region than the above recognition motif are 
important for the interaction (Scott et al 2002). There are two isoforms of the α subunit; 
α1 (548 residues) encoded by the gene on chromosome 5p11 (Stapleton et al 1997) and 
α2 (552 residues) encoded by the gene on chromosome 1p31 (Beri et al 1994) (Stapleton 
et al 1996). Both isoforms migrate on SDS-PAGE at approximately 63 kDa and are 
activated by AMP and by the phosphorylation of Thr172 by AMPKK (Stapleton et al 
1996). They show high sequence similarity at the N-terminal catalytic domain but less 
similarity at the C-terminal region (Stapleton et al 1996). Truncation studieshaveshown 
that the C-terminal region (313-473) of the α subunit is required for association with the β 
and γ subunits (Figure 1.3) (Crute et al 1998; Iseli et al 2005). A truncated α1 subunit 
lacking the C-terminal region (α1 (312)) is constitutively active and the presence of an 
autoinhibitory domain has been suggested in the region between residues 312-392 (Crute 
et al 1998). The α1 mRNA and protein is generally expressed but α2 mRNA and protein 
is most abundant in heart, skeletal muscle and liver (Stapleton et al 1996). In terms of the 
activity, α2 AMPK activity is predominant in the heart and skeletal muscle, while α1 
AMPK activity is predominant in lung, kidney, testis, brain and pancreas (Cheung et al   27 
2000). Both α1 and α2 AMPK contribute equally in the liver (Cheung et al 2000). In the 
heart, α1 AMPK contributes to about 30% of the total AMPK activity (Cheung et al 
2000). 
The α1 and α2 isoforms display a number of differences. The α2 activity is stimulated by AMP to 
a greater extent than α1 in vitro (Salt et al 1998). This effect was seen for both the allosteric 
effect of AMP and for the stimulation of the Thr172 phosphorylation by an upstream kinase. This 
difference in the sensitivity to AMP may explain the greater activation of α2 AMPK than α1 
AMPK during cardiac ischemia (Li et al 2006) and the isoform-specific AMPK activation during 
skeletal muscle contraction. Low or moderate skeletal muscle contraction has been generally 
found to selectively activate α2 AMPK while α1 activation is only seen during high intensity 
contraction (Vavvas et al 1997; Stephens et al 2002; Wojtaszewski et al 2000; Chen et al 2000), 
although a recent study by Toyoda et al has shown a selective activation of α1 AMPK bylow 
intensity contraction in the epitrochlearis muscle (Toyoda et al  2006). Both isoforms are 
deactivated similarly by PP2C but α2 is deactivated by PP2A to a much greater extent than α1 
(Salt et al 1998). α1 and α2 AMPK may also have distinct physiological functions. It has been 
shown only α2 AMPK co-purifies with heart ACC (Dyck et al 1999) suggesting a role for this 
isoform in the regulation of cardiac ACC. α2 AMPK has also been suggested to be the isoform 
involved in the regulation of glucose homeostasis (Jorgensen et al 2004). A selective activation of 
α2 has been also observed in skeletal muscle in response to leptin.  Both α1 and α2 AMPK are 
found in the cytosol but α2 AMPK is also found in the nucleus in INS-1 cells and CCL13 cells 
(Salt et al 1998). This localisation is not dependent on the activation state of α2 or association 
with the β and γ subunits (Salt et al 1998). 
The β-subunit composition of the AMPK heterotrimer complex does not have enzymatic activity. 
There is no evidence of a preferential association of the two β subunit isoforms with different α 
isoforms in vitro (Thornton et al.; 1998). The β subunit binds both the α and γ subunits and is 
thought to act as a scaffold protein. Both isoforms are widely distributed. The liver expresses   28 
mainly β-1  and  a  small  amount  of  β-2, while the opposite pattern is seen in skeletal muscle 
(Thornton et al.; 1998). The heart expresses both β isoforms but β-2 is slightly more abundant 
than β-1 (Thornton et al.; 1998). The yeast homologues of the β subunit contain domains termed 
KIS and ASC which are involved in the association with Snf1p and Snf4p, respectively (Yang et 
al.; 1994). The internal region of the β subunits which overlaps with the putative KIS domain has 
been identified as the glycogen binding domain (GBD), that is closely related to the isoamylase 
domain found in glycogen and starch branching enzyme (Polenkhina et al.; 2003). The β subunit 
is myristoylated at its N terminus (Thornton et al.; 1998). The myristorylation is involved in the 
membrane association of AMPK (Mitchelhill et al.; 1997). The removal of the myristoylation has 
also been shown to increase AMPK activity through a mechanism that is independent of a change 
in the α-Thr 172 phosphorylation (Arden et al.; 2001). 
 The  γ-subunit carries four cystathione-β-synthase motifs  (CBS), organized into two pairs 
(CBS1/2) and (CBS3/4) called Bateman domains, which are proposed to bind AMP and ATP 
(Adams et al.; 2004). Mutation in these domains makes AMPK insensitive to AMP (Hamilton et 
al.; 2001). Moreover, several naturally occurring mutations in the human γ-2 subunit, which are 
associated with the development of the Wolf Parkinson-White syndrome, are found within the 
CBS domains, and these mutations have been shown to decrease the sensitivity of AMPK to 
AMP (Daniel and Carling; 2002). γ-1 and γ-2 isoforms are expressed widely whereas γ-3 mRNA 
is found only in skeletal muscle (Cheung  et al.; 2000). The heart expresses both γ-1, which is the 
predominant form, and γ-2 Lie et al.; 2006) (Figur e 1.2).   29 
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Figure 1. 2:  Structure of AMPK.  The mammalian (a) AMPK (α1 and α 2), (b) 
AMPK (β 1 and β2) and (c) AMPK (γ1, γ2γ 3). The α -subunits contain the Thr 172 residue 
that must be phosphorylated by upstream kinases for activity and an autoinhibitory sequence 
domain that inhibits the activity of the kinase domain. The C-terminal domain is required for 
binding the β - and γ-subunits. The β -subunits contains a central glycogen-binding domain 
and a C-terminal domain that is required for binding the α - and γ- subunits. The three γ-
subunit isoforms have variable N-terminal domains and four conserved cystathionine beta-
synthase motifs (CBS1-4). The CBS motifs act in pairs to form two Bateman domains that 
bind the AMP or ATP.    30 
1.3.3 General features of the regulation of AMPK  
AMPK is activated by  phosphorylation  of  the  α-Thr172 of the  α  subunit by AMPK kinases 
(LKB1, TAK1 and CaMKKβ). The mutation of α-Thr172 to alanine completely abolishes the 
activation of AMPK by partially purified AMPKK (Stein et al.;  2000). The identity of the 
upstream kinase(s) that phosphorylate α-Thr172 was elusive for a long time. Earlier studies on 
AMPKK mostly used a partially purified AMPKK fraction from rat liver. Recently, three yeast 
AMPKK homologes have been identified (Pak1p, and Tos3p and Elm1p) which  can 
phosphorylate the residue equivalent to α-Thr172 in the activation loop of Snf1p (Hong et al 
2003.; Sutherland et al.; 2003). Subsequently, LKB1 in mammals, which has a catalytic domain 
related to these three yeast kinases, has been shown to phosphorylate α-Thr172 and activate 
AMPK in vitro (Hong et al.; 2003; Hawley et al.; 2003.; Woods et al.; 2003; Shaw et al.; 2005). 
LKB1 is known as a serine/threonine kinase, which has a tumour suppressor role. The mutation 
of LKB1 causes Peutz-Jeghers syndrome (Boudeau et al.; 2003). LKB1 (~ 50kDa) purified from 
rat liver is associated with two accessory proteins; STRADα  (~ 45/48 kDa) and MO25α  (~ 
40kDa) (Hawley et al.;  2003). The heterotrimeric complex of LKB1 is required for its full 
activity towards AMPK (Hawley  et al.;  2003). LKB1 seems equally to activate AMPK 
complexes containing different subunit isoforms (Woods et al.; 2003). The role of LKB1 as an 
AMPKK in vivo is supported by several observations. First, an anti-LKB1 antibody could remove 
most of the AMPKK activity from the partially purified liver AMPKK fraction (Hawley et al.; 
2003; Woods et al.; 2003). Second, in cultured cell lines, the inhibition of LKB1 through the 
expression of catalytically inactive LKB1 inhibited the increase in α-Thr172 phosphorylation 
induced by AICAR and H2O2 (Woods et al.; 2003; Shaw et al.; 2003). Third, in HeLa cells, 
which lack endogenous LKB1, and in MEF cells from a LKB1 knock out mouse, AICAR or H2O2 
failed to increase  α-Thr172 phosphorylation (Hawley et al.; 2003; Shaw et al.; 2003). Lastly, in 
transgenic mice, the deletion of LKB1 in the liver or    31 
 
skeletal  muscle  greatly  decreased  the  basal  α-Thr172 phosphorylation and almost completely 
abolished the increase in α-Thr172 phosphorylation caused by metformin, AICAR, or skeletal 
muscle contraction (Shaw et al.; 2005; Sakamoto et al.; 2005). The heart from the transgenic 
mice lacking the cardiac expression of LKB1 also showed an almost complete abolition of the 
basal activity of α-2 AMPK and a moderate reduction in the activity of α-1 AMPK, indicating a 
significant role of LKB1 in cardiac AMPK regulation (Sakamoto et al.; 2006). 
Despite the lack of LKB1, a small amount of α-Thr172 phosphorylation could still be detected in 
the HeLa cells and mouse embryo fibroblasts (MEFs) cells from LKB1 knock out mice (Hawley 
et al.; 2003). This was not due to the non-phospho specific binding of the anti-Thr172 antibody, 
as it was almost completely abolished by incubation with PP2A (Hawley et al.; 2005). 
 A Ca
2+ ionophore was shown to increase α-Thr172 phosphorylation and AMPK activation in 
HeLa cells. These observations prompted the search for an AMPKK other than LKB1. The 
AMPKK activity towards recombinant AMPK present in an HeLa cell lysate could be completely 
abolished by STO-609, an inhibitor of CAMKKα and β (Hurley et al.; 2005). The effect of a Ca
2+ 
inophore to activate AMPK in the HeLa cells was also inhibited by STO-609 or by small 
interfering RNA (siRNA) against CAMKK α  or  β, although the inhibitory effect of siRNA 
against CAMKKβ was much greater than that for CAMKKα (Hurley et al.; 2005; Hawley et al.; 
2005; Woods et al.;  2005). Both CAMKKα  and  β can  phosphorylate  α-Thr172 and activate 
recombinant AMPK in vitro, but CAMKKβ activates AMPKK more readily than CAMKKα 
(Hawley et a.;l 2005; Woods et al.; 2005). These observations strongly suggest that, in addition 
to LKB1, CAMKKβ and possibly CAMKKα also act as AMPKKs in vivo. In brain slices, the 
activation of AMPK by depolarisation or by  an increase in Ca
2+  induced by increasing K
+ 
concentration has been shown to be inhibited by STO-609, suggesting a role for CAMKKs in the 
regulation of AMPK in this organ (Hawley et al.; 2005). However, although CAMKKα and β are   32 
highly expressed in the brain, they are poorly expressed in other tissues (Anderson et al.; 1998). 
The heart has  
 
been reported to express CAMKKβ  but not CAMKKα  (Allard  et al.;  2006). The role of 
CAMKKβ in the regulation of cardiac AMPK remains to be determined.  
There still remains the possibility of the existence of AMPKKs different from LKB1 or 
CaMKKs. The possibility of a yet unidentified AMPKK that is activated during ischemia has 
been reported in the heart (Aharejos et al.; 2005) . Suzuki and co-workers  have demonstrated 
that, in several cultured cell lines, including the human pancreatic cancer cell line (PANC-1), 
HeLa and human fibroblast cell lines, AMPK α-Thr172 phosphorylation is increased by 
incubation with growth factors, such as IGF-1 (Suzuki et al.; 2004). The tyrosine phosphorylation 
of ATM (ataxia telangiectasia mutated) appears to be involved in this effect, as the activation of 
AMPK was blocked by genistein or antisense mRNA for ATM (Suzuki et al.; 2004). The ATM 
immunoprecipitated from the IGF-1-stimulated cells phosphorylated the AMPK α  catalytic 
domain in vitro, suggesting that ATM may be directly upstream of AMPK (Suzuki et al.; 2004). 
In addition to α-Thr172, AMPK is known to be phosphorylated at several sites on the α and β 
subunits.The α subunit has been shown to be phosphorylated at two other sites, α-Thr258, and at 
Ser485 (α1) or Ser 491 (α2) (Woods et al.; 2003). The mutation of α-Thr258 or Ser485/491 to 
aspartic acid to mimic phosphorylation did not affect the kinase activity or sensitivity of AMPK 
to AMP (Woods et al.; 2003). Using constitutively active and catalytically inactive mutants of 
AMPK, these sites were shown to be phosphorylated by both autophosphorylation and by a 
partially purified AMPKK (Woods et al.;  2003). However, the upstream kinases that 
phosphorylate  α-Thr258 and Ser485/491 were thought to be different from those that 
phosphorylate α-Thr172 because the sequences surrounding the α-Thr258 and Ser485/491 were 
similar to each other but different from the sequence surrounding the α-Thr172 (Woods et al.; 
2003). Unlike α-Thr172, the Ser485 phosphorylation was also resistant to incubation with PP2C,   33 
PP1 or PP2A (Woods et al.; 2003). Recently, Horman et al have confirmed that α-Thr258 and 
Ser485 are autophosphorylated but they are not phosphorylated by LKB1 (Horman et al.; 2006).  
Moreover, PKB has been shown to phosphorylate recombinant α1β1γ1 and α2β1γ1 AMPK in 
vitro at Ser485/491. The phosphorylation of Ser485 did not directly affect the kinase activity, but 
the in vitro preincubation of AMPK with PKB and phosphorylation of Ser485 decreased the α-
Thr172 phosphorylation and the activation of AMPK by LKB1, suggesting a hierarchical 
mechanism whereby the prior phosphorylation of Ser485 inhibits the subsequent phosphorylation 
at α-Thr172 (Horman et al.; 2006).   
The β1 subunit has been reported to be phosphorylated at Ser24, Ser25, Ser96, Ser101, Ser108, 
and Ser182 (Mitchelhill et al.;  1997; Woods et al.;  2003; Chen et al.;  1999). The 
phosphorylations of Ser24/25 are mutually exclusive (Mitchelhill et al.; 1997). The only reported 
phosphorylation  on  the  β-2 subunit is Ser182 (Chen et al.;  1999). Phosphorylation of these 
residues may regulate the AMPK activity, cellular localisation, or interaction with substrate. 
Warden  et al.    showed that mutation of Ser108 to alanine decreased AMPK activity, while 
mutation of Ser24/25 or Ser182 did not affect the activity but increased the nuclear localisation of 
the enzyme (Warden et al.; 2001). Ser108 is within the GBD, and mutating it to glutamic acid has 
been shown partially to inhibit the association of GBD with glycogen (Polekhina et al 2003). 
Most of the β phosphorylation sites identified are autophosphorylation sites (Mitchelhill et al.; 
1997; Woods et al.; 2003). However Ser182 and some of the other sites are also likely to be 
phosphorylated by separate kinases (Mitchelhill et al.; 1997). The catalytically inactive mutant of 
AMPK has been reported to be phosphorylated at the β subunit by a partially purified AMPKK 
(Mitchelhill et al.; 1997; Stein et al.; 2000), although this was not observed by other investigators 
(Woods et al.; 2003). This discrepancy is likely to be due to the difference in the composition of 
the partially purified AMPKK used in these studies. Recently, the incubation of recombinant 
AMPK with PKB has been shown to increase phosphate incorporation into the β-1 but not the β-2   34 
subunit (Horman et al.; 2006). The significance of PKB phosphorylation on the β subunit in the 
regulation of AMPK remains to be determined.   
 In vitro, AMP activates AMPK by a direct allosteric mechanism and by a decrease in the 
dephosphorylation of AMPK at α-Thr172 by protein phosphatase (Carling et al.; 2007)  
 
This phosphorylation is the key event which accounts for most of the activation of AMPK by 
AMP. Recent studies in cultured cells and in skeletal muscle lacking LKB1 expression have 
suggested that LKB1 is required for the phosphorylation of AMPK by treatments that increase the 
AMP/ATP ratio (Carling et al.; 2007). However, it has been shown that AMP does not directly 
activate LKB1, although the phosphorylation of AMPK by LKB1 is stimulated in the presence of 
AMP (Hawley et al.;  2003; Woods et al.;  2003; Shaw et al.;  2003). The activity of LKB1 
purified from cultured cells or from skeletal muscle treated with agents that increase AMP/ATP is 
also no different from that in untreated cells (Woods et al.; 2003; Shaw et al.; 2003; Sakamoto et 
al.; 2004). LKB1 is known to be phosphorylated at up to eight residues (Boudeau et al.; 
2003), and LKB1 immunoprecipitated from a liver AMPKK fraction exists as several species, 
which seem to represent different phosphorylation states of LKB1 (Woods et al.;  2003). 
However, none of the phosphorylations of LKB1 appear to regulate LKB1 catalytic activity 
(Sapkota et al.; 2001 and 2002). Consistent with this, the preincubation of LKB1 with PP1, PP2A 
or PP2C does not affect the phosphorylation of AMPK by LKB1 (Woods et al.; 2003), although 
LKB1 appears to be the predominant AMPKK in the liver. 
Whether CAMKK is involved in the phosphorylation of AMPK in response to an increase in 
AMP/ATP is not clear. CAMKKα  and  β  are activated by Ca
2+/calmodulin but they are not 
directly activated by AMP (Hawley et al.; 2005; Woods et al.; 2005). This observation alone 
does not rule out the possibility that AMP facilitates the phosphorylation of Thr172 by CAMKKβ 
which has been reported to have some activity in the absence of stimulation by Ca
2+/calmodulin   35 
(Anderson et al.; 1998). Several other observations suggest that CAMKKs specifically mediate 
the phosphorylation of Thr172 in response to Ca
2+. In HeLa cells, which lack LKB1, AMPK is 
not activated by AICAR or H2O2 but is activated by a Ca
2+  ionophore (Hurley et al.; 2005; 
Hawley et al.; 2005). In brain slices, STO-609 inhibited the activation of AMPK by Ca
2+ but it 
did not affect the activation of AMPK by Phenformin which increased the cellular AMP/ATP 
(Hawley et al.; 2005). In contrast to these studies, Woods and co-workers showed that the Thr172 
phsophorylation could be increased by H2O2 in HeLa cells and in LKB1-deficient MEF cells 
(Woods et al.; 2005). Moreover, the transfection of HeLa cells with siRNA against CAMKKβ 
decreased the basal AMPK activity and both H2O2 and ionomycin stimulated AMPK activity 
(Woods et al.; 2005). They also showed that in NIH3T3 cells, which express both LKB1 and 
CAMKKs, the activation of AMPK by ionomycin, AICAR and H2O2 were only partially inhibited 
by STO-609, whereas in the LKB1-deficient MEF cells, their effects were completely inhibited 
by the inhibitor, suggesting that Ca
2+ and AMP activate AMPK via both LKB1 and CAMKKβ 
(Woods et al.; 2005). Offering a possible explanation for the discrepancy between this study and 
those by Hurley et al.; 2005 and  Hawley and co-worker described above, these authors suggested 
that although LKB1 and CAMKKβ are likely to be responsible for the activation of AMPK by 
AMP and Ca
2+ signalling, respectively, the distinction is likely to be blurred in vivo because an 
increase in Ca
2+ is often associated with an increase in AMP and vice versa, possibly due to the 
action of the Ca
2+  pump  (Woods  et al.;  2005). Recently, (Sanders et al.; 2007), using a 
recombinant  preparation of AMPK and LKB1, failed to detect any stimulation of α  Thr172 
phosphorylation by AMP under any condition. Another group published results using 
recombinant  AMPK  in  which  they  are  unable  to  detect  an  effect  of  AMP  on  α  Thr172 
phosphorylation by LKB1 or CaMKKβ (Suter et al.; 2006) (Figure 1.3). However, the authors 
were unable to account for the apparent discrepancy between their results and those of previous 
studies. The only explanation for this discrepancy is that the partially purified preparation of 
AMPK/LKB1 used in previous studies examining AMP stimulation could contain an additional   36 
factor that mediates the effect of AMP on α Thr172 phosphorylation. AMPK has been reported to 
be inhibited in vitro by physiological concentrations of phosphocreatine (PCr) (5-40mM), and 
this effect has been shown to be antagonised by creatine (Cr) (Ponticos et al.;  1998). The 
regulation of AMPK activity by Cr/CrP is consistent with the energy sensing role of AMPK. The 
effect of Cr/CrP on AMPK is not  
affected by the presence of AMP, suggesting that Cr/PCr binds to a site distinct from the AMP 
binding site (Ponticos et al.; 1998). Whether CrP/Cr affects the phosphorylation of Thr172 by 
AMPKKs remained unknown. Recently, (Taylor  et al.;  2006)  showed that physiological 
concentrations of CrP (5-50 mM) did not affect the activation of recombinant α1β1γ1 or α2β2γ2 
by the recombinant LKB1 complex or the activation of AMPK purified from the liver by 
recombinant LKB1. Moreover, the activity of α1β1γ1 or α2β2γ2 were not inhibited by CrP, and 
Cr did not activate α2β2γ2 or α2β2γ2 by AMPK complex recombinant LKB1 (Taylor et al.; 
2005). However, they did observe an inhibitory effect of CrP on crude AMPK purified from rat 
liver and skeletal muscle by polyethylene glycerol PEG) precipitation. However, this effect was 
not specific for CrP (glucose-6-phosphate also inhibited crude AMPK), and the inhibitory effect 
by CrP or glucose-6-phosphate was not seen in the purer preparation of AMPK obtained by 
immunoprecipitation. This suggests that the inhibitory effect of CrP seen in the crude AMPK 
preparation and possibly that observed by Ponticos and co-workers may be an artefact due to 
contaminating enzymes, such as creatine kinase and phosphatases, that act on CrP or other small 
phosphomolecules and possibly perturb the concentrations of free  phosphate, ATP or AMP 
(Taylor et al.; 2005). Furthermore a recent study has been unable to detect a direct allosteric 
effect on AMPK activity or on its upstream kinase by PCr or Cr in the concentration range of 0.3-
20 mM (Neumann et al.; 2006). 
The recombinant AMPK heterotrimer has been shown to be activated by β-NAD
+ and inhibited 
by β-NADH in vitro (Rafaeloff-Phail et al.; 2004). This effect depends on the concentrations of 
AMP and ATP; increasing the concentration of AMP increased the potency of NADH to inhibit   37 
AMPK and slightly increased that of NAD
+ to activate AMPK (Rafaeloff-Phail et al.; 2004). The 
ability of NADH to inhibit AMPK is decreased with increasing concentration of ATP (Rafaeloff-
Phail  et al.;  2004).  The physiological significance of this effect is unclear. The effect of 
NAD
+/NADH on covalent modification of AMPK is unknown. Neuman and co-workers observed 
that AMPK activity is altered by  
 
neither NADH nor NAD
+ at concentrations of up to 300 mM. Therefore the originally attractive 
hypothesis that AMPK could act as a sensor for the cellular redox potential should be carefully 
re-evaluated. 
There appears to be a complex relationship between AMPK activity and the cellular glycogen 
content. High cellular glycogen was shown to be associated with decreased basal and AICAR-
stimulated  α2  AMPK  activity  in  skeletal  muscle (Wojtaszewski et al.;  2002). Moreover, the 
activation of AMPK in skeletal muscle induced by AICAR or by glucose withdrawal was 
accompanied by a decrease in glycogen synthase activity (Wojtaszewski et al.; 2002; Halse et al.; 
2003). These observations suggest a reciprocal relationship between AMPK and the cellular 
glycogen level. The inactivation of glycogen synthase is probably due to the direct 
phosphorylation of glycogen synthase by AMPK, which has been shown in vitro (Carling and 
Hardie 1989). The mechanism by which glycogen inhibits AMPK is unclear. It has been shown 
that glycogen does not directly inhibit AMPK activity (Polekhina et al.; 2003). The inhibitory 
effect may involve glycogen-associated phosphatases or  other glycogen-associated enzymes. 
However, this reciprocal relationship between AMPK and glycogen has not been observed under 
some conditions. Aschenbach et al demonstrated that in vivo AICAR administration increased 
glycogen in skeletal muscle despite the activation of α-2 AMPK (Aschenbach et al.; 2002). These 
authors attributed the glycogen accumulation to increased glucose uptake because no change in 
the activity of glycogen synthase or phosphorylase was observed (Aschenbach et al.; 2002). 
Several naturally occurring mutations in the human AMPK γ2 gene have been shown to cause   38 
excessive glycogen accumulation in the heart. The myocardial glycogen accumulation causes 
ventricular pre-excitation, the condition called Wolff-Parkinson-White syndrome, which is 
associated with the development of cardiac hypertrophy. Transgenic mice expressing some of 
these mutations (N488I, R302Q, R531G) have been generated (Arad et al.; 2003; Davies et al.; 
2006; Sidhu et al.; 2005). All of these mice showed glycogen accumulation in the heart and 
cardiac hypertrophy (Arad et al.; 2003; Davies et al.; 2006; Sidhu et al.; 2005). The AMPK 
activity is decreased in the heart of R302Q-expressing mice (Sidhu et al.; 2005), consistent with 
the reciprocal relationship between AMPK and glycogen. The cardiac AMPK activity of the mice 
expressing the R531G mutation was found to be no different at 1 week of age and there was also 
no glycogen accumulation at this age (Davies et al.; 2006). However, glycogen accumulation was 
seen at four weeks of age and this was associated with decreased AMPK activity (Davies et al.; 
2005). In contrast to these mutations, the N488I mutation is associated with the accumulation of 
glycogen despite the increased AMPK activity (Arad et al.; 2003). Thus, the precise relationship 
between AMPK and glycogen is unclear and requires further research.  
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Figure 1.3:  Current ideas on the regulation of AMPK activity and 
phosphorylation status by AMP.(Based on these publication Hardie 
2007, Suter et al.; Sander et al.; 2007)   40 
 
 
1.3.4 The major roles of AMPK in myocardial energy utilization 
 
Myocardial Glucose Utilization: AMPK plays a key role in regulating cardiac glucose utilization 
at several levels, and stimulates glucose uptake, glycolysis (Marsin et al.; 2000) and possibly 
glycogen metabolism (Carling and Hardie 1989). AMPK promotes the translocation of GLUT4 to 
the sarcolemma of the myocyte in an insulin-independent manner (Bertrand  et al.;  2006). 
However, it is also possible that AMPK activation decreases GLUT4 recycling from the 
sarcolemma, thus increasing the overall GLUT4 levels in the plasma membrane (Yang and 
Holman 2006). The mechanism by which AMPK activation promotes increased GLUT4 levels in 
the plasma membrane is not clearly defined, there is some evidence that this may be mediated by 
nitric oxide (Young. et al.; 2004) since pharmacological inhibition of eNOS and the downstream 
cGMP pathway partially inhibits AICAR-induced GLUT4 translocation to the plasma membrane 
(Young et al.; 2004). Besides, another study showed that NO donors inhibited AMPK activity 
and GLUT4 translocation to the plasma membrane in canine ischemic myocardium (Lei et al.; 
2005).  Whereas the involvement of NO in the regulation of AMPK-mediated GLUT4 
translocation to the plasma membrane is controversial, it is likely that further pathways are 
involved. The effects of insulin and muscle contraction/cellular stress on glucose transport are 
additive, providing evidence for an independent pathway in the regulation of glucose metabolism 
(Holman et al.; 2006). However, both signals eventually lead to the mobilization of GLUT4 to the 
cell surface, which suggests that a point of convergence exists within these distinct signalling 
pathways. The point of the converging signalling event(s) remained unknown until it was recently 
realized that the  Akt substrate AS160, a Rab-GTPase activating protein and a key regulator of 
GLUT4 traffic lies at a critical node and is regulated by both Akt and AMPK (Holman  et al.; 
2006)( Figure1.4).   41 
In addition to simply providing extra substrate for glycolysis, AMPK activation promotes the 
production of ATP by glycolysis (Merrill et al.; 1997) through the direct phosphorylation and 
activation of heart phosphofructokinase PFK-2  at Ser466 (Marsin et al.; 2000). This enzyme 
produces fructose 2,6-bisphosphate, which is a potent stimulator of glycolysis. Together, both the 
direct and indirect activation of glycolysis by AMPK further increases the supply of pyruvate for 
glucose oxidation (Depre et al.; 1998). As previously mentioned, when the energy demands of the 
heart are fulfilled, excess glucose can be stored in the form of glycogen. This process is regulated 
primarily by the enzyme glycogen synthase. AMPK has been shown to inhibit glycogen synthase 
activity in vitro (Richter et al.; 2002) and it is expected that, during times of diminished ATP 
levels, there is a reduction in intracellular glycogen content in vivo. The effect that AMPK may 
have on glycogen synthase would ultimately increase the ATP supply by directing glucose to the 
energy producing pathways. Despite this rationale, based on in vitro evidence showing that 
AMPK activation may inhibit glycogen synthesis, the in vivo data do not necessarily support this 
function for AMPK in the heart (Longnus et al.; 2003). Indeed, glycogen levels are lower or 
unchanged in transgenic hearts possessing impaired AMPK activity compared to hearts from wild 
type mice (Young et al.; 2004). 
Myocardial Fatty Acid Utilization:  Fatty acids are imported into the cardiac myocyte and 
oxidized in the mitochondria to produce ATP.  Utilization of fatty acids by heart appears to be 
mediated by AMPK via number of processes. For instance, the activation of AMPK has been 
shown to be involved in the recruitment of cardiac lipoprotein lipase (LPL) to the endocardial 
surface, thus promoting fatty acid availability to the heart (An D et al.; 2005). Furthermore, an 
evidence has shown that AMPK activation induced by myocyte contraction can mediate 
translocation of CD36 (a fatty acid transport protein) from the intracellular compartments to the 
plasma membrane, suggesting that AMPK is also involved in the regulation of fatty acid transport 
(Luiken et al.; 2003). In addition to increasing fatty acid levels within the cardiac myocyte, 
AMPK activation also increases fatty acid oxidation for the generation of ATP (Kudo et al.;   42 
1995). This occurs through the phosphorylation and subsequent inhibition of acetyl CoA 
carboxylase (ACC) (Witters and Kemp 1992). ACC produces malonyl CoA, which is an inhibitor 
of carnitine palmitoyl transferase (CPT1), the enzyme responsible for the regulation of the import 
of long chain fatty acyl units into the mitochondria. As a consequence of AMPK activation, a 
lower malonyl CoA level relieves the inhibition of CPT1, accelerates fatty acyl unit transport into 
the mitochondria and results in the enhanced β-oxidation of fatty acids and subsequent ATP 
generation (Hall J et al.;  1996). Therefore, by promoting fatty acid availability, fatty acid 
transport and fatty acid oxidation, AMPK is a central mediator of fatty acid utilization in the heart 
(Saggerson and Clark 2004). 
  Glucose and fatty acid are the major fuels for the heart. Glucose has been shown to decrease α-
Thr172 phosphorylation and AMPK activity in pancreatic ß-cells and skeletal muscle (da Silva 
Xavier et al 2000 and 2003; Itani et al.;2003; Halse et al.; 2003). By contrast, physiological 
concentrations of long chain fatty acids (LCFA) such as palmitate have been shown to increase α-
Thr172 phosphorylation and to activate AMPK in heart and skeletal muscle (Hickson-Bick et al 
2000; Clark et al 2004; Fediuc et al 2006; Watt et al 2006), although this effect has not been 
observed by some investigators (Olsen and Hansen 2002; Dobrzyn et al.; 2005; Crozier et al.; 
2005; Folmes et al.; 2006). The following sections will focus on the effect of glucose, fatty acids 
and hormones on AMPK during physiological and pathological conditions. 
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Figure 1.4 Insulin leads to autophosphorylation of its receptor which, in turn, leads to tyrosine 
phosphorylation of IRS. This couples to the activation of PI 3-kinase (phosphoinositide 3-kinase) 
which produces PIP3 (phosphatidylinositol trisphosphate) in the plasma membrane. PDK1, PDK2 
and Akt become associated with PIP3 and together lead to the phosphorylation and activation of 
Akt. Activated Akt then phosphorylates ASI60 and this leads to the suppression of its GTPase-
activating activity. This may occur directly or indirectly through the association of the 
phosphorylated proteins (Rab-GAP-p) with 14-3-3 protein and relocation to the cytoplasm. 
Following the reduction in GLUT4-vesicle-associated Rab GAP activity, the vesicle-associated 
Rabs are converted into their active GTP-loaded forms and this switch facilitates the trafficking of 
the vesicles to the plasma membrane and possibly enhanced docking at the plasma membrane. 
AS160 is a key regulator of GLUT4 trafic which  is regulated by both AMPK and Akt.(Adapled 
from Koumanov& Holman 2007 , sakamato & Holman 2008) 
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1.4 The glucose fatty acid cycle (Randle Cycle) 
The Randle cycle has been invoked to explain the reciprocal relationship between fatty acid 
oxidation and glucose oxidation which, simply stated, says that increased fatty acid oxidation 
causes a decrease in glucose oxidation leading to a decrease in glucose uptake (Randle et al., 
1963). The oversupply of lipid to the muscle increases the amount of lipid-derived acetyl-CoA. A 
high [acetyl- CoA]/ CoA] ratio in mitochondria inhibits the pyruvate dehydrogenase complex, 
and increases citrate concentration. An elevated cytoplasmic citrate level inhibits 
phosphofructose-kinase-1 activity and causes the accumulation of glucose-6-phosphate, which 
eventually leads to a feedback inhibition of glucose uptake Figure 1.5. Shulman’s group using 
the nuclear resonance technique NMR,  showed that, after lipid-heparin infusion to increase 
plasma NEFA concentration, glucose oxidation and muscle glycogen synthesis were 50-60% 
lower than in the control group, which is consistent with Randle’s theory. Oon the contrary 
Shulman suggests that the initial inhibition occurs at the glucose transport step instead of 
pyruvate dehydrogenase. This is supported by the observation of decreased intracellular glucose 
and glucose-6-phosphate levels during lipid infusion (Dresner et al.; 1999). However, whether the 
defect in glucose transport is a direct effect of NEFA on glucose transporter trafficking or an 
indirect effect through upstream signaling or both remains unclear (Pfanner et al.; 1989, 1990). 
The NEFA and their metabolites also directly interfere with the insulin signaling pathways. Lipid 
infusion into a of muscle biopsy resulted in  a decrease in IRS-1 associated PI-3 kinase activity in 
parallel to diminished IRS-1 tyrosine phosphorylation, possibly due to the activation of PKC and 
other Ser/Thr kinase pathways by increasing intracellular fatty acyl-CoA and its metabolites, such 
as diacylglycerol (Dresner et al.; 1999). This leads to Ser/Thr phosphorylation of the insulin 
receptor and IRS-1 (Nishizuka et al.; 1995; Schmitz-Peiffer.; 2002). The PKC-mediated serine 
phosphorylation of IRS-1 inhibits its tyrosine phosphorylation by the insulin receptor kinase and 
its downstream signaling to PI-3 kinase (Griffin, et al.; 1999). Fatty acid metabolites can activate 
pathways that lead to the down regulation of insulin stimulated glucose disposal in muscle. The   45 
NEFA, mainly, oleate, palmitate and linoleate, are converted to long chain fatty acyl-CoA. 
Palmitate only serves as a substrate for the de novo synthesis of ceramide, which appears to 
interfere with insulin signaling through decreasing Akt/PKB phosphorylation (Chavez  et al.; 
2003). As the major insulin-stimulated site of glucose uptake, skeletal muscle is of particular 
importance. Experiments with lean normoglycemia offsprings of parents with Type 2 diabetes 
mellitus  ( T2DM) showed insulin resistance in muscle before the onset of frank hyperglycemia, 
indicating alteration of glucose metabolism in muscle, is an early event in the pathogenesis of 
T2DM (Rothman et al.; 1995). However, this has long been implicated as a potential mechanism 
for hyperglycemia and T2DM. 
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Figure 1.5 Interaction of free fatty acids (FFA) with glucose (GLU). FFA are taken up by the fatty 
acid transporter protein-1 (FATP-1) and activated to fatty acyl-coenzyme A (FA-CoA), whereas GLU is 
taken up by glucose transporter-4 (GLUT-4) and phosphorylated by hexokinase-II (HK). A: glucose-
fatty acid cycle (Randle hypothesis). FA-CoA oxidation would increase the mitochondrial ratios of 
acetyl-CoA/CoA and of NADH/NAD
+, which inhibit the pyruvate dehydrogenase (PDH) complex. 
Increased citrate should further inhibit phosphofructokinase (PFK). These changes would slow down 
the oxidation of GLU and pyruvate (PYR) and increase glucose-6-phosphate (G6P), which would 
probably stimulate glycogen (GLY) storage, inhibit hexokinase (HK), and decrease GLU transport. B: 
FFA interaction with glucose uptake activates isoforms of protein kinase C (PKC) and other Ser/Thr 
kinase pathways. 
 
FFA Interaction with Glucose Uptake 
Glucose fatty acid cycle   47 
1.5 Glucose 
 
The rate of glucose utilization by the heart is primarily linked to the rate of glucose uptake into 
the cell. This process is mediated by facilitated diffusion through specific transporters, and the 
rate is controlled by the concentration gradient, the number of transporters and their affinity for 
substrate (King and Opie, 1998). Once inside the cells, glucose is phosphorylated to glucose 6-
phosphate. Various metabolic factors play a role in determining the rate of glucose utilization. 
Such factors include dietary state, the availability of alternative substrate and the levels of 
secreted hormones. Glucose transport is rate limiting for glucose metabolism in unstimulated 
perfused rat heart (Morgan et al.; 1961). Increasing extracellular glucose results in an increase in 
glucose 6-phosphate without an increase in intracellular free glucose. Glucose fulfils multiple 
functions in cells that extend far beyond its use as an energy source. Metabolites driven from 
glucose has been found to act as signalling molecules, such as malonyl-CoA and fructose 2,6-
bisphosphate. Other metabolites have an effect on gene expression. The regulation of gene 
expression via intracellular glucose concentrations has been observed for a number of genes 
products. These include glucose transport, glycolytic and lipogenic enzymes, such as pyruvate 
kinase and acetyl CoA carboxylase (Vaulont et al.; 2000). In adipose tissue and muscle, the 
hexosamine pathway  may be responsible for some of the transcriptional effects  of glucose 
(Sayeski  et al.; 1996).  Protein phosphatase inhibitors (eg okadaic acid) inhibit the glucose 
induction of liver-PK expression (Datta et al.; 1999). Recently, it has been demonstrated that the 
activation of AMPK by 5-amino-4imidazolecarboxamide riboside (AICAR) inhibits the 
activation of many glucose-regulated genes in primary hepatocytes (Leclerc et al.; 1998). 
1.5.1 Glucose transport 
There are two mechanisms for facilited glucose uptake in animal cells. Na
+- dependent
 glucose 
transporters, driven by the Na
+  gradient, are not found in the heart. The specific glucose   48 
transporters in the heart are members of the GLUT family of transporters. Unlike active 
transporters, which require energy to drive their translocation mechanism, this facilitated 
transport of glucose occurs down a concentration gradient.  
The major glucose transporter expressed in cardiomyocytes is the GLUT4 isoform. The GLUT1 
transporter, which is present in most tissues, is also found in cardic myocytes, but is only a fifth 
as abundant as GLUT4 (Kraegen et al.; 1993). GLUT1 has higher affinity for glucose and is 
likely to be accountable for efficient transport at low circulating glucose concentrations. At 
normal cardiac workload, circulating insulin regulates the rate of glucose extraction by 
cardiomyocytes (Taegtmeyer et al.; 1985). An increase in workload increases glucose uptake in 
an insulin independent manner, by a mechanism which is mediated by AMPK-activated protein 
kinase. In the absence of insulin, glucose transport is the rate limiting step in the utilization of 
exogenous glucose in normoxic perfused hearts (Kobayashi & Neely, 1979). In the presence of 
insulin, glucose transport is no longer rate-limiting and imposes little restraint on glucose uptake 
and utilization. (Kobayashi & Neely 1979). 
A number  of other factors are also known to increase the rate of glucose transport in heart 
muscle, including hormones, such as insulin, a lack of oxygen or increasing the energy demand of 
the heart (during exercise), and it is decreased by alternative substrates, such as  fatty acid and 
ketone bodies. The products of intermediary metabolism have been shown to decrease glucose 
transport in isolated cardiac myocytes, such as pyruvate, lactate and propionate (Fischer et al.; 
1998). 
 1.5.2 Glycolysis 
Glycolysis is a metabolic pathway that is found in the cytosol of cells in all living organisms. The 
process converts one mol of glucose into two mol of pyruvate, with a net yield of two mol of 
ATP. Actually four molecules of ATP per glucose are produced; however, two are consumed   49 
during the preparatory phase. The initial phosphorylation of glucose is required to destabilize the 
molecule for cleavage into two triose  sugars. During the pay-off phase  of glycolysis, four 
phosphoryl groups are transferred to ADP by substrate-level phosphorylation to make four ATP, 
and two NADH are produced when the triose phosphate are oxidized. The overall reaction can be 
expressed as follows: 
Glucose + 2 NAD
+ + 2 Pi + 2 ADP → 2 pyruvate + 2 NADH + 2 ATP +2H
+ + 2 H2O  
 
The principal function of glycolysis is to produce ATP.  Therefore  it must be regulated so that 
ATP is generated only when needed. In the normally oxygenated heart, the amount of 
glycolytically-generated ATP is small compared to that produced
 by oxidative phosphorylation in 
the mitochondria.
 Aerobic glycolysis has been shown to be critical for normal
 cardiac excitation-
contraction (E–C) coupling. The inhibition
  of aerobic glycolysis may lead to the decline  of 
excitability and [Ca
2+]i transients in cardiac myocytes. The strict functional coupling between 
glycolysis
 and E–C coupling is thought to be due to a close association
 of glycolytic enzymes and 
ion channels, transporters, and pumps
 participating in the E–C coupling process (Han et al;. 1992;
 
Xu  et al.;  1995).  A  number of membrane transport
  systems are regulated preferentially by 
glycolytically-derived
  ATP, including the sarcolemmal KATP  channel (Weiss & Lamp, 1987,
 
1989), voltage-gated Ca
2+ channels (Losito et al.; 1998), the Na
+–H
+ exchanger (Wu & Vaughan-
Jones, 1994), 
 the Na
+–K
+ pump (Glitsch & Tappe, 1995), and the sarcoplasmic reticulum (SR) 
Ca
2+ pump (Xu  et al.; 1995).
  
In addition, some studies also revealed that the ion channels involved
 in E–C coupling may be 
modulated directly by the intermediates
 of the glycolytic pathway. For example, the ryanodine 
receptor
 (RyR), the Ca
2+ release channel of the SR, was found to be stimulated
 by glucose and 
fructose phosphates (Kermode  et al.;  1998).  Also it was suggested that the activity of the 
sarcolemmal
 Na
+ channel is modulated directly by 2,3-bisphosphoglycerate
 and glyceraldehyde 3-   50 
phosphate (Kohlhardt et al.;  1989), while
  later studies found no evidence for the  direct 
modulation
 of the Na
+ channel when the myocardial fuel metabolism is tightly regulated and 
closely
  parallels the rate of cardiac work. However, under pathological
  conditions, the 
significance of glucose metabolism increases.
 Hypertrophy is known to increase the reliance of 
the heart on
 glycolytic metabolism. Conversely, diabetes results in a major
 decline in cardiac 
glycolysis (Luigino et al.; 2004) that is associated with diabetic cardiomyopathy.
 In ischemic 
hearts, the AMPK signaling pathway stimulates glucose transportation and PFK-2 by 
phosphorylating it at Ser466 (Lopaschuk et al.; 2008). This stimulates glycolysis. In fact, the 
stimulation of glycolysis with glucose and
 insulin has been used successfully to protect patient 
hearts
  from ischemic damage. A number of reports have suggested that ATP derived from 
glycolysis is preferentially utilized to support membrane functions in the heart (Terence et al.; 
1973) 
 1.5.2.1 Hexokinase 
 
Glucose phosphorylation by hexokinase is the initial regulatory
  step that commits glucose to 
further metabolism. Two different isozymes of hexokinase are present in the heart,
 hexokinases I 
and II. (Printz et al.; 1993) Hexokinase I is predominant in the
 foetal and newborn heart. The 
phosphorylation
 of glucose by hexokinase maintains intracellular free glucose
 concentrations at a 
low level, providing the concentration gradient
  required for sustained glucose flux into the 
myocytes. Hexokinase
 is therefore necessary for the regulation and continuance of
 myocardial 
glucose uptake (Wilson et al.; 2003).
 Insulin-responsive tissues express two hexokinase isoforms,
 
hexokinase I (HK I) and hexokinase II (HK II) (Burcelin et al.; 1993).
  Under physiological 
conditions, HK II is mainly located
 in the cytosol (Foucher et al.; 1984), whereas HK I is mainly
 
bound to the mitochondria (Lynch et al.; 1996, Ritov  et al.; 2001). The binding of hexokinase
 to 
the mitochondria is thought to make hexokinase less susceptible to product inhibition (Hue  et al.; 
1998),
 providing hexokinase with better access to mitochondrially
 produced ATP (Depre et al.;   51 
1998, Wilson et al.; 1997), and providing the mitochondria with
  ADP for oxidative 
phosphorylation (Penso et al.; 1998, Sothworth et al.; 2007). The interface of
 hexokinase with the 
mitochondria has also been proposed to play
 beneficial nonenzymatic roles in cellular protection 
by decreasing
 mitochondrial superoxide leakage (Da Silva  et al.; 2004) and preventing apoptosis
 
(Zohar , et al.; 2004, Hay  et al.; 2004).
  
In skeletal muscle, insulin has been shown to promote the translocation
 of HK II from the cytosol 
to mitochondrial  membranes (Vogt et al.;  2000). Thus,
  insulin's effect of increasing glucose 
uptake by externalizing
  GLUT4 is complemented by an increased capacity to phosphorylate
 
glucose by insulin-mediated hexokinase translocation to the
 mitochondria. This double response 
means that the limit at
 which hexokinase becomes a rate-limiting step to glucose accumulation
 is 
raised (Fueger et al.; 2003). Whether cardiac hexokinase also responds to
 insulin in this manner is 
presently controversial, with the
  most recent study concluding that cardiac hexokinase 
translocation
 does not occur (Southworth, et al.; 2007, Vogt et al.; 1998). Although GLUT4 is 
known to translocate
  to the cardiac sacrolemma during ischemia, no studies to date have
 
investigated whether hexokinase also translocates to the mitochondria
 to sustain cardiac glucose 
accumulation.
  
Characterizing hexokinase behaviour in tissue is problematic because
 its activity is directly linked 
to its intracellular location
  and chemical microenvironment. Assessing hexokinase activity
  in 
tissue homogenates, as has been done in the past (Lawrence and Trayer 1985, Ritov and Kellek 
2001),
  is likely to have limited relevance to hexokinase activity in
  situ, since hexokinase-
mitochondrial interaction is likely to
  be disrupted or absent. An estimation of the extent of 
mitochondrial
  binding by cellular fractionation has also been shown to be
  of limited value. 
Although the extent of hexokinase-mitochondrial
 binding in astrocytes by fractionation has been 
measured as
 15–40%, parallel studies in an intact cell population
 by confocal microscopy showed 
that  70% of hexokinase was mitochondrial
 bound (Lynch et al.; 1991). Tissue homogenization   52 
would thus appear to lead
 to a dissociation of hexokinase from the mitochondria and invalidate 
the results. Heat lability, used in the past to discriminate between
 HK I and HK II isoforms, has 
also been discredited. Because
 hexokinase lability is highly influenced by a number of factors,
  
including solvent conditions, the presence of other proteins,
  and in particular mitochondrial 
binding, the use of this technique
 to distinguish the isoforms is imperfect (Ritov et al.; 2001, 
Wilson  et al.; 2003).  
 1.5.2.2 Phosphofructokinase –1 
 Phosphofructokinase-1 (PFK-1) is a key enzyme in glucose metabolism. It catalyses the second 
irreversible step of glycolysis to generate fructose 1,6-bisphosphate.  PFK-1 is a tetrameric 
enzyme composed of four identical subunits. Like other allosteric proteins (haemoglobin) and 
enzymes such as aspartate transcarbamoylase (ATCase), the binding of allosteric effectors and 
substrates is communicated to each of the active sites. Quaternary changes are concerted and 
preserve the symmetry of the tetramer. PFK-1 has two sets of alternative interactions between the 
subunits which are stabilized by hydrogen bonds and electrostatic interactions. The two set of 
conformations are called the T and R states. These two conformational states are in equilibrium: 
T – R 
 ATP is both a substrate and an allosteric inactivator of PFK-1, which has two binding sites for 
ATP. One is the substrate binding site and the other is an allosteric inhibitory site. The PFK-1 
substrate binding site binds ATP equally well in both the T and R states. The inhibitory ATP 
binding site only binds ATP when the enzyme is in the T formation. The other substrate fructose-
6-phosphate binds only to the R state. High concentrations of ATP shift the equilibrium towards 
the T conformation which decreases the affinity of the enzyme for F6P. AMP binds preferentially 
to the R state of PFK-1. AMP concentration levels in the cell can rise due to the enzymatic 
activity of adenylate kinase. The steady state concentration of ATP in the cell is normally 4 times   53 
greater than the concentration of ADP, and normally 20 times the concentration of AMP. As a 
result of the activity of adenylate kinase, a 10% decrease in the concentration of ATP can result in 
a 400 % increase in the concentration of AMP. 
 
 
Other allosteric effectors of PFK-1 
ADP is another allosteric effector of PFK-1.  ADP, like AMP, reverses the inhibitory effects of 
ATP and is therefore considered an allosteric activator. The activity of PFK-1 is dependent on the 
ATP, ADP and AMP concentrations which play an essential role in the cellular energy status. 
Under aerobic conditions, the pyruvate formed by glycolysis is fed into the citric acid cycle where 
it is completely oxidized to CO2 and H2O. Citrate is a metabolite of the citric acid cycle. When 
acetyl-CoA provision exceeds the need of the citric acid cycle, the citrate concentration in 
mitochondria and the cytosol increases, which leads to a decrease in glycolytic flux. Citrate binds 
preferentially to the T state of PFK-1. Thus, high concentrations of citrate inactivate the enzyme. 
PFK-1 is also potently activated by fructose 2-6-bisphosphate. Fructose 2-6-bisphosphate binds to 
the R-state of the enzyme and increases the affinity of the enzyme for fructose-6-phosphate. 
The accumulation of AMP decreases the sensitivity of PFK-1 to [H
+].  PFK-1 activity is sensitive 
to intracellular pH, especially over the physiological range pH 6.8 to 7.3. Studies using purified 
heart enzyme reveal a sigmoidal relationship between enzyme activity and the concentration of 
F6P at pH 6.9, and a marked sensitivity to allosteric regulation. At pH 8.2, PFK-1 exhibits 
Michaelis-Menten kinetics, has increased activity, and is not subject to allosteric regulation 
(Trivedi & Danforth, 1966). The product of the PFK-1 reaction, fructose 1,6-bisphosphate ( F-
1,6BP), a potent inhibitor of the enzyme PFK-1, has two binding sites , a low affinity site and a 
high affinity site (Proffit et al.; 1976). Binding to the low affinity site probably accounts for 
allosteric regulation at pH 6.9, while binding to the high affinity site affects catalytic activity even 
at pH 8.2. Adrenaline increases PFK-1 activity in muscle (Tag et al.; 1972), which may be the   54 
result of the more extensive binding of the effectors, especially F1 ,6BP. Adrenaline also 
stimulates PFK-1 activity in rat heart by Ca
2+ - dependent α- and β-adrenergic mechanisms (Clark 
& Patten 1984). 
In vitro studies of cardiac PFK-1 have shown it to be a substrate for cyclic AMP-dependent 
(PKA) and Ca
2+/calmodulin-dependent (CAMK) protein kinases (Mahrenholz et al.; 1991). 
Phosphorylation resulted in an increase in the sensitivity of PFK-1 to inhibition by ATP as well 
as an increase in its Km  for F6P. These effects are minor, compared to the allosteric effects and it 
is unknown whether the phosphorylation of cardiac PFK-1 has a regulatory role in vivo. 
 1.5.2.3 Fructose 2, 6-bisphosphate 
Fructose 2,6-bisphosphate (F2,6BP) most convincing potent activator of phosphofructokinase-1. 
The synthesis and degradation of this unique sugar bisphosphate are controlled by the 
bifunctional enzyme fructose 6-phosphate  2-kinase and fructose 2,6-bisphosphatase. Various 
tissues contain tissue-specific isozymes of the bifunctional enzyme, and these isozymes have 
different relative kinase and phosphatase activites (Uyeda et al.; 1991). Several of these isozymes 
from various mammalian tissues have been characterized. They are all homodimers, consisting of 
subunits with Mr ranging from 54,000 to 60,000 Da. The amino acid sequences of the enzymes 
from skeletal muscle (Crepin et al.; 1992), the heart (Sakata & Uyeda, 1990), the liver (Lively et 
al.; 1988), the testis (Sakata et al.;  1991), and the brain (Watanabe et al.; 1994) have been 
determined. The amino acid sequences of both catalytic domains are highly conserved among 
these isozymes, but the amino and carboxyl termini are completely different. These differences in 
the terminal peptides appear to regulate the relative activities of the kinase and the phosphatase, 
which in turn regulate the F2,6BP concentrations in each tissue.  The activity ratio of the enzyme 
can also be modulated by phosphorylation/dephosphorylation. The phosphorylation of the C-
terminus of the heart enzyme results in the activation of the kinase without any effect on 
phosphatase activity (Kitamura & Uyeda, 1987; Kitamura et al.; 1988). In contrast, the   55 
phosphorylation of the N-terminus of the liver enzyme results in the inhibition of the kinase and 
the activation of the phosphatase ( Van Shaftingen  et al.; 1981; Maghrabi et al.; 2001).   
 
 Some isozymes including the rat testis bifunctional enzyme lack such phosphorylation sites. It is 
known that the kinase domain resides in the amino-terminal half and the phosphatase domain in 
the carboxyl-terminal half of the enzyme. Heart PFK-2 activity is inhibited by citrate and sn-
glycerol-3-phosphate  (Hue & Rider, 1987) and activated by insulin. Insulin activates PFK-2 
possibly through the phosphatidylinositol 3-kinase pathway (Hue et al.; 1995). Conditions which 
reduce glycolysis, such as the oxidation of fatty acids, ketone bodies or lactate, are citrate 
mediated and accompanied by decreases in F 2,6BP2, levels (Hue et al.;  1995), whereas the 
stimulation of glycolysis by glucose, insulin, adrenaline or increased workload is paralleled by an 
increase in the F 2,6BP2  content of isolated perfused hearts (Hue & Rider 1987). F 2,6BP2 can 
therefore act as an interacellular signal to control glycolysis in various tissues under normoxic 
conditions (Hue & Rider, 1987). 
Heart PFK-2 was phosphorylated on Ser466 and activated by AMPK in vitro. In perfused rat 
hearts, anaerobic conditions or the inhibitors of oxidative phosphorylation (oligomycin and 
antimycin) induced AMPK activation, which correlated with PFK-2 activation and with an 
increase in fructose 2,6-bisphosphate concentration.  Moreover, in cultured cells transfected with 
heart PFK-2, oligomycin treatment resulted in a parallel activation of endogenous AMPK and 
PFK-2 (Hue et al.; 2000). In these cells, the activation of PFK-2 was due to the phosphorylation 
of Ser466. A dominant-negative construct of AMPK abolished the activation of endogenous and 
cotransfected AMPK, and prevented both the activation and phosphorylation of transfected PFK-
2 by oligomycin. AMPK-mediated PFK-2 activation is likely to be involved in the stimulation of 
heart glycolysis during ischaemia (Hue et al.; 2000). 
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 1.5.2.4 Glyceraldehyde-3-phosphate Dehydrogenase 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an enzyme involved in glycolysis, 
which catalyzes the NAD
+-dependent oxidation of glycerol 3-phosphate (G3P) to 1,3-
bisphosphoglycerate (1,3-BPG) and NADH. This is the first step in which a high energy 
phosphate compound (acyl phosphate) is generated. GAPDH is inhibited by its product, 1,3-
bisphosphoglycerate and NADH, and by lactate (Mochizuki & Neely, 1979) and ATP 
(Meriwether & Park, 1971). Activation of PFK-1 leads to an accumulation of Fru 1,6-P2 and, 
under specific situations, to a restriction of glycolytic rate further down the pathway. The control 
of glycolytic rate is shifted from PFK-1 to GAPDH in hearts perfused under anoxic or ischaemic 
conditions, resulting in the accumulation of F1,6BP2 and triose phosphate ( Eaton et al.; 2002) 
Under ischemic or anoxic conditions, the reoxidation of NADH to NAD
+    is impaired (Eaton et 
al.; 2002). The resulting increase in NADH inhibits GAPDH. 1, 3-bisphosphoglycerate is used to 
generate the first molecule of ATP from glycolysis by the transfer of the phosphoryl group from 
the acyl phosphate of 1, 3-  bisphosphoglycerate to ADP, a reaction catalysed by 
phosphoglycerate kinase. 
Recent evidence suggests that mammalian GAPDH is also involved in a great number of 
intracellular processes, such as membrane fusion, microtubule bundling, phosphotransferase 
activity, nuclear RNA export, DNA replication and DNA repair (Hessler et al.; 1998). During the 
last decade, many findings have been made concerning the role of GAPDH in different pathologies, 
including prostate cancer progression, programmed neuronal cell death and age-related neuronal 
diseases, such as Alzheimer’s and Huntington’s. GAPDH is constitutively expressed in almost all 
tissues at high levels. There are, however, some physiological factors, such as hypoxia and diabetes 
that increase GAPDH expression in certain cell types.  
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 1.5.2.5 Pyruvate Kinase 
 
Pyruvate kinase is the  enzyme  catalyses the transfer of a phosphate group from 
phosphoenolpyruvate (PEP) to ADP, yielding one molecule of ATP and one molecule of 
pyruvate.The heart isoform is inhibited by ATP.  This is similar to the effect of ATP on PFK-1. 
The binding of ATP to the inhibitor site reduces its affinity for PEP. The liver enzyme is also 
controlled at the level of synthesis. Increased carbohydrate ingestion induces the synthesis of PK, 
resulting in elevated cellular levels of the enzyme. This slower form of control, which responds to 
long-term dietary and environmental factors, is referred to as transcriptional regulation. 
The majority of pyruvate produced from glycolysis in heart and skeletal muscle is transported 
into the mitochondria, where it can be converted to acetyl-CoA by the action of pyruvate 
dehydrogenase (PDH). When oxygen is lacking, NADH accumulation causes inhibition of PDH 
and the citric acid cycle and pyruvate is converted to lactate by lactate dehydrogenase.  The 
conversion of pyruvate to lactate as opposed to acetyl-CoA depends upon the oxidation state of 
the cell, the level of NADH and acetyl-CoA and PDH activity.  
 1.5.2.6 Pyruvate dehydrogenase 
 
 PDH complex is one of the main control points in carbohydrate metabolism. It exists in both 
active and inactive forms, which are interconvertible by phosphorylation and dephosphorylation. 
It is located in the mitochondrial matrix of eukaryotes. The pyruvate dehydrogenase complex 
catalyzes the oxidation and decarboxylation of pyruvate to form acetyl-CoA, NADH and CO2. 
The mammalian PDH complex contains multiple copies of pyruvate dehydrogenase (E1), 
dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide dehydrogenase (E3), which 
together catalyse the decarboxylation reactions, two regulatory enzymes (PDH kinase and PDH 
phosphatase) and protein X which links E3 to the complex.   58 
Pyruvate dehydrogenase (E1) 
Pyruvate dehydrogenase  (E1) is the first component enzyme  of the pyruvate dehydrogenase 
complex (PDC) and performs the first two reactions within the PDC: a thiamine pyrophosphate-
dependent decarboxylation of substrate 1 (pyruvate) and a reductive acetylation of substrate 2 
(lipoic acid). Lipoic acid is covalently bound to dihydrolipoamide acetyltransferase (E2), which is 
the second catalytic component enzyme of PDC. The phosphorylation  of E1 by pyruvate 
dehydrogenase kinases inactivates E1 and subsequently the entire complex. This is reversed by 
pyruvate dehydrogenase phosphatase. Pyruvate dehydrogenase kinase activity is stimulated by 
acetyl-CoA and NADH (Kerbey et al.; 1976) and inhibited by pyruvate and the pyruvate. 
Dihydrolipoyl transacetylase (E2) 
 
Interaction of the three enzyme are affected by lipoate bound covalently to the mobile arm of E2 
which visitis the active site of the three enzymes sequentially  ( Reed , 1969) and transfers acetyl 
(to CoASH) and 2e
- via the flavoprotein E3 to NAD
+ 
. Dihydrolipoyl dehydrogenase (E3) 
The lysine residue of the comples bound to the dihydrolipoate then migrate to the dihydrolipoyl 
dehydrogenase  (E3)  active site,  where it undergoes a flavin-mediated oxidation, identical in 
chemistry to disulfide isomerase. First, FAD oxidizes the dihydrolipoate back to its lipoate resting 
state, producing FADH2. Then, NAD
+ oxidizes FADH2 back to its FAD resting state, producing 
NADH. 
Regulation 
 
PDH kinase activity is stimulated by increasing the mitochondrial ratios of acetyl-CoA/CoASH, 
NADH/NAD
+ and ATP/ADP (Kerbey et al.; 1976). The activating effects of acetyl-CoA and   59 
NADH involve the reduction of the lipoyl moiety of the complex, and are antagonised by CoASH 
and NAD
+.    PDH kinase is inhibited by pyruvate and the pyruvate analogue dichloroacetate 
(McVeigh and Lopaschuk 1990). The stimulatory effect of pyruvate on PDH activity can be 
overcome by fatty acids and is impaired in diabetes. The oxidation of fatty acids and ketone 
bodies decreases the amount of PDH in its active form. Fatty acid oxidation results in increases in 
the mitochondrial NADH/NAD
+  and acetyl-CoA/CoA ratios, which are able to cause the 
feedback allosteric inhibition of PDH, as well as resulting in the activation of PDH kinases and 
conversion of PDH to the inactive phosphorylated form. PDH phosphatases are dependent upon 
Mg
2+ and is activated by a physiological concentration of Ca
2+ (0.1-10 µM). The perfusion of 
isolated hearts with increasing Ca
2+ concentrations has been shown to increase the amount of 
PDH in the active dephosphorylated form (Pettit et al.; 1972). The perfusion of rat hearts with 
adrenaline increases the activity of PDH, probably by increasing the cellular Ca
2+ levels, which, 
in turn, activates PDH phosphatase. In adipose tissue, PDH is activated by insulin, whilst in the 
heart no effects of insulin have been observed. 
Increased cardiac work may also decrease the mitochondrial acetylCoA/CoASH and 
NADH/NAD
+  ratio, thereby relieving the inhibition of PDH by its phosphorylation by PDH 
kinases. In addition, during  starvation, PDH kinase activity and expression (PDH kinase 4) 
increases in amount in most tissues, including skeletal muscle. These changes together with a 
shift in metabolism toward fatty acid oxidation the fasting state greatly decrease the muscle to 
catabolize glucose whilst increasing the output of the gluconeogenic precursor alanine. Such 
glucose as is available under these conditions is spread for use by the brain or by other tissue for 
which glucose is essential. 
 15.2.7 Pyruvate 
Pyruvate, a product of glycolysis it has been shown to improve the mechanical performance of 
the heart under normoxic conditions (Zweier & Jacobus, 1987) as well as during ischaemia-  60 
reperfusion injury (Mallet et al.; 1994) Current studies have suggested that pyruvate is able to 
potentiate the positive inotropic effects of β-adrenergic stimulation (Hermann et al.; 2000) and to 
improve the contractile performance of isolated failing human In spite of  growing agreement 
about the beneficial effects of pyruvate on cardiac performance, the cellular mechanisms of 
pyruvate action have remained uncertain or even contradictory. There is, however, solid support 
that pyruvate improves the energetic conditions of cardiac cells. With normal oxygen supply, 
pyruvate undergoes oxidation in the mitochondria, leading to the augmentation of the 
NADH/NAD
+  ratio and therefore to an increase in the energetic force for ATP synthesis 
(Laughlin & Heineman, 1994) The uptake of pyruvate into cardiac myocytes is mediated by a 
sarcolemmal H
+-monocarboxylate symporter (Poole & Halestrap, 1993). Thus, pyruvate uptake is 
likely to cause intracellular acidification, which, in turn, could affect contractility in multiple 
ways (Hasenfuss et al.; 2002).  
Aside from its  beneficial effects on cardiac performance, pyruvate may also exert pro-
arrhythmogenic effects by causing cardiac alterations. Recent data suggest that pyruvate can elicit 
alternations in the [Ca
2+]i transient amplitude, contraction strength, and action potential duration 
in both atrial and ventricular myocytes from the cat heart (Hüser et al. 2000; Kockskämper & 
Blatter, 2002).  Pyruvate  induced Ca
2+  alterations was particularly noticeable in the atrial 
myocytes, where it caused large subcellular inhomogeneities and could produce arrhythmogenic 
Ca
2+ waves.  
 
 1.5.2.8 Lactate 
Lactate is found in essential cells of the body but particularly in muscle cells during exercise. 
Accumulation occurs when the supply of oxygen to the cells is restricted either because the 
muscle cells are working so hard that the oxygen supply cannot keep up or because the supply 
itself is lacking for some reason.    61 
Throughout everyday activities, such as walking, the oxygen supply to muscle cells is sufficient 
to enable the cells to make use of energy from various sources without recourse to the lactic acid 
route. However, when there is an unexpected need for excessive muscular effort lactic acid 
formation is available to enable activity to continue, even though the oxygen supply is 
inadequate. This is known as the anaerobic phase of exercise in contrast to the aerobic phase 
which implies a sufficient oxygen supply to the muscle cells. Under normal conditions, lactic 
acid, an important respiratory substrate for the heart, is transported into the cardiac myocyte and 
oxidized. In contrast, lactic acid must be transported out of the cell to prevent intracellular 
acidification during hypoxia or any othercondition that increases lactic acid production or 
diminishes intracellular oxidation of the molecule.  
 1.5.3 The pentose phosphate pathway 
 The pentose phosphate pathway (also called the Hexose Monophosphate Shunt [HMP shunt] or 
Phosphogluconate Pathway) is a process that synthesizes pentose (5-carbon) sugars and serves to 
generate NADPH. The pathway consists of two distinct phases.  NADPH is generated by the 
oxidative arm. 5-carbon sugars are also generated by the oxidative phase, and the non-oxidative 
phase is a potential alternative way of making these sugars (Heckmann and Zimmer 1992)( 
Figure 1.6) Ribulose 5- phosphate is formed through the oxidation subsequent decarboxylation of 
the glucose 6-phosphate. Ribulose 5-phosphate can be converted by phosphopentose isomerase to 
ribose 5-phosphate. The oxidation and decarboxylation of glucose-6-phosphate to ribulose-5-
phosphate occurs in three steps, accompanied by the generation of two mol of NADPH.  The first 
step is the oxidation of the hydroxymethylene group at position one to a carbonyl group, (cyclic 
ester) and a molecule of NADPH.  The second step is then to hydrolyze the lactone to the free 
carboxylic acid.  The carboxyl group of the carboxylic acid is then removed by oxidative   62 
decarboxylation, converting the 6-carbon sugar acid to a 5-carbon sugar, with the accompanying 
production of another mol of NADPH. 
 The ribose-5-phosphate produced can now be utilized in the synthesis of nucleotides for 
incorporation into nucleic acids.  The reaction proceeds through an enediol (C=C double bond 
and two hydroxyl groups) intermediate, as the enzyme takes advantage of the dissociability of the 
hydrogen on the terminal hydroxyl group to create an oxyanion and move the C=O double 
bond to the terminal carbon, producing the aldehyde and reducing the ketone to an alcohol. 
 It is important to control ribose synthesis, a mechanism exists to remove this sugar when it is in 
excess, by converting it into glycolytic intermediates.  A series of three enzymatic steps are 
carried out, transferring two- and three-carbon fragments from one sugar to another, and all of 
these steps are similar in mechanism to an aldol condensation (recall that aldolase, the enzyme in 
glycolysis, which fragments the six-carbon, bisphosphorylated sugar fructose 1,6-bisphosphate 
into two phosphorylated three-carbon fragments, breaks the carbon-carbon bond through the 
reverse mechanism of aldol condensation.  Transketolase,  is the enzyme which transfers a two-
carbon fragment terminating on the interior side in a carbonyl, and transaldolase, transfers a 
three-carbon fragment terminating on the central side in a hydroxymethylene group. 
The convertion of ribose 5-phosphate to glycolytic intermediates is catalysed by transketolase, by 
the transfer of the 1-  and 2-carbons from xylulose 5-phosphate to the 1-carbon of ribose 5-
phosphate.  This leaves the last three carbons from xylulose-5-phosphate as glyceraldehyde 3-
phosphate, the first three-carbon fragment encountered in glycolysis, and sedoheptulose 7-
phosphate, produced from the ribose 5-phosphate, which is a seven-carbon sugar. By inverting 
the cofigration at carbon -3, xylulose 5-phosphate can be produced from ribulose 5-phosphate. 
This reaction is carried out by the enzyme phosphopentose epimerase, and is freely reversible. 
Thus, in the first reaction, converting ribose-5-phosphate to glycolytic intermediates, both ribose-  63 
5-phosphate and ribulose 5-phosphate (the latter in the form of xylulose 5-phosphate) are being 
degraded to other species, and eventually carried off in glycolysis. 
 Transaldolase mediates the second reaction which leads from the intermediates in the pentose 
phosphate pathway to glycolytic.  This enzyme transfers a three-carbon fragment (carbons 1, 2 
and 3) from the sedoheptulose 7-phosphate just formed in the first reaction to the glyceraldehyde 
3-phosphate just formed in the first reaction, yielding a four-carbon  fragment, erythrose 4-
phosphate, and a six-carbon fragment, fructose 6-phosphate.  The fructose 6-phosphate is now 
liberated to enter the glycolytic pathway. 
Transketolase catalyses the final reaction,s linking the pentose pathway to the glyolytic pathway. 
In this reaction, another molecule of xylulose 5-phosphate is cleaved, and the two-carbon 
fragment consisting of carbons 1 and 2 is transferred to the molecule of erythrose 4-phosphate 
just formed in the transaldolase reaction, generating a molecule of glyceraldehyde 3-phosphate 
and another molecule of fructose 6-phosphate. Both of these products are capable of entering 
glycolysis directly, and so there are no leftover fragments formed in this overall convertion.  
Because another molecule of xylulose 5-phosphate has entered the reaction, the overall 
conversion consists of two molecules of xylulose 5-phosphate and one molecule of ribose 5-
phosphate going to two molecules of fructose 6-phosphate and one molecule of glyceraldehyde 3-
phosphate, and so the net reaction is the removal to glycolysis of three molecules of ribose 5-
phosphate. 
 For different purpose NADPH and ribose 5-phosphate  produced by the pentose phosphate 
pathway it is sometimes necessary to produce them in differing proportions.  Therefore, the cell 
has different modes in which the pentose phosphate pathway can function.  In the case, where 
much more ribose-5-phosphate is required than NADPH, the ribose 5-phosphate may be 
produced from glyceraldehyde 3-phosphate and fructose 6-phosphate through the reversal of the 
transaldolase and transketolase reactions.  This allows the cell’s NADP
+  supply to remain 
relatively unaffected.   64 
When both NADPH and ribose 5-phosphate are desired in large amounts, the principal reaction 
used by the cell to generate them is the conversion of glucose-6-phosphate to ribose 5-phosphate, 
with the liberation of two molecules of NADPH for each molecule of glucose 6-phosphate 
converted. 
The important role of the NADPH produced in the pentose phosphate pathway is the maintenance 
of the glutathione in its reduced state through the action of gluthathione reductase. In terms 
reduced glutathione plays an important role in protection of the cell against oxidative damage.   65 
 
 Figure 1.6 : The pentose phosphate pathway 
 
      Oxidative phase 
1. Glucose 6-phosphate + NADP
+ → 6-phosphoglucono-δ-lactone + NADPH  (glucose 6-     
phosphate dehydrogenase) 
2.  6-phosphoglucono-δ-lactone + H2O → 6-phosphogluconate + H
+ (lactonase) 
3. 6-phosphogluconate + NADP
+ → ribulose 5-phosphate + NADPH + CO2 ( 6- 
phosphogluconate dehydrogenase) 
        Non-oxidative phase 
4.  ribulose 5-phosphate → ribose 5-phosphate (phosphopentose isomerase)  
5.  ribulose 5-phosphate → xylulose 5-phosphate (phosphopentose epimerase)  
6.   xylulose 5-phosphate + ribose 5-phosphate → glyceraldehyde 3-phosphate +       
      Sedoheptulose 7-phosphate (transketolase) 
7.  Sedoheptulose 7-phosphate + glyceraldehyde 3-phosphate → erythrose 4-phosphate +  
     fructose 6-phosphate (transaldolase) 
6.  Fructose 6-phosphate + erythrose 4-phosphate → glyceraldehyde 3-phosphate +  
     Glucose 6-phosphate (transketolase) 
 
 
 
 
 
 
   66 
 
1.5.3.1 Xylulose 5-phosphate 
Xylulose 5-phosphate is a product of pentose phosphate pathway. It has been reported to activate 
PP2A allosterically (Nishimura et al.; 1995).  In the liver xylulose 5-phosphate regulates the 
bifunctional enzyme through allosteric activation of protein phosphatase  (Pelech  et al.)  The 
activation of PP2A by Xu 5-P in rat liver, represents one of only two examples of metabolite (or 
small  M   compounds) that allosterically activate PP2A. The other is the activation of a 
heterotrimeric form of PP2A of rat T9 glioma cells by ceramide (Dobrowsky and Hunnun, 1992) 
(Dobrowsky  et al., 1993). However, a more recent report (Law and Rossle, 1995) indicated that 
even the catalytic subunit is activated by ceramide and this effect lacks substrate specificity. This 
is in contrast to the Xu 5-P-activated PP2A, because activation by Xu 5-P shows the substrate 
specificity, thus reflecting the differences in the activation mechanism. Since PP2A is not only 
the most abundant form of protein phosphatase, especially in cytoplasm, but also shows broad 
substrate specificities, it is possible that other PP2As may be regulated by specific metabolites. 
1.5.3.2 Glucose 6 - phosphate dehydrogenase  
Glucose 6-phosphate dehydrogenase (G6PD) functions as the first and rate-limiting enzyme in the 
pentose phosphate pathway (PPP), responsible for the generation of  NADPH in a reaction 
coupled to oxidation of glucose 6- phosphate and the de novo production of cellular ribose 5-
phosphate. The activity of G6PD is rapidly increased in response to cellular oxidative stress, by 
the translocation of G6PH to the cell membrane.  Inhibition of G6PD leads to the depletion of the 
cytosolic reduced glutathione (GSH) (Eaton et al.; 1999). In cardiomyocytes, GSH resides in two 
separate compartments, mitochondria and cytosol. When its level is depleted, the subsequent 
result in cardiomyocytes is contractile dysfunction through the dysregulation of calcium 
homeostasis. G6PDH is a critical cytosolic antioxidant enzyme, essential for the maintenance of 
cytosolic redox status in adult cardiomyocytes (Mohit et al.; 2003).    67 
In the isolated perfused rabbit heart ischemia induced a rapid decline of contractility, associated 
with a reduction in the content of tissue GSH with no significant changes in GSSG. Reperfusion 
induced a small recovery of contractility, a substantial release of total glutathione in the cytosol 
and a further decrease in the content of tissue GSH, with a significant increase in tissue GSSG. 
Glutathione reductase and glutathione peroxidase activities were unaffected by ischemia and 
reperfusion. This study suggests a possible role for glutathione in the determination of functional 
damage induced by myocardial ischemia and reperfusion (Curello  et al.; 1987). 
 1.5.3.3 Transketolase       
  Transketolase is a dimeric enzyme with the active sites located at the interface between the two 
identical subunits. The cofactor, vitamin B1 derived thiamine pyrophosphate, is bound at the 
interface between the two subunits. The enzyme subunit is composed of three domains of the 
alpha/beta type. The diphosphate moiety of thiamine diphosphate is bound to the enzyme at the 
carboxyl end of the parallel beta-sheet of the N-terminal domain and interacts with the protein 
through a Ca
2+ ion. The thiazolium ring interacts with residues from both subunits, whereas the 
pyrimidine ring is buried in a hydrophobic pocket of the enzyme, formed by the loops at the 
carboxyl end of the beta-sheet in the middle domain of the second subunit.  Structural analysis 
identifies the amino acids that are critical for cofactor binding and provides mechanistic insights 
into thiamine catalysis. 
.  1.5.3.4 D- Ribose and Xylitol 
D-ribose is ubiquitous in living matter; it is ingested through our diet.  Recent research suggests 
that supraphysiological amounts of this sugar may have cardioprotective effects, particularly for 
the ischemic heart. Ribose has been shown greatly to increase ATP recovery in situations such as 
postischemia, when all of the ATP has been depleted by catabolism. Furthermore, metabolic 
studies have reported that both sugars and alcohols  (ribose and xylitol) can support energy   68 
metabolism, presumably after conversion to substrates for glycolysis. In hearts perfused with 
ribose, xylitol or no substrate, the rate pressure product and the stroke volume rapidly declined 
after an initial brief stable period corresponding to glycogen depletion (Mahoney et al.; 1989). By 
contrast, either glucose or pyruvate supported steady levels of ATP and myocardial oxygen 
consumption, maintained the energy charge, and supported the stroke volume, rate pressure 
product, and cardiac work. Thus, although the heart is able to metabolize ribose and xylitol 
through the hexose monophosphate pathway, the rate of  utilization  through glycolysis and 
presumably the TCA cycle is insufficient for these compounds to serve as exclusive substrates for 
the isolated working heart (Mahoney et al.; 1989). 
15.3.4 Thiamine 
Thiamine plays an essential role in the metabolism of glucose. Previous studies have 
demonstrated that thiamine has a cytoprotective effect against ischemic damage to the heart and 
to heat shock protein 70 (Hsp70). This thiamine effect also protects cardiac cells from lethal 
ischemia/hypoxia (Jaattla, 1999; Latchman, 2001). Thiamine (Vitamin B1) is also a clinically 
important factor in heart function, and its deficiency leads to heart failure (Ozawa et al.; 2001). 
The accumulation of glycerol 3-phosphate, and the increased formation of the potent glycating 
agent, methylglyoxal, in intracellular hyperglycaemia, is implicated in the development of 
diabetic complications. A strategy for countering this is to stimulate the anaerobic pentose 
phosphate pathway of glucose metabolism by maximising transketolase activity by thiamine 
supplementation. This leads to the consumption of glyceraldehyde-3-phosphate, an increase in the 
formation of ribose 5-phosphate (R 5-P). Increased R 5-P may stimulate de novo purine synthesis 
by increasing the availability of ribosylpyrophosphate. R 5-P is a glycating agent, but is much 
less reactive than methylglyoxal and is present at a low concentration (20μM) in cells. 
   69 
 
 1.5.4 Hexosamine biosynthetic pathway 
 
Glucose phosphorylated by hexokinase to glucose 6-phosphate is converted to fructose 6-
phosphate in the next step of glycolysis. Fructose 6-phosphate can be converted into  
UDP-N-acetylglucosamine (UDPGlcNac) by glutamine: fructose 6-phosphate-amidotransferase 
(GFAT), the first and rate-limiting enzyme of the hexosamine biosynthetic pathway. UDPGlcNac 
serves as the substrate for the O-GlcNacylation of proteins by the enzyme O-GlcNac transferase 
(OGT). O-GlcNacylation has been shown to compete for phosphorylation sites of signalling 
proteins and transcription factors, thereby modifying their activity (McClain et al.; 2002). 
1.5.4.1 Glutamine fructose 6-amidotransferase   
Glutamine fructose 6-  phosphate amidotransferase (GFAT) is the rate limiting enzyme in 
hexosamine biosynthesis pathway, an important pathway for cellular glucose sensing. It also has 
been implicated in insulin resistance. GFAT has
 two isoforms GFAT1 and GFAT2. GFAT1 is 
ubiquitous, whereas GFAT2 is expressed mainly in the central nervous system (Deharen et al.; 
2001). The mouse GFAT2
 cDNA was cloned, and the protein was expressed with either an
 N-
terminal glutathione S-transferase or His tag (Deharen et al.; 2001). The purified
  protein 
expressed in mammalian cells had GFAT activity. The
  Km  values for the two substrates of 
reaction, fructose 6-phosphate
  and glutamine, were determined to be 0.8 mM for fructose 6-
phosphate
 and 1.2 mM for glutamine, which are within the ranges determined
 for GFAT1. The 
protein sequence around the serine 202 of GFAT2
 was conserved to the serine 205 of GFAT1, 
whereas the serine
 at 235 in GFAT1 was not present in GFAT2. Previously it was shown
 that 
phosphorylation of serine 205 in GFAT1 by the catalytic
 subunit of cAMP-dependent protein 
kinase (PKA) inhibits its
 activity. Like GFAT1, GFAT2 was phosphorylated by PKA, but GFAT2
 
activity increased approximately 2.2-fold by this modification.
 When serine 202 of GFAT2 was 
mutated to an alanine, the enzyme
 not only became resistant to phosphorylation, but the increase
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in activity in response to PKA also was blocked. The phosphorylation of serine 202 was 
necessary
 and sufficient for these alterations by PKA. GFAT2 was modestly
 inhibited (15%) by 
UDP-GlcNAc but not through detectable O-glycosylation.
 GFAT2 is, therefore, an isoenzyme of 
GFAT1, but its regulation
  by cAMP is the opposite, allowing differential regulation of
  the 
hexosamine pathway in specialized tissues (Hue et al.; 2004). Recent study has proved that 
phosphorylation of GFAT1 at Ser243 by AMPK has an important
 role in the regulation of the 
GFAT1 enzymatic activity (Yonezawa   et al.; 2009) 
1.5.5 Glycogen 
 Glycogen is a high-molecular-weight polysaccharide that serves
 as a repository for glucose units 
for utilization in times of
 metabolic need. The glycogen pool in the heart
 is relatively small ( 30 
µmol/g wet wt compared with  150
 µmol/g wet wt in skeletal muscle) (Arad et al.; 1994, Opie et 
al.; 1991) and has
 a relatively rapid turnover, despite stable tissue concentrations
 (Henning et al.; 
1996). An alternative source of glucose 6-phosphate for the heart is the
 intracellular glycogen 
store. Glycogen concentrations are increased by a high
  supply of exogenous substrate and/or 
hyperinsulinemia (Kruszynska et al.; 1991, Laughlin et al.; 1994). Glycogenolysis is activated by 
adrenergic stimulation
 (e.g., increases in cAMP and Ca
2+), a fall in the tissue content
 of ATP, and 
a rise in inorganic phosphate, that occurs during ischemia or intense exercise. (Hue et al.; 1995). 
Recently, there
 has been considerable focus on the role of AMPK in
 regulating the glycogen 
content of the heart (Arad et al.; 2003). Constitutively
 inactive AMPK, due to a mutation in a 
regulatory subunit of the
  enzyme, was recently shown to be linked with increased glycogen 
content
 and hypertrophic cardiomyopathy (Arad et al.; 2003, Seidman et al.; 2003). In contrast 
acute
 activation of AMPK has been shown to activate glycogenolysis (Longnus 2003, Polekhina 
et al.; 2003). Clinically, patients with a mutation in the gamma-2
 regulatory subunit of AMPK 
have Wolff-Parkinson-White syndrome
 and conduction system disease in the absence of cardiac   71 
hypertrophy
 (Gollob et al.; 2003, Gollob et al.; 2001), although the cellular mechanisms linking 
abnormal
 AMPK activity and the electrophysiological abnormalities remain
 unclear.
  
Mammals express two isoforms of glycogen synthase, encoded by
 the GYS1 and GYS2 genes. 
GYS1, encoding the muscle isoform of
 glycogen synthase, is expressed in skeletal muscle, cardiac
 
muscle, adipose tissue, kidney and brain (Kaslow et al.; 1984). GYS2 expression
 has been found 
only in the liver (Tan al et.; 1985). Many cells can synthesize
 glycogen but, in absolute amounts, 
the major stores are in the
 liver and skeletal muscle. Although its essential role as an energy 
reserve is common to all cells, there are differences in glycogen
 function between tissues. Liver 
glycogen contributes primarily
 to blood glucose homeostasis, being synthesized during periods
 of 
nutritional sufficiency, and subsequently converted to glucose,
  which is released into the 
bloodstream to counteract hypoglycemia
  (Roche et al.; 2001). 
 In the fed state, glycogen is also synthesized in skeletal muscle,
 where it functions as an energy 
reserve for fuel contraction
 (Roch et al.; 2001). Glycogen provides a part of the glucose utilized 
by
 the aerobic working adult heart (Depre et al.; 1999) and is preferentially oxidized
 compared to 
exogenous glucose (Goodwin et al.; 1996). Although long-chain
  fatty acids are normally the 
major substrates for the adult
 heart, when blood glucose and insulin concentrations are high,
 such 
as after a meal, glucose becomes a more prominent energy
 source (Nakal  et al.; 1994  (Henning  
et al.;1996). Various stresses also trigger a greater reliance
 on glycogen. When the workload of 
the heart is increased, after stimulation by adrenaline (Nakal et al.; 1994; Taegtmeyer et al.; 
1998) and/or by increased
  exercise (Goodwin et al.; 1996; Henning et al.; 1996), glycogen 
provides a readily reasonable source
 of additional energy. In ischemia, glucose assumes a more 
important role as a fuel for the heart, since fatty acid oxidation is
 limited and glycogen supplies 
glucose for anaerobic glycolysis (Depre   et al.; 1999).  
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 1.6 Lipid fuels 
Fatty acids are an important source of energy for many organisms. Excess glucose carbon can be 
stored efficiently as fat. Triacylglycerols (TAG) yield more than twice as much energy for the 
same mass as do carbohydrates or proteins. All cell membranes are composed of phospholipids, 
each of which contain fatty acids. Fatty acids are also used for protein modification. The 
metabolism of fatty acids, therefore, consists of catabolic processes which generate energy and 
primary metabolites from fatty acids, and anabolic processes which create biologically important 
molecules from fatty acids and other dietary carbon sources. 
Cardiac myocytes have a very low capacity for de novo fatty acid synthesis and so rely on supply 
of fatty acids from the circulation. These fatty acids may be oxidized to provide energy or 
esterfied to form an endogenous TAG store. Fatty acids are present in the blood as either 
unesterified molecules, or incorporated into phospholipids, cholesteryl ester or as acylglycerols. 
The solubility of free fatty acids in the plasma is increased by the formation of a fatty acid – 
albumin complex. Over 90% of plasma fatty acids are present as esters, which are associated with 
proteins other than albumin to increase their solubility (Fredrickson and Gordon, 1958). Blood-
borne TAG is an important source of myocardial fatty acids. These hydrophobic TAG molecules 
form the core of lipoprotein articles, such as Very Low Density Lipoproteins (VLDL) and 
chylomicrons, which are surrounded by a hydrophilic layer composed of phospholipids, 
cholesterol and apoproteins. 
The transport of fatty acids to the myocardium requires that they first cross the endothelial cell 
barrier surrounding the myocardium. Due to its large size, albumin cannot diffuse between 
endothelial cells, so the transport of fatty acids through the endothelium in complex with albumin 
is unlikely (Den et al.; 1992). The release of fatty acids from albumin is believed to involve the 
binding of albumin to the luminal surface of the endothelial cell followed by the direct transfer of   73 
the fatty acids (Bassingthwaighte  et al.; 1989). Although endothelial  cells are capable of 
internalising lipoprotein particles, the majority of fatty acids transported as TAG are obtained by 
its hydrolysis, at the endothelial cell surface through the action of lipoprotein lipase (Cryer et al.;  
1989). The rate of hydrolysis of the circulating TAG is largely dependent on TAG concentration 
in the circulation and the amount of LPL at the endothelials luminal surface. The full activity of 
LPL also depends on the presence of apoprotein CII which is found on the surface of lipoproteins. 
The accumulation of free fatty acids and monoacylglycerols inhibit the hydrolytic activity of LPL 
(Crona et al.; 1987). The short-term regulation of LPL activity is mainly due to alterations in the 
rates of secretion and loss of enzyme from the endothelial cell surface. The long-term regulation 
of LPL activity is likely to occur as a result of alterations in the rates of enzyme synthesis and 
degradation within the myocytes. Rats treated with corticosteroids, adrenocorticotrophic hormone 
(ACTH) and thyroxine showed a long-term stimulation of total activity. Diabetes has also been 
shown to increase LPL activity in the heart (Stam et al.; 1984). The increase in LPL activity 
which occurs during fat feeding is likely to be due to glucocorticoids (Pedersen et al.; 1981). 
Unlike skeletal muscle, where it causes a decrease in LPL synthesis, in the heart, insulin does not 
alter LPL activity (Stam et al.; 1984). 
Hormone-Sensitive Lipase (HSL) is the enzyme responsble for hormonally stimulated lipolysis. It 
has been shown to be present in tissue other than adipocytes, including heart and skeletal muscle 
(Small et al.; 1989). HSL can be regulated by phosphorylation /dephosphorylation reactions. Two 
sites have been identified which are phosphorylated both in vitro and in vivo. Residue 563 has 
been idetified in rat HSL as the position which is phosphorylated by PKA in response to lipolytic 
stimulation (Garton et al.; 1988). A second phosphorylation site is located at residue 565 in the 
rat sequence (Stralfors   et al.; 1984). A number of protein kinases act at this site, including 
AMPK (Garton et al.; 1989). The activity of HSL can also be regulated by protein phosphatases, 
such as protein phosphatase 1, 2A and 2C.   74 
When blood sugar is low, glucagon signals the adipocytes to activate hormone sensitive lipase, 
and to convert TAG into free fatty acids. These have very low solubility in the blood, typically 
about 1 μM. However, the most abundant protein in the blood, serum albumin, binds free fatty 
acids, increasing their effective solubility to ~ 1 mM. Thus, serum albumin transports fatty acids 
to organs such as the muscle, heart and liver for oxidation when the blood sugar is low. Fatty acid 
degradation is the process whereby fatty acids are broken down, resulting in a release of energy.  
1.6.1 Fatty acids 
Fatty acids are carboxylic acids with long hydrocarbon chains. The hydrocarbon chain length may 
vary from 10-30 carbons (commonly 12-18 in mammals). In acids with only a few carbons, the 
acid functional group dominates and gives the whole molecule a polar character. However, in 
long chain fatty acids, the non-polar hydrocarbon chain gives the molecule a non-polar character. 
1.6.1.1 Fatty acid oxidation 
Fatty acid oxidation is an important metabolic process carried out in the mitochondria.  Heart 
fatty acids are the central source of energy under a variety of conditions (Neely and Morgan 
1974). The pathway and enzymology of mitochondrial fatty acid oxidation have been reviewed 
(Schulz et at.; 1991). The first step on this pathway is the cellular uptake of free fatty acids. The 
mechanism of this process remains a matter of dispute, with some studies concluding that plasma 
free fatty acids enter the cells by a carrier mediated uptake, and others claiming that the uptake 
occurs due to the spontaneous diffusion of fatty acids across the cellular membrane. In the 
cytosol, free fatty acids are associated with fatty acid-binding proteins (FABPs). Because all of 
the tissues active in fatty acid metabolism contain at least one of these low-molecular weight 
proteins, they have been proposed to function in fatty acid uptake and intracellular transport. 
Fatty acids are trapped within the cells due to their conversion to CoA thioesters catalyzed by 
acyl-CoA synthetases. The long-chain acyl-CoA synthetases are membrane-bound enzymes that   75 
are connected with the outer mitochondrial membrane as well as with the endoplasmic reticulum 
and peroxisomes.  
Medium-chain acyl-CoA synthetase is present in the mitochondrial matrix, whereas short-chain 
acyl-CoA synthetase is located both in the cytosol and in the mitochondrial matrix. Because the 
inner mitochondrial membrane is a barrier to free CoA (CoASH) and acyl-CoA, fatty acyl 
residues are carried across this membrane as carnitine esters. Carnitine palmitoyltransferase I 
(CPTI), which is located at the outer mitochondrial membrane, transfers fatty acyl residues from 
CoA to L-carnitine. The resulting fatty acyl carnitines pass through the inner mitochondrial 
membrane via carnitine: acylcarnitine translocase by 1:1 exchange for carnitine or other 
acylcarnitines, including acetylcarnitine.Carnitine palmitoyltransferase II (CPTII) associated with 
the mitochondrial inner membrane catalyzes the transfer of fatty acyl residues back from carnitine 
to acyl- CoA in the mitchondrial matrix. 
 Medium-chain fatty acids, in contrast to long-chain ones, can pass directly through the inner 
mitochondrial membrane and can be activated in the matrix by medium-chain acyl-CoA 
synthetase. Acyl-CoA, created in the matrix from long-chain acylcarnitines or medium-chain 
fatty acids, are substrates for the β-oxidation spiral that yields acetyl-CoA, NADH, and FADH2. 
The latter two compounds are reoxidized by the mitochondrial electron transport chain, whereas 
acetyl-CoA is oxidized to CO2 by the tricarboxylic acid cycle which regenerates CoASH. The 
enzymes catalyzing the reactions of the β-oxidation spiral are acyl- CoA dehydrogenase, enoyl-
CoA hydratase, L-3-hydroxyacyl-CoA dehydrogenase, and 3-ketoacyl-CoA thiolase. At least two 
isoforms of each of the four enzymes are present in mitochondria. The isozymes which have 
different but overlapping chain length specificities cooperate during the complete degradation of 
fatty acids to acetyl-CoA.  Because  the  intermediates  of  β-oxidation do not build up to any 
significant extent and because the ability of this process dramatically declines when the 
mitochondria are disrupted, it  has  been  speculated  that  the  enzymes  of  β-oxidation exist as   76 
organized complexes in involvement with the inner mitochondrial membrane. This situation 
makes it impossible to study the regulation of β-oxidation with soluble mitochondrial extracts. 
The rate of fatty acid β-oxidation in the heart depends on the availability of exogenous fatty acids 
and on the utilization of energy by the tissue (Neely and Morgan 1974). Because the release of 
free fatty acids from the adipose tissue is regulated via hormone-sensitive lipase (Stralfors et al), 
hormones like glucagon, adrenaline and insulin indirectly influence myocardial β-oxidation by 
controlling the availability of substrate. 
 1.6.1.2 Ketone Bodies 
Ketone bodies are molecules that the body makes when there is insufficient insulin in the blood 
and it must break down fat instead of glucose for energy. The ketone bodies, acetoacetate, and β-
hydroxybutyrate are acidic and are harmful when in excess.  Acetoacetate and β-hydroxybutyrate 
are formed from fatty acids by the liver, and are transported in the bloodstream for use as 
metabolic fuel by other tissues. Acetoacetate is chemically unstable and breaks down to acetone, 
which is poorly metabolized, and is excreted in the urine and on the breath. 
The  heart  extracts  and  oxidizes  ketone  bodies  (β-hydroxybutyrate
  and acetoacetate) in a 
concentration-dependent way (Chen et al.; 1984).  Plasma ketone bodies are produced from  fatty 
acids
 in the liver, and the arterial plasma concentration in the fed state is normally
 very low; thus 
they are normally a minor substrate for the myocardium.
 Through starvation or poorly-controlled 
diabetes, plasma ketone
 body concentrations rise as result of low insulin and
 high fatty acids, and 
they become a significant substrate for the
 myocardium (Avogaro et al.; 1990). 
 
 Cardiac fatty acid oxidation is inhibited by ketone bodies oxidation
  (Forsey  et  al.; 1987), 
Lammerant et al.; 1985). The  diabetic myocardium has
 a relatively low rate
 of fatty acid uptake 
and a high rate of β-hydroxybutyrate uptake (Hall  et al.; 1996), signifying that, in diabetic   77 
patients,
 raised plasma ketone concentrations can act to inhibit fatty
 acid uptake and oxidation. 
Clinical studies demonstrate that high fatty acids
 result in an increase in plasma ketone body 
concentration
 that appears to be secondary to elevated fatty acid levels (Lommi et al.; 1997);
 
however, data on myocardial ketone body metabolism have not
 been reported from animals or 
patients with high fatty acids. The biochemical
 mechanisms responsible for the inhibition of fatty 
acid β-oxidation
 by ketone bodies are not well understood, but do not appear
 to be related to 
changes in malonyl-CoA or the acetyl-CoA/
 CoA ratio (Stanley  et al.; 2003). 
 Raising the rates of β-hydroxybutyrate and acetoacetate
  oxidation could inhibit fatty acid β-
oxidation by increasing
 the intramitochondrial ratio of NADH to NAD
+ which would inhibit
 the 
ketoacyl-CoA dehydrogenase step of the fatty acid β-oxidation
 spiral (Kunau et al.; 1995). Vusse 
and workers recently showed
  that palmitate oxidation was considerably enhanced in isolated
 
cardiomyocytes from streptozotocin diabetic rats in the absence
 of acetoacetate; however, when 
measurements were made in the presence of ketone bodies, the rate of palmitate oxidation was
 not 
influenced by diabetes (Vusse et al.; 2003). They also noted a greater fatty acid
 uptake in the 
myocytes of diabetic rats and suggested that ketone-induced impairment of fatty acid oxidation 
might be accountable
 for the greater TAG storage in the heart with diabetes
 (Denton and Randle 
1967).
  
 1.6.1.3 Acetyl-CoA Carboxylase 
.Acetyl-CoA carboxylase  (ACC) is a biotin-dependent enzyme that catalyzes the irreversible 
carboxylation of acetyl-CoA to produce malonyl-CoA through its two catalytic activities: biotin 
carboxylase and carboxyltransferase. 
Mammalian ACC is expressed as two proteins, termed ACC265,000, ACC-1 or ACC-α and ACC 
280,000, ACC-2 or ACC-β.  ACC-  α  is  thought  to  function  more,  but  not  exclusively,  as  a   78 
provider of malonyl-CoA for lipogenesis, wherease ACC- β is thought to function primarily as 
source of malonyl-CoA  to  regulate  CPT1  and  control  mitochondrial  β-oxidation. ACC-  α  is 
essential for embryonic development in mice (Abu-Elheiga et al.; 2005). It is the most abundant 
form of ACC protein in lipogenic tissue such as liver, white adipose tissue, and mammary gland 
(Bianchi A et al.; 1990) but it also found in other tissues such as heart (Saddik   et al.; 1993) and 
pancreatic islet (Louis et al.; 1988). Knockout of the ACC β gene results in a nonlethal phenotype 
in which animal have increased β-oxidation in liver and muscle, are lean, and hyperphagic. These 
animals are resistant to obesity and diet-induced diabetes. In muscle, they have a decreased 
malonyl-CoA content wherease hepatic malonyl-CoA is unchanged (Abu-Elheiga et al.; 2002). 
Compared with ACC-α  ACC-  β  has  approximately  140  extra  amino  acid  residues  as  its  N-
terminus, which contains a motif that allows targeting and /or binding to the mitochondrial outer 
membrane. It suggested that this could permit control of the malonyl-CoA concentration near the 
malonyl- CoA binding site of CPT1 (Kim et al.; 1997). 
 
Regulation of ACC activity can be by allosteric effectors and reversible phosphorylation. Citrate 
is an important feed-forward activator of ACC increasing its activity in vitro up to 50 fold (Hardie 
and Guy 1980). However changes in cellular citrate concentration do not always correspond to 
change in ACC activity and sensitivity of ACC to citrate. 
Long  –chain fatty acyl  CoA  thioesters  allosterically  inhibit  ACC.  ACC  α  contains  several 
potential serine phosphorylation sites. Those phosphorylated by protein kinase A (PKA) ( Ser 
1200) and AMPK(Ser79) produce inactivation of ACC in vivo. AMPK and PKA both increased 
the Ka  for  citrate.  Nutritional  and  hormonal  control  of  ACCα  gene  expression  occurs.  ACC 
expression is decreased in liver and white adipose tissue by fasting and diabetes and is restored by 
reefeding but these manipulations have no appreciable effect on ACC expression in muscle tissue 
(Barber et al.; 2005). 
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1.7
 Citric acid cycle 
Under aerobic conditions acetyl-CoA derived from glucose or fatty acids is completely oxidized 
to CO2 by the mitochondrial enzymes of the citric acid cycle. This series of reaction generates 2 
molecules of CO2 3NADH and 1 FADH2. NADH and FADH2 produced during glycolysis, β-
oxidation and the citric acid cycle are oxidized in the presence of molecular O2 by the electron 
transport chain to drive ATP synthesis and regenerate NAD
+ and FAD. Although molecular O2 is 
not directly involved in the enzymatic reaction, the citric acid cycle can operate only under 
aerobic conditions as O2 is necessary for the regeneration of the NAD+ and FAD cofactors. 
The rate of flux through the citric acid cycle is adjusted to meet the cellular ATP requirements. 
The most crucial regulator of cycle activity are its substrates acetyl-CoA, oxaloacetate and NAD
+.  
Acetyl-CoA and oxaloacetate are present in mitochondria at concentrations below the Km for 
citrate synthase (LaNoue et al.; 1970), and changes in their levels result in an altered rate of this 
reaction. Production of acetyl-CoA from pyruvate and fatty acids is controlled by PDH and the β-
oxidation reactions respectively. When heart are perfused with octanoate ,acetyl-CoA for citrate 
synthase is derived from β-oxidation, a situation which favours pyruvate carboxylation (Comte et 
al.; 1997) Under these conditions the high availability of both acetyl- CoA  and oxloacetate 
favours the formation of citrate. Oxaloacetate can also be formed from malate, the concentrations 
of both vary according to the NADH:NAD
+. Under conditions where intrmitochondrial NADH 
decreases there is increased conversion of malate to oxloacetate and greater flux through the 
citrate synthase reaction n (Bowman 1966). Aspartate transamination is also an important 
mechanism for the generation of oxaloacetate. 
Two other mechanisms are involved in regulating citric acid cycle activity. First the redox state of 
FAD and NAD
+  and secondly the allosteric control of citrate synthase and dehydrogenase 
reactions ( LaNoue et al.; 1970). Four   reactions require NAD
+ or FAD, the concentrations of 
which fall when the cellular energy status is high. High ATP levels reduce the activity of citrate 
synthase by increasing the Km  for acetyl-CoA, and also inhibit the isocitrate dehydrogenase   80 
reaction. Isocitrate dehydrogenase is inhibited by NADH and stimulated by ADP which decrease 
the Km for reaction substrates isocitrate and NAD
+ . α-ketogluarate dehydrogenase is inhibited by 
its reaction products succinyl-CoA, an effect enhanced by NADH. Both isocitrate dehydrogenase 
and  α-ketoglutarate dehydrogenase can be activated by increases in mitochondrial Ca
++ 
concentration (McCormack et al.; 1990). 
1.8 Oxidative phosphorylation 
In eukaryotes, oxidative phosphorylation occurs in the mitochondrial cristae. It comprises the 
electron transport chain that establishes a proton gradient (chemiosmotic potential) across the 
inner membrane by oxidizing the NADH and FADH produced from the Krebs cycle and β-
oxidation and other processes. ATP is synthesised by the ATP synthase enzyme when the 
chemiosmotic proton gradient is used to drive the phosphorylation of ADP. The electrons are 
finally transferred to exogenous oxygen, with the addition of two protons to form water.  
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1.9 Hormones 
1.9.1 Insulin 
Insulin that is produced in the Islets of Langerhans in the pancreas is a polypeptide hormone that 
regulates carbohydrate and lipid metabolism.  Insulin stimulation of glucose transport is due to 
increased translocation of GLUT4 transporters to the plasma membrane from intracellular storage 
vesicles.  The protein phosphatase inhibitor okadaic acid is able to mimic the effect of insulin on 
glucose transport in muscle (Tanti et al.; 1991) and adipose tissue (Lawrence  et  al.;  1990), 
implying that an insulin stimulated phosphorylation event promotes GLUT4 recruitment.  This 
effect is indirect in that the phosphorylation state of the glucose transporter itself is unchanged. 
Inclusion of insulin in heart perfusion media containing 5mM glucose and 0.4mM palmitate 
results in increased rates of glucose oxidation (Sakamoto  et al.; 2004), an effect which was 
overcome by increasing the concentration of palmitate to 1.2mM (with 20 mM glucose).  Insulin 
has also been shown to enhance glycogen synthesis and inhibit glycogenolysis in perfused rat 
hearts (Goodwin et al.; 1995).  These effects are due to insulin modulation of the activities of 
glycogen synthase and phosphorylase. 
Insulin causes dephosphorylation and activation of glycogen synthase, an effect mediated by the 
inactivation of glycogen synthase kinase-3, as well as dephosphorylation and inactivation of 
glycogen phosphorylase.  Taken together with the hormonal stimulation of glucose uptake these 
two dephosphorylation events explain the increased tissue glycogen content of tissues exposed to 
insulin.   
 
In addition to its role in regulating glucose metabolism, insulin stimulates lipogenesis, diminishes 
lipolysis, and increases amino acid transport into cells. Insulin also  modulates transcription, 
altering the cell content of numerous mRNAs. It stimulates growth, DNA synthesis, and cell 
replication, effects that it holds in common with the insulin-like growth factors (IGFs) and   82 
relaxin. Insulin has been shown to inhibit AMPK activity in the heart (Gamble and Lopaschuk 
1997; Clark et al.; 2004). This effect was shown to be independent of changes in the AMP/ATP 
ratio (Beauloye et al.; 2001). Moreover, insulin markedly decreased the extent of the AMPK 
activation and Thr172 phosphorylation increased by ischemia or anoxia by a mechanism which 
was again independent of the AMP/ATP and Cr/CrP (Soltys et al.; 2006).  
1.9.1.1 Insulin Receptor 
The insulin receptor is a transmembrane glycoprotein with four subunits, two α2 and  two β2. The 
extracellular α-subunit contains the insulin-binding site, and the intracellular portion of β-subunit 
contains a tyrosine kinase domain. The insulin receptor gene is mapped to the short arm of human 
chromosome 19, and it contains 22 exons (Ebina et al.;1985; Ullrich et al.; 1985). The insulin 
receptor is synthesized as a single polypeptide precursor. Following its transport to the plasma 
membrane, two monomers aggregate to form a dimeric proreceptor which is then cleaved at the 
four-amino-acid site (RKRR) to produce the heterotetrameric insulin receptor (Alarcon et al.; 
1995). The insulin receptor is expressed ubiquitously. The highest levels are found in major 
insulin target tissues (e.g., liver, skeletal muscle and adipose tissue), and lower levels are found in 
relatively insulin-unresponsive tissues (e.g., circulating erythrocytes and brain) (Bruning et al.; 
2000).  
The insulin receptor gene is alternatively spliced to yield two isoforms that differ by the absence 
or presence of exon 11. In the carboxyl terminus of α subunit, isoform A (IR-A) lacks the amino 
acids encoded by exon 11 that are present in isoform B (IR-B). The functional difference between 
IR-A and IR-B is small, except that IR-A has a higher affinity for insulin and IGF-1 (Amaguchi et 
al.; 1995) and mediates an accelerated rate of receptor mediated insulin internalization (Vogt  et 
al.; 2003). 
 In normal Sprague-Dawley rats, IR-B is the predominant isoform of insulin receptor expressed in 
liver, adipose tissue, and kidney, whereas IR-A is predominant in muscle, hypothalamus and 
cerebral cortex (Luo et al.; 1998). A similar distribution pattern was observed in cell lines of   83 
corresponding tissue origins (Moller et al.; 1989). The biological significance of having two 
isoforms of IR is still unclear. Isoform switching of the insulin receptor has been documented 
during development, with a higher percentage of IR-A in early stages, and a higher expression of 
IR-B in the adult (White, et al.; 2002). A similar shift in expression patterns of the two isoforms 
has been reported in diabetes; however, this issue remains inconclusive due to contradictory 
evidence (Sbraccia et al.; 1998).  
1.9.1.2    Insulin Receptor Substrate-1  
IRS-1 acts as a docking protein that mediates multiple interactions among other proteins in cells. 
It plays a key role in transmitting signals from the insulin and insulin-like growth factor-1 (IGF-
1) receptors to intracellular pathways such as PI3K / Akt and Erk / MAP kinase pathways. The 
insulin receptor is composed of two extracellular α subunits and two transmembrane β subunits 
linked together by disulphide bonds. Binding of insulin to the α subunit induces a conformational 
change resulting in the autophosphorylation of a number of tyrosine residues present in the β 
subunit (Obberghen et al.;  2001). These residues are recognised by phosphotyrosine-binding 
(PTB) domains of adaptor proteins such as members of the insulin receptor substrate family (IRS) 
(Saltiel and Kahn 2001). Receptor activation leads to the phosphorylation of key tyrosine residues 
on IRS proteins, some of which are recognised by the Src homology 2 (SH2) domain of the p85 
regulatory subunit of PI 3-kinase (a lipid kinase). 
IRS-1 plays an important biological function for both metabolic and mitogenic (growth 
promoting) pathways. Mice deficent in IRS1 have only a mild diabetic phenotype, but 
pronounced growth restriction. IRS-1 knockout mice only reach 50% of the weight of normal 
mice. IRS-1 may also play a role in cancer, as it has been shown that transgenic mice 
overexpressing IRS-1 develop breast cancer (Dearth et al.; 2006). The cellular protein levels of   84 
IRS-1 are regulated by the Cullin7 E3 ubiquin ligase, which targets IRS-1 for ubiquitin mediated 
degradation by the proteasome (Sarikas et  al.;  2008). 
 
1.9.1.3 Phosphoinositide 3-kinases 
PI3Ks are lipid kinases that phosphorylate the inositol ring of phosphatidylinositol (PtdIns) and 
various phosphatidylinositol phosphates at the 3 position. PI3Ks are grouped into three classes; 
classes I, II, and III. In vivo, class I PI3Ks predominantly phosphorylate PtdIns (4, 5) P2 to 
generate PtdIns (3, 4, 5)P3, whereas class II and III mainly phosphorylate PtdIns to generate 
PtdIns (3) P (Oudit et al 2004). 
Class I 
 
 The class I PI3Ks are heterodimeric enzymes consisting of catalytic and regulatory adaptor 
subunits, and they are further divided into class IA and IB. There are three isoforms for class IA 
catalytic subunits; p110α, p110β, and p110δ, and three isoforms for the adaptor subunit; p85α, 
p85β, and p55γ. The class IB PI3K (PI3Kγ) is composed of the catalytic subunit p110γ tightly 
bound to the regulatory subunit p101. The adaptor subunits for the class IA PI3Ks contain a SH2 
domain as well as a p110 binding domain, and they recruit the catalytic subunit to the plasma 
membrane upon tyrosine phosphorylation following, for example, receptor tyrosine kinase 
activation by insulin. In contrast, the regulatory subunit of PI3Kγ lacks the SH2 domain. Instead, 
both the catalytic and regulatory subunits of PI3Kγ contain the binding sites for Gβγ (Wymann et 
al 2003). PI3Kγ is recruited and activated by Gβγ following activation of GPCRs (Stephens et al 
1997; Alloatti et al 2004; Naga Prasad et al 2000).  Both class IA PI3Ks and PI3Kγ catalytic 
subunits also contain the C2 domain involved in phospholipid binding, the PIK domain involved   85 
in protein-protein interaction, and the Ras binding domain. Ras-GTP binding enhances the 
catalytic activity of both class IA PI3K and PI3Kγ (Wymann et al 2003). 
Class II and Class III 
Class I PI3K is differentated from class PI3KS II and III by its function and structure. 
Class II unlike class I and III  has no regulatory protein. It has three catalytic isoform (C2α, C2β, 
and C2γ). These enzymes catalyze the formation of PI (3)P from PI  and may also produce 
PI(3,4)P2 from PI(4)P). C2α and C2β are widely expressed through the body, however expression 
of C2γ is limited to hepatocytes. The distinct feature of Class II PI3Ks is the C-terminal C2 
domain. This domain lacks vital Asp residues to coordinate binding of Ca
2+, which suggests class 
II PI3Ks bind lipids in a Ca
2+ independent manner. 
Class III are similar to class II in that they control the production of PI(3)P from PI, but are more 
similar to class I in structure, as they remain as heterodimer of a catalytic(Vps34) and a 
regulatory (p150) subunit. Class III seems to be principally involved in the trafficking of protein 
and vesicles. There is however, evidence that they are able to contribute to the usefulness of 
several process important to immune cells, not least phagocytes. 
 
Mechanism 
PI3-kinases formed 3-phosphorylated phosphoinositide which are (PtIlns3P, 
PtdIns(3,4)P2  PtdIns(3,5)P2  and PtdIns(3,4,50P3) function in a mechanism by which 
various group of signalling protein, containing a  pleckstrin homology domains (PH) PX 
domain, FYVE domain and other phosphoinositide-binding domains, are recruited to a 
variety of cellular membranes. PI3-kinases are inhibited by the worttmanin drugs except 
class 11 PI3-kinase family shows decreased sensitivity to the drugs.  
An extraordinary varied group of cellular functions have been linked to PI3-kinase 
including cell growth, motility, proliferation, differentiation and intracellular trafficking. 
Many of these functions associate to ability of class 1 PI 3-kinase to activate protein 
kinase B (PKB, Akt). The class 1A PI 3kinase p110α is mutated in many cancers cells. M 
any of these mutations cause the kinase more active .The PtdIns (3,4,5)P3 phosphatase   86 
PTEN which atagonised PI 3-kinase signalling is absent from many tumors. The p110δ 
and p110γ isoform regulate different aspect of immune responses. PI 3-kinase plays a key 
role in insulin signaling pathway. Hence there is great interest in the role of PI 3-kinase 
signaling in diabetes mellitus.  PKB activation require PI3-kinase signalling pathway in 
order to be translocated to the plasma membrane. At P1P3, PKB is then phosphorylated by 
other kinases called phosphoinositide dependent kinase1 and 2 (PDK1) (PDK2), and is 
thereby activated. 
The "PI3-k/Akt" signaling pathway has been shown to be needed for an extremely various 
selection of cellular activities - most notably cellular proliferation and survival. 
 
1.9.1.4 Protein kinases PDK-1 PDK-2 
  PDK1 and PDK2 are distinct kinases in insulin signalling pathway. PDK1 is predominantly 
localized in the cytosol, whereas PDK2 is associated with both the plasma membrane (PM) and 
low density microsomes (LDM). Further characterization of the PM fraction using high salt 
extraction and differential centrifugation revealed that PDK2 activity co-sediments with a  
subpopulation of the PM fraction that is enriched in proteins associated with the actin 
cytoskeleton, including proteins present in focal adhesions but that this fraction is devoid of 
PDK1 activity (Richard  et al.;2000). PDK2 is responsible for phosphorylation of Akt at Ser-473. 
The protein kinase responsible for phosphorylating  Akt  on Thr-308 is the recently identified 
phosphoinositide-dependent PDK1 (Alessi et al.; 1997).   
 
1.9.1.5 Protein kinase B (PKB) / Akt 
 
Akt  is a serine/threonine kinase, has emerged as an  essential enzyme in signal transduction 
pathways implicated in cell proliferation, apoptosis, angiogenesis, and diabetes. In mammals, 
three isoforms of Akt (Akt 1, 2, 3) are reported to show a high degree of sequence homology, but 
vary slightly in the localization of their regulatory phosphorylation sites. Akt1 is the main isoform 
in most tissues, whereas the highest expression of Akt2 is observed in the insulin-responsive   87 
tissues (Garofalo et al.; 2003) and Akt1 is abundant in brain tissue (Hemmings et al.; 2004). Akt2 
is an important signaling molecule in the Insulin signaling pathway. It is required for insulin to 
stimulate glucose transport. The role of Akt3 is less clear, though it appears to be predominantly 
expressed in brain. It has been reported that mice lacking Akt3 have small brains (
 Hemmings et 
al.; 2004).   
 
The activation of PKB by PI3K involves the recruitment of PKB to the plasma membrane 
through the interaction of PtdIns(3,4,5)P3  with the PH domain, and phosphorylation by the 
phosphoinositide dependent  kinase 1 (PDK1), which is also recruited to the membrane by the PH 
domain. PDK1 phosphorylates PKB at Thr308 in the catalytic domain (Mora et al 2004). PtdIns 
(3,4,5)P3  is thought to promote the phosphorylation of PKB by PDK1 by causing a 
conformational change of PKB which exposes Thr308 and by bringing constitutively active 
PDK1 to the proximity of PKB (Alessi et al 1997 and 1998; Stokoe et al 1997; Anderson et al 
1998). PKB is additionally phosphorylated at Ser473 in the C-terminal hydrophobic region (‘the 
PDK2 site’). The identity of the kinase(s) that phosphorylates Ser478 is the subject of intense 
investigation (Dong and Liu 2005).  Several candidate kinases, including mTOR/rictor complex, 
have been reported (Dong and Liu 2005). The Thr308  phosphorylation is essential for PKB 
activity. The role of Ser473 is less clear but it may stabilise the active configuration and/or it may 
assist the phosphorylation of Thr308 by PDK1 (Dong and Liu 2005). However, Thr308 
phosphorylation has been seen in the absence of Ser473 (Morisco et al 2005).  
In neonatal and adult rat cardiac myocytes, isoproterenol or β2 receptor stimulation has been 
shown to increase PKB activity (as measured by GSK3α phosphorylation) and/or phosphorylation 
of Ser478 (Morisco et al 2000; Zhu et al 2001). It has been reported that phenylephrine does not 
affect Ser478 phosphorylation of PKB in adult rat cardiac myocytes, suggesting PKB may not be 
downstream of the α1 receptor (Wang et al 2001). However, the lack of PKB phosphorylation 
under conditions that increase PI3K activity has been reported by several other studies (Till et al   88 
2000; Zou et al 2002 and 2003) and it may be due to compartmentation of PI3K signalling. The 
activation of PKB by the β adrenergic receptor is sensitive to inhibitors of PI3K (Morisco et al 
2000; Zhu et al 2001). However, several observations suggest that PKB may also be activated by 
PI3K-independent pathways. It has been shown in 293 cells that cAMP-raising agents activate 
PKB by a PKA-dependent but PI3K-independent pathway (Fillippa et al 1999). The activation of 
PKB by cAMP-raising agents was associated with increased phosphorylation of Thr308 but it 
was seen in the absence of Ser473 phosphorylation (Fillippa et al 1999). This is in contrast to the 
activation of PKB by insulin, which required phosphorylation of both Thr308 and Ser473 
(Fillippa et al 1999). It appears that the increase in Thr308 phosphorylation by cAMP-raising 
treatments is not due to direct phosphorylation of PKB by PKA (Fillippa et al  1999). The 
possibility that PKB is also activated by the PKA pathway in cardiac myocytes is supported by 
the recent study by Morisco et al  (Morisco  et al  2005). These investigators showed that 
isoproterenol caused phosphorylation of PKB at Thr308 and Ser473 with different time-courses; 
the phosphorylation of Thr308 could be detected within 1 minute of stimulation and it returned to 
the basal level after 60 minutes, whereas the phosphorylation of Ser 473 increased after 10 
minutes and was sustained for 2 hours (Morisco  et al  2005). They showed that the early 
phosphorylation of Thr308 (10 minutes), but not the later phosphorylation of Ser473 (60 
minutes), was insensitive to wortmannin (Morisco et al 2005). The phosphorylation of Thr308 
was blocked by H89, nifidepine, or KN93, suggesting the possibility that PKA regulates PKB 
phosphorylation through activation of the L-type Ca
2+  channel and CAMKII (Morisco et al 
2005). How Ca
2+/CAMKII might be linked to PKB is not clear.  
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Figure 1.6:  Mechanism of activation of PKB/Akt. The activation of PKB requires the 
phosphorylation of its both site Thr308 or Ser 473. Following growth factor (GF) activation of 
receptor tyrosine kinases (RTKs, or other cell surface receptors, not shown), PI-3K is recruited to 
the receptor and activated resulting in the production of PIP3.  The translocation of PKB/Akt to 
the membrane where it is phosphorylated on Th308 within the catalytic domain by PDK-1 and on 
S473 within the regulatory domain by defined mechanism, possibly involving (a) 
autophosphorylation, (b) PDK-1, (c) integrin-linked kinase( ILK), or (d) an unidentified PDK-2. 
PKB/Akt is then released from the membrane and translocates to other subcellular compartments. 
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1.9.2 Catecholamines 
Circulating catecholamines, adrenaline (A) and noradrenaline (NA), originate from two 
sources. A is released by the adrenal medulla upon activation of preganglionic sympathetic 
nerves innervating this tissue. This release activation occurs during times of stress (e.g., 
exercise, heart failure, hemorrhage, emotional stress or excitement, pain). Adrenergic agents 
increase the force and rate of heart contraction as well as decreasing the rate of heart 
relaxation. 
 During adrenergic stimulation of the heart, fatty acid, glucose oxidation and glycolysis are 
stimulated but glucose use is preferentially increased over fatty acid oxidation. In perfused 
working rat heart adrenergic stimulation increased ATP production by 50% and this was 
related with an increase in glycolysis, glucose oxidation and moderate 10% fatty acid 
oxidation (Collins et al.; 1994). Adrenaline increased glucose oxidation through an increase 
in Ca
2+ and activation of PDH. The increase in glycolytic rate in response to adrenaline could 
be due to stimulation of PFK-2 via PKA phosphorylation. 
NA is also released by the adrenal medulla (about 20% of its total catecholamine release is 
NA). The primary source of circulating NA is spillover from sympathetic nerves innervating 
blood vessels. Normally, most of the NA released by sympathetic nerves is taken back up by 
the nerves (some is also taken up by extra-neuronal tissues) where it is metabolized. A small 
amount of nonadrenaline, however, diffuses into the blood and circulates throughout the 
body. At times of high sympathetic nerve activation, the amount of NA entering the blood 
increases dramatically. Catecholamine content increases substantially in heart during cardiac 
infarction (Rundqvist et al.; 1997).  
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1.9.4 Adipokines  
Adipokines (hormones secreted by adipocytes) either stimulate or inhibit AMPK activity. For 
example, adiponectin has been shown to stimulate AMPK activation, whereas resistin inhibits it. 
 1.9.4.1 Adiponectin 
Adiponectin is a recently described adipokine that has been recognized as a key regulator of 
insulin sensitivity and tissue inflammation. It is produced by adipose tissue (white and brown) 
and circulates in the blood at very high concentrations. It has direct actions in the liver, skeletal 
muscle and the vasculature, with prominent roles in improving hepatic insulin sensitivity, 
increasing fuel oxidation [via up-regulation of AMPK activity] and decreasing vascular 
inflammation (Yamauchi et al.; 2002). Adiponectin increased AMPK α Thr172 phosphorylation 
in HL-1 atrial cardiac myocyte cells (Pineiro et al.; 2005). It exists in the circulation as varying 
molecular weight forms, produced by multimerization. Recent data indicate that the high-
molecular weight (HMW) complexes undertake the predominant action in the liver. In contrast to 
other adipokines, adiponectin secretion and circulating levels are inversely proportional to body 
fat content. The levels are further reduced in subjects with diabetes and coronary artery disease. 
Adiponectin antagonizes many effects of tumour necrosis factor-alpha (TNF-alpha) and this, in 
turn, suppresses adiponectin production. Furthermore, adiponectin secretion from the adipocytes 
is enhanced by thiazolidinediones (which also act to antagonize the TNF-alpha effects). Two 
adiponectin receptors, termed AdipoR1 and AdipoR2, have been identified and these are 
ubiquitously expressed. AdipoR1 is most highly expressed in skeletal muscle and has a prominent 
action to activate AMPK, and hence promote lipid oxidation. AdipoR2 is most highly expressed 
in the liver, where it enhances insulin sensitivity and reduces steatosis via the activation of 
AMPK and increased peroxisome-proliferator-activated receptor alpha ligand activity. T-
cadherin, which is expressed in the endothelium and smooth muscle, has been identified as an 
adiponectin-binding protein with a preference for HMW adiponectin multimers. Given the low   92 
levels of adiponectin in subjects with the metabolic syndrome, and the beneficial effect of the 
adipokine in animal studies, there is exciting potential for adiponectin replacement therapy in 
insulin resistance and related disorders. 
1. 9.4.2 Leptin 
An adipocyte-derived hormone leptin has been shown to have different effects on AMPK in 
different tissues. Leptin activates α2 but not α1 AMPK in skeletal muscle (Minokoshi et al.; 
2002). However, leptin inhibits AMPK in the hypothalamus (Andersson et al.; 2004; Minokoshi 
et al.; 2004), while it seems to have no effect on AMPK in the perfused heart (Atkinson et al.; 
2002). The in vivo administration of leptin has been shown to activate AMPK by two pathways; 
the direct effect of leptin on  skeletal muscle itself  and an indirect slower effect through the 
hypothalamic-sympathetic nervous system (Minokoshi et al.; 2002). The direct effect of leptin 
seems to be mediated by the AMP-dependent pathway, as an increase in AMP was observed 
immediately after leptin administration (Minokoshi et al.; 2002). However, the delayed indirect 
effect is  likely to be mediated by the α1  adrenergic receptor via an AMP/ATP independent 
mechanism, as the in vivo  effect was sensitive to phentolamine and phenylephrine activated 
AMPK in isolated skeletal muscle (Minokoshi  et al.;  2002).  
1.9.4.3 Resistin 
Increasing resistin levels through
 peripheral infusion or transgenic overexpression impairs insulin
 
action (Pravenec et al.; 2003). Resistin is a cysteine-rich
 protein implicated in insulin resistance 
and inflammation
 (Mojiminiyi and Abdella, 2007). The ablation of the
 retn gene or reduction of 
resistin via antisense oligonucleotide
 treatment enhances insulin sensitivity, leading to a decrease
 
in hepatic glucose production and an increase in glucose uptake
 by the muscle and adipose tissue 
(Banerjee et al.; 2004). Furthermore, other studies suggest that
 an increase in resistin after high-
fat feeding is the primary
 cause of hepatic insulin resistance (Muse et al.; 2004) by inhibiting
 the 
activity of AMPK (Kahn et al.; 2005).   93 
1.10 Pathological alterations in cardiac energy metabolism 
 1.10.1 Diabetes 
Diabetes mellitus is the metabolic syndrome characterizes by the body’s inability to 
regulate blood sugar and lipid level. It is divided into two types.  
 Type  1  is characterized by the loss of insulin production beta cells of the islets of 
Langerhans in the pancreas, leading to the deficiency of insulin. 
  Type 11 is characterized by abnormal glucose and lipid metabolism because of insulin 
resistance inadequately compensated for by increased insulin secretion.  
 In uncontrolled diabetes, despite decrease carnitine content, the heart shows an increased 
dependence on fatty acid oxidation which is able to supply over 90% of the ATP required 
of the tissue (Wall and Lopaschuk 1989). High rates of fatty acids oxidation are due to 
the high plasma concentration of fatty acids in diabetic subjects, as well as decreased 
rates of glucose uptake from the circulation and an increase in the Km for glucose 
phosphorylation (Morgan et al.;  1961). The enhanced rates of fatty acids oxidation 
observed in diabetic heart has been proposed to involve the regulation of CPT1 by 
malonyl-CoA. No change in the sensitivity of CPT I to malonyl-CoA occurs in diabetic 
heart tissue, and the de-inhibition of the enzyme is associated with decreases in the 
malonyl-CoA concentration of diabetic pig heart (Hall et al.; 1996). This decreases in 
malonyl-CoA concentration is not associated with changes in the activity of either ACC 
or AMPK and has been proposed to result from the increased expression and activity of 
MCD measured in diabetic rat hearts ( Sakamoto et al.; 2000) 
Increased rate-s of β-oxidation is associated with increased production of both acetyl-
CoA and NADH, which are able to inhibit PDH. Glucose oxidation rates have been   94 
shown to be depressed in perfuced diabetic hearts compared to controls (Saddik and 
Lopaschuk 1994) 
Diabetic hearts also have large store of TAG compared to healthy tissue, and this is 
probably due to an increase fatty acyl-CoA content which results from increase fatty acid 
availability and the increased synthesis of CoASH observed in diabetic hearts 
(Lopaschuk  et al.; 1986). This expanded TAG pool can be rapidly mobilised and is able 
to provide 70% of the ATP requirements of diabetic hearts perfused in the absence of 
exogenous fatty acid ( Saddik and Lopaschuk 1994) 
1.10.2 Cardiac Hypertrophy 
The  development of hypertrophy by the heart is associated with congestive heart failure, 
increased risk of myocardial infraction and sudden death. The hypertrophied heart also undergoes 
metabolic alterations and impaired energy metabolism has been proposed to play a role in the 
deterioration of heart function. Decreases in total tissue creatine (Conway et  al.;  1999) and 
NADH (EI Alaoui-Talibi  et al.;  1997) levels have been measured in hypertrophied hearts 
implying an alteration in the intracellular energy reserve. Citrate synthase activity is reduced in 
hypertrophy and has been proposed to be responsible for the reduced oxidative capacity of 
affected heart (Kalsi et al.; 1999) 
1.10.2.1 Physiological Hypertrophy 
Heart continues to develop for a restricted period
 to adapt to increased workload. In particular 
after birth,  the left side
 of the heart undergoes hypertrophy, while the right side actually
 gets 
slightly smaller due to changes in blood pressure throughout
 the heart that happens soon after 
birth. The first few breaths
 after birth fill the lungs with air, decreasing afterload on
 the right side 
of the heart and increasing pulmonary vascular
 blood flow. This increases blood flow to the left   95 
side of the
 heart, increasing preload. Mean arterial blood pressure rises
 throughout the infant’s 
body and increases the mechanical
 after load on the heart. It is the increased workload on the
 
heart, particularly on the left side, that leads to increased
 heart size. The changes in cardiac size 
after birth result from
 both hypertrophy and hyperplasia of cardiomyocytes but as cardiomyocytes 
terminally  differentiate during the first few weeks of life;
  further increases in heart size 
throughout life are due principally
 to hypertrophy (Oparil et al.; 1994).
  
Cardiac hypertrophy also occurs following (typically long-term)
  exercise training. The heart 
increases in size and mass subsequent to
 resistance training such as weight lifting, although there 
is
  some discussion as to whether true hypertrophy occurs in this scenario.
  Normalizing the 
increased heart weight to the increased body
 weight of the athletes appears to greatly reduce the 
increased
 ratio typically observed in true hypertrophy (Oakley, 1992)
 Nevertheless, resistance 
athletes frequently
 demonstrate some degree of concentric hypertrophy (increased
 wall thickness 
with normal chamber dimensions). In the case
 of isotonic training (e.g., distance running), cardiac 
hypertrophy
 is much more noticeable and often presents as an eccentric hypertrophy
 (increased 
wall thickness with increased chamber dilation) (Oakley et al.; 
  1992).
  
1.10.2.2
 Pathological Hypertrophy 
Pathological forms of cardiac hypertrophy commonly occur following
  acute events, such as 
myocardial infarction, or associated
  chronic abuse such as hypertension. In these examples, 
hypertrophy
 is thought to be an attempt to relieve increased transmural
 wall stress in the heart by 
thickening the wall (Morisco et al.; 2003).  A range of inherited
 genetic disorders also results in 
cardiac hypertrophy as either
  a principal or secondary endpoint. For example, hypertrophic 
cardiomyopathy
 is an inherited disease that can result from a wide variety
 of genetic lesions, 
including mutations in contractile proteins
 such as ß-myosin heavy chain that may directly result
 
in cardiac hypertrophy (Arad et al.; 2002). Alternatively, hypertrophy
 may represent a secondary   96 
response to a distal lesion, such
 as that which occurs in pheochromocytoma, a tumor that wildly 
releases
 epinephrine and norepinephrine to continually activate adrenergic
 pathways in the heart 
(Prichard et al.; 1994). Pathologic hypertrophy
 thus typically represents an attempt by the heart to 
alleviate
 a stress or a response to unsuitable modification of prohypertrophic
 signaling pathways.
  
 A number of signaling pathways has been involved in the regulation of cardiac hypertrophy, 
although the exact mechanism that causes hypertrophy has not yet been resolved.  It has been 
proved that during chronic pressure overload AMPK activity increases (Tian et al.; 2006). This 
suggests that AMPK activation may cause a maladaptive alteration in the hypertrophy process or 
might be the cause of cardiac hypertrophy.  The AMPK pathway has been involved in the 
regulation of myocyte growth. This increase in AMPK activity in the hypertrophied heart also 
increases glucose uptake which accelerates glycolytic ATP production ( Tian et al.; 2001). In 
some situations, AMPK activation would appear to be helpful to heart. By contrast to this AMPK 
activation can become an enemy to cardiac function. The role of AMPK in the hypertrophic 
process may be variable depending on the severity of hypertrophy. 
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1.10.3 Ischemia 
Ischaemic heart disease, which is a common cardiovascular disease,
 cruelly endangers health and 
is a most important focus of medical studies
 (Lazzarino et al.; 1994; Pierce &  Czubryt, 1995) 
that are
 carried out at the level of the whole body (Toyoda et al.; 2000),
 whole heart (Cerniway et 
al.; 2002), tissue (Nishioka et al.; 1984)
 and single cardiomyocyte (Louch et al.;2002). The use
 of 
varied ischaemia-mimetics and models of cardiac ischaemic
 injury are essential to research into 
this condition.  
Cardiac ischemia is associated with an increase in AMP/ATP and activation of AMPK through 
the phosphorylation of Thr172 (Kudo et al 1995; Baron et al.; 2005). Sakamoto and co-workers 
studied the role of LKB1 in the activation of AMPK during ischemia using transgenic mice 
lacking cardiac expression of LKB1 (Sakamoto et al.; 2006). The deletion of LKB1 in the heart 
prevented the increase in the Thr172 phosphorylation of AMPK in response to ischemia, 
suggesting that LKB1 mediates the activation of AMPK during ischemia (Sakamoto et al.; 2006). 
However ischemia has been shown to have no effect on the catalytic activity of LKB1, as 
measured by in vitro phosphorylation of recombinant AMPK by LKB1 immunoprecipitated from 
the ischemic heart, or on the protein abundance of LKB1, although LKB1 purified from the heart 
is able to phosphorylate α312 (the truncated catalytic subunit which can be phosphorylated and 
activated in the absence of AMP), confirming the constitutive activity of LKB1 (Sakamoto et al.; 
2006; Altarejos et al.; 2005). Thus, as suggested for other AMP/ATP raising conditions, the 
phosphorylation of Thr172 by LKB1 during ischemia is also likely to be due to the effect of AMP 
to inhibit the dephosphorylation of AMPK by protein phosphatase.  
Recent studies suggest that in addition to LKB1, the activation of AMPK during ischemia also 
involves some other AMPKK which, unlike LKB1, is activated by ischemia. In the 
aforementioned study by Sakamoto and co-workers, whereas the Thr172 phosphorylation of α2   98 
AMPK induced by ischemia was completely abolished, ischemia could still increase the Thr172 
phosphorylation of α1 AMPK in LKB1-deficient hearts (Sakamoto et al.; 2006). This suggests 
that LKB1 is the major AMPKK mediating the α2 AMPK activation during ischemia but α1 
AMPK is also activated by some other AMPKK, as well as by LKB1 (Sakamoto et al.; 2006). 
Other groups found that although LKB1 can be completely precipitated with 5% PEG 6000 and it 
is not present in the supernatant, AMPKK activity still remained in the supernatant and this 
AMPKK activity was increased by ischemia (Altarejos et al.;  2005). Moreover, Baron et al have 
shown that the total AMPKK activity present in a heart homogenate is increased by ischemia 
(Baron et al.; 2005). Given that LKB1 activity is not increased by ischemia, this result further 
supports the idea that the activation of AMPK during ischemia involves an AMPKK whose 
catalytic activity is activated by ischemia. Whether this AMPKK is a CAMKK or a yet 
unidentified AMPKK is unknown. The mechanism by which ischemia activates this AMPKK 
also remain to be determined. However, AMP does not appear to activate this AMPKK as the 
total cardiac AMPKK in the study by Baron et al was not directly activated by AMP in vitro 
(Baron et al.;  2005).    
Recent studies have revealed that mild ischemia or hypoxia increases α-Thr172 phosphorylation 
and AMPK activity without affecting AMP/ATP or Cr/CrP (Altarejos et al.; 2005; Frederich et 
al.; 2005). This raises the possibility that during severe ischemia, AMPK is activated by two 
parallel pathways; the AMP pathway and a pathway which is independent of AMP but dependent 
on some factors that are generated or activated during mild ischemia or hypoxia. Despite the lack 
of changes in the high energy phosphates, Altarejos et al still observed the activation of the non-
LKB1 AMPKK activity present in the 5% PEG 6000 supernatant by mild ischemia (Altarejos et 
al.; 2005). Thus, this non-LKB1 AMPKK may be responsible for the activation of AMPK during 
hypoxia/mild ischemia and for AMP-independent activation of AMPK during severe ischemia. 
However the involvement  of LKB1 in the AMP-independent  activation  of AMPK during 
ischemia/hypoxia cannot be ruled out because it is conceivable that  ‘non-AMP factors’ may   99 
stimulate the phosphorylation of AMPK by LKB1 by modifying the interaction of AMPK with 
LKB1 or by modifying a property of AMPK such as the affinity of AMPK for AMP. Supporting 
the latter possibility, that hypoxia increases the sensitivity of AMPK to stimulation by AMP 
(Frederich et al.; 2005).   
1.11 Aims of the Project 
It is important to regulate the fuel consumed by the heart. During normal conditions, fatty acids 
are the most dominant fuel of the heart. High levels of fatty acids are detrimental to the ischemic 
myocardium and during reperfusion. Glucose is the principal fuel during numerous types of stress 
such as ischemia in which glycolysis is the only source of ATP for the heart. Regulation of fatty 
acid and glucose metabolism is essential under these conditions. Numerous studies have 
investigated the effects of AMPK in the regulation of energy metabolism in the heart during 
normal and pathological conditions. Recent studies have proved that AMPK can be regulated by 
hormones and nutrients. 
The aim of this project was to investigate the effect of glucose on AMPK phosphorylation in 
cardiac myocytes. This effect has previously been investigated in skeletal muscle (Samar I et 
al.;2003), where it was found that increasing glucose concentration caused inactivation of AMPK 
and a  decrease in AMPK  phosphorylation at α-Thr172. The approach in the present study was to 
investigate this effect on cardiac myocytes and to initially determine whether the effect is due to 
glucose or its metabolites. Glucose has multiple functions, when it is transported into the cells. It 
is  phosphorylated to generate glucose 6-phosphate, which can give rise to many metabolic 
products. 
 The objective of this study was to verify which pathway of glucose has the potential to inhibit 
AMPK activity and phosphorylation at α-Thr172 and then to establish the mechanism by which 
glucose affects AMPK activity and phosphorylation.   100 
Alteration of glucose metabolism occurs in the heart in response to hormones and nutrients. An 
additional aim was to test the  relationships between fructose 2,6-bisphosphate, glycogen 
concentration and the activity of PFK-2 and AMPK under the same conditions that were used in 
the previous experiments (cells incubated with different glucose concentrations, with and 
without). 
Cardiac myocytes were used as the experimental system for this study because myocytes from the 
same heart can be incubated under multiple conditions. 
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Materials and Methods 
2.1 Commercial preparations  
Commonly used reagents were obtained from Sigma-Aldrich or BDH (VWRI international). The 
following were supplied by: 
Sigma-Aldrich:  (-)-Epinephrine, BSA (essentially fatty acid free, fraction V), palmitic acid 
sodium salt, protein G-Sepharose, 2-deoxy-D-glucose, phenazine methosulfate, trans-
dehydroandrosterone, 3-O-methyl-D-glucopyranose, glucose 6-phosphate disodium salt, D-
fructose 2,6-bisphosphate, tetrasodium salt, D-ribulose 5-phosphate, 3-epimerase, fructose 6-
phosphate kinase, β-nicotinamide adenine dinucleotide reduced disodium salt, lactic acid sodium 
salt, xylulose 5-phosphate, thiamine pyrophosphate, bicinchoninic acid protein assay kit, xylitol 
and Azaserine. 
BDH :  Purified water used for cardiac myocyte isolation. 
BOC Ltd :  O2:CO2 (95%:5%) cylinders. 
Merial :  Sodium Pentobarbitone. 
Worthington Biochemical Corporation:  Collagenase Type 2 , hyaluronidase. 
Roche:  DNaseI, NADH, disodium salt, NADP
+, disodium salt, Glucose 6-phosphate 
Dehydrogenase, Aldolase, Amyloglucosidase, GDH/Triosephosphate Isomerase, NAD
+  cryst 
lithiumsalt, Glyceraldehyde 3-phosphate  Dehydrogenase,  Pyruvate, Fructose 6-phosphate. 
Fluka : D-xylulose, D-ribose 5-phosphate disodium salt, D-ribose. 
American Radiolabeled Chemicals : D–glucose[1-
14C], D-glucose[2-
14C], D-glucose[6-
14C], D-
glucose[3/4-
14C]. 
Wako Chemicals Inc: NEFA C Test kit. 
 Calbiochem (Merck Biosciences): AICAR, oligomycin, Okadaic Acid and Endothall. 
Santa Cruz Biotechnology: Anti- α2 AMPK antibody (goat). 
Cambridge Research Biochemical s:  SAMS  peptide.   103 
N.E.N: [γ-
33P] ATP,  [9,10-
3H] palmitate,  [U-
14C] glucose. 
Cell Signalling Technology : Anti-phospho-Thr172 AMPKα antibody (rabbit), anti-phospho-
Ser485/491 AMPKα antibody (rabbit), anti-AMPKα antibody (rabbit), anti-phospho-Ser79 ACC1 
antibody (rabbit), anti-ACC antibody (rabbit), anti-phospho-Thr308 PKB antibody (rabbit), anti-
phospho-Ser473 PKB antibody (rabbit), anti-PKB antibody (rabbit), HRP-linked anti-rabbit 
secondary antibody. 
Rockland :  RDye
TM800-conjugated anti-rabbit secondary antibody. 
Invitrogen:  NuPAGE® 4-12% Bis-Tris gels, PVDF membranes. Buffers used for SDS-PAGE 
and Western blotting (NuPAGE® LDS Sample Buffer, Sample Reducing Agent, Antioxidant, 
MOPS SDS Running Buffer, and Transfer Buffer). 
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2.2 Laboratory preparations 
2.2.1 Palmitate bound to albumin 
Palmitate was bound to albumin by a modification of the method described by Evans and Muller 
(1963). Sodium palmitate was added to a solution containing 15% (w/v) of bovine serum albumin 
(BSA), and 0.9% (w/v) NaCl (250 mg of sodium palmitate was added per 50 ml of the solution). 
The mixture was sonicated in a sonicating water bath until an even suspension was obtained. The 
mixture was incubated  at 50°C for 30 minutes, followed by incubation at 4°C overnight. 
Undissolved sodium palmitate was removed by filtration through Whatman No.1 filter paper at 
4°C, followed by centrifugation at 26,000g for 30 minutes at 4°C in a Beckman Sorvall RC5-B 
centrifuge. The supernatant was collected and the pH was adjusted to 7.4 with NaOH. After 
determining the concentration of palmitate bound to albumin (Section 2.11), the preparation was 
aliquoted and stored at -20°C. 
 
2.2.2 AMPK antibody bound to protein G 
Protein G sepharose was washed and resuspended as a 50:50 slurry in a 50 mM Hepes buffer pH 
7.4 containing 50 mM NaF, 5mM Na4P2O7, 10% (v/v) glycerol, 1mM EDTA and 1mM 
dithiothreitol (DTT). 100 μl of α2 AMPK antiserum, or pre-immune sheep serum as a control, 
was added to 500 μl of slurry and mixed at 4 ˚C for 2 hours. After binding, the slurries were 
washed twice in Hepes buffer as above and stored at 4˚C until used.  
2.3 Animals 
The animals used in these experiments were male Sprague-Dawley rats bred in the animal colony 
at University College London. The rats selected for experimentation had a 250-300g body weight 
(6-8 weeks old). They were maintained at 20-22˚C and had constant access to drinking water and 
Rat and Mouse Breeding Diet (Special Diet Services, Witham, Essex, UK).  The diet contains 
21% protein, 4% fat and 39% starches and sugars (by weight). The light/dark cycle was 
13hr/11hr, with light from 06:00 to 19:00hr.   105 
2.4 Heart perfusion 
Rats were anaesthetised by an intraperitoneal injection of sodium pentobarbitone (300mg/Kg). 
The hearts were removed and placed in ice-cold Krebs-Henseleit Bicarbonate Buffer (KHB) that 
had been freshly-prepared (25 mM NaHCO3, 18.5 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 
mM KH2PO4, pH7.4, 3 mM CaCl2  and 5 mM glucose and pre-gassed with O2/CO2 (95:5)  . This 
was followed by a retrograde perfusion through the aorta, as previously described (Mowbray and 
Ottaway 1973), using KHB containing 2% (w/v) BSA, 1.3mM CaCl2. The concentration of 
glucose used in the perfusion buffer varied (0, 5, 10 or 25 mM) depending on the experimental 
conditions. The perfusion buffer was constantly gassed with O2:CO2 (95 %:5 %) and maintained 
at  37°C. The perfusion pressure (preload) was 70 ± 5 cm H2O and the perfusion rate was 
approximately 15 ml/min. All hearts were initially perfused for 5 minutes in non-recirculation 
mode to remove blood and endogenous hormones. Perfusion was then continued for a further 60 
minutes, with recirculation of the perfusate. At the end of the perfusion, the hearts were removed 
from the cannula and freeze-clamped using tongs pre-cooled to the temperature of liquid N2. The 
frozen hearts were powdered under liquid N2 and stored in liquid N2.  
2.5 Rat cardiac ventriceular myocyte isolation 
Myocytes were isolated using a slight modification of the method described by Fuller et al 
(1990). The buffers used in the isolation procedure were Buffer A consisting of KHB + 10 mM 
glucose + 1.3 mM CaCl2, Buffer B consisting of KHB + 10 mM glucose + 0.1 mM EGTA, Buffer 
C consisting of KHB + 10 mM glucose + 0 to 5 μM added CaCl2, Wash Buffer consisting of 
KHB + 10 mM glucose + 0.2 mM CaCl2 + 2 % BSA + 0.5 mg/ml DNase I, and resuspension 
Buffer consisting of KHB + 1.3 mM CaCl2 + 2 % BSA + 5 mM glucose. All buffers were 
prepared with purified H2O, with minimal contamination with Ca
2+.  The buffers (except for ice-
cold Buffer A) were maintained at 37ºC and constantly gassed with O2:CO2 (95%:5%).  The rats 
were anaesthetised and their hearts were removed and put in ice-cold buffer A, followed by a 
brief washout perfusion at 37ºC with Buffer A, as described above. After perfusion with   106 
recirculating buffer A for 10 minutes, the perfusate was switched to Buffer B, and Ca
2+ was 
washed from the heart. Perfusion with Buffer B was continued for a further 5 minutes, followed 
by washing with Buffer C to remove EGTA.  The hearts were then perfused with Buffer C, 
containing 0.1 % (w/v) BSA, 1 mg/ml collagenase (type 2), and 0.4 mg/ml hyaluronidase for 20 
to 30 minutes until they became soft. The exact amount of Ca
2+ added to Buffer C (<5 μM) 
depended on the batch of digestive enzymes and the level of Ca
2+ contamination. The myocytes 
were gently dispersed in perfusion Buffer C containing 0.1 % BSA, 1 mg/ml collagenase, 0.4 
mg/ml hyaluronidase, and 0.5 mg/ml DNase I by shaking in a water bath set at 37 ºC (~150 
oscillations/min) for 5 minutes with gasing. DNase I was included to minimise the loss of 
myocytes due to the clumping of the cells by DNA released from dead cells. The digested heart 
was filtered through nylon mesh and the cells were allowed to settle under gravity for 5 minutes 
at 37ºC. The supernatant, which contained non-settled dead cells, was removed and the cell pellet 
was resuspended in Wash Buffer. The myocytes were again allowed to settle under gravity for 3 
minutes. The supernatant was removed and the cells were resuspended in fresh Wash Buffer. The 
Ca
2+ concentration was then gradually increased every 2 minutes, from 0.4, 0.6, 0.8, 1.0 to 1.3 
mM, while the cells were shaken gently at 37ºC with gassing. Finally, the myocytes were allowed 
to settle under gravity for 5 minutes and the cell pellet was resuspended in Resuspension Buffer 
(cells: buffer 1:10 (v/v)) as a Cell Stock. 
2.6 Measurement of cardiac myocyte viability 
Myocyte preparations containing more than 70% viable cells were used for metabolic studies. 
The viability was assessed using a haemocytometer and Trypan Blue (0.4%) which stains non-
viable cells. Viable cells which excluded Trypan Blue were of a typical rod shape with visible 
cross striations. Non-viable cells did not exclude Trypan Blue and were rounded with no distinct 
ultrastructure. Each preparation was assessed for viability before use, and cells which had less 
than <70 % viability were discarded.  
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2 .7 Preparation of myocytes for individual experiments.  
 
The myocytes were incubated in 18 ml plastic scintillation vials under different conditions, as 
described in each individual experiment. At the end of the incubation period, the cells were 
centrifuged at 500xg for 1 minute, then washed twice with free BSA Buffer and stored under 
liquid N2 for the measurement of metabolite or enzyme activity. For the flux studies, the cells 
were treated as described in section 2.8. The diagram below illustrates the usages of myocyte for 
various experiments: (Figure 2.1) 
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22.8 Measurement of glucose oxidation by myocytes 
The incubation buffer (KHB) which contained 5 mM [U-
14C] glucose (approximately 20 
µCi/mmol) was gassed with  (O2:CO2) before use. Myocytes were incubated at 37ºC, with gentle 
shaking in a total volume of 2.5 ml (0.5 ml Cell Stock + 2 ml buffer) in sealed 50 ml siliconised 
glass metabolic flasks fitted with centre wells. At the end of the indicated incubation period, 0.2 
ml of 60% perchloric acid (PCA) and 0.5 ml of 1M benzethonium hydroxide was injected 
through the stopper to the outer compartment (containing myocytes) and the centre well, 
respectively. Flasks were incubated at 37°C, with shaking for a further 60 minutes in order to 
collect [
14C]CO2  (method of CO2 trapping). The contents of the centre wells were transferred to 
18 ml plastic scintillation vials. The centre wells were then rinsed twice with 0.5 ml methanol, 
which was then also transferred to the scintillation vials and 10 ml of Ecoscint A was added. The 
radioactivity was measured by liquid scintillation counting. Similar experiments were conducted 
using different labelled glucoses ( 1-
14C, 6-
14C, 2-
14C, and  3/4-
14C). 
In order to eliminate background counts due to fluorescence, the vials were stood in the dark 
overnight before counting. 
 
2.9 Determination of metabolite contents 
2.9.1 Glycogen    
Glycogen was extracted by boiling cell pellets (section 2.7) in 5 ml glass tubes containing 1 ml of 
0.5 mM K0H for 20-30 minutes until these were judged to be completely digested by observing 
an even suspension. The mixture was then vortexed and cooled on ice. Glycogen was precipitated 
from the alkaline digest by adding 2 ml of cold 95% (w/v) ethanol. The mixture was vortexed and 
placed on ice for 30 minutes and then centrifuged for a further 30 minute at 5000g. The 
supernatant was discarded and the tubes inverted on tissue to drain for several minutes. The 
pellets were used for the determination of glycogen. 
   109 
Glycogen hydrolysis 
The above pellets were placed in 5 ml stoppered glass tubes and dissolved in 100 µl of water, 
followed by the addition of 50 μl of 43 mM KHCO3 and 1.0 ml of glucoamylase solution. The 
mixture was incubated at 40 ˚C for 2h in a shaking water bath, and then 0.5 ml of 210 mM 
perchloric acid was added, mixed well and centrifuged at 5000g for 10 minutes. The supernatants 
were neutralised with solid KHCO3, centrifuged again. The supernatant was used for glucose 
determination. 
 Glucose determination 
Glucose released from the hydrolysis of myocyte glycogen was measured by the method of 
(Devos P et al.; 1983)).   
 Principle of the assay :  
     
(a)    ( glycogen)n      +   n-1 H2O                                n glucose 
              
(b)    Glucose  +    ATP        HK          Glucose 6-P      +   ADP 
 
(C)  Glucose 6-P  +  NADP
+       G6P-DH       6P-gluconolactone  +  NADPH   + H
+ 
 
Assays were carried out in duplicate in a final volume of  1.50 ml  in a 3 ml plastic cuvette 
containing 0.5 ml sample, 1.0 ml of assay mixture that contained 50 mM Tris- HCl buffer (pH 
8.0) 0.5 mM ATP, 0.2 mM NADP
+ and 0.02% (w/v) BSA). The blank cuvette contained 0.5 ml of 
water and 1.0 ml of assay mixture. The blank and sample cuvettes were placed in the 
spectrophotometer. 10 μg of glucose phosphate dehydrogenase was added to both cuvettes (to 
remove any glucose 6-phosphate that might have been present in the cell extracts). The 
absorbance was read at 340 nm. When a steady reading had been obtained, the reaction was 
initiated by adding 10 µg hexokinase and the increase in the absorbance was read after 5-10 
minutes until a constant absorbance value had been obtained.  The glycogen content was   110 
expressed in mM glucosyl units (the molar extinction coefficient of NADH at 340 nm is 6.22x 
10
3 L. mol
-1.cm
-1). 
Radioactive method for measuring glycogen 
Tissues were weighed, and then transferred into 15 ml vials containing 5 ml KHB Buffer and 5 
μCi  D-[U-
14C] glucose. The vials were transferred to the shaking water bath adjusted to 37  ˚C 
and gased continuously for an hour. The tissue was removed and frozen in liquid nitrogen. The 
tissue was then ground to a powder under liquid nitrogen. The powder was homogenized in a 10 
ml tube containing 2 ml of 3 M KOH, then heated at 70 ˚C for 30 minutes. After cooling the 
homogenate to room temperature, 4.7 ml of 100% ethanol was added, followed by storage at -20 
˚C  overnight.  Glycogen was precipitated by centrifugation at 5000 g for 10 minutes. The 
precipitate was suspended in 2m of 90% ethanol, vortexed, and then recentrifuged. This last step 
was repeated once more. The precipitate was suspended in 0.2 ml water followed by 4 ml 
scintillation fluid, and the radioactivity was measured.  
2.9.2 D-Fructose 2,6-Bisphosphate  
Preparation of cardiac myocyte  extracts  for  assay of fructose 2,6-
bisphosphate: 
5- 10 mg samples of frozen myocytes were placed in 2 ml plastic tubes and homogenised in 1.0 
ml of 0.1 M NaOH. The pH of the resulting mixture should be above 11.0 to denature protein and 
stabilize fructose 2,6-bisphosphate. The homogenates were heated for 5 min at 80 ˚C, then cooled 
and centrifuged at 6000g for 5 minutes. The resulting supernatants were neutralized at 0˚C with 
1.0 M ice-cold acetic acid in the presence of 20 mM Hepes pH 7.0.  This results in the 
precipitation of protein. Fructose 2,6-bisphosphate was assayed in the last supernatants. When the 
sample contained endogenous inhibitors, it was necessary to purify the extract by adding 1-2 ml 
to a column of Dowex AG1x8 (4 x 40 mm Cl
- form). The column was washed with 1 ml water 
and 3 ml of 0.15 M NaCl, then F-2,6-P2 was eluted in 2 ml of 0.3 M  NaCl.   111 
Fructose 2,6- bisphosphate was measured spectrophotometrically by the method of (Van et al.; 
1980). 
Principle of the assay: 
                                     F 2,6-P2 
 
                                  
         F 6-P  +PPi        PPi PFK        F 1,6-P2  + Pi 
 
 
         F 1,6-P2              ALD               GAP  + DHAP 
 
           GAP                   TIM              DHAP 
 
DHAP    +   NADH   + H
+           GDH                 glycerol-3-P  +  NAD
+ 
 
Assays were carried out in duplicate at 25 ˚C in a final volume of 1 ml containing 50 mM Tris 
Buffer (pH 8.0), 2 mM magnesium acetate, 1mM F-6-P, 0.15 mM NADH, 6 ug PPiPFK, 40ug 
(Glycerophosphate dehydrogenase/ triosephosphate isomerase) (GDH/ TIM), F2,6-P2 < 10 nmol 
and 0.5mM PPi. The mixture was vortexed well and incubated for 5 minutes at 25 ˚C. The ini tial 
absorbance was read at 340 nm using a Unicam SP8-100 spectrophotometer against a blank 
containing water in place of the sample. The reaction was initiated by the addition of 0.05 ml of a 
10 mM pyrophosphate solution. The decrease in absorbance was measured at approx 10 minutes 
after the start and used to calculate the Fructose 2,6-bisphosphate concentration. The sample 
should not contain more than 1 picomol of Fru-2,6-P2. A calibration curve was established with 
20,  50,  100  μl  from  a  10  nM  F-2-6P2 solution, corresponding to 0.2, 0.5 and 1 picomol, 
respectively. 
For the standards, the changes in absorbance were plotted versus the corresponding concentration 
of fructose 2, 6-bisphosphate, pmol/ml (Figure 2.2) 
+   112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Fructose 2,6-bisphosphate standard curve The standard curve 
showing the average absorbance for the concentration range between 0.1 to 1.0 pmol 
of fructose 2,6-bisphosphate.   113 
2.9.3 Xylulose 5-Phosphate (Xu5P) 
Preparation of tissue extracts for xylulose 5-phosphate measurement 
10 mg samples of frozen myocytes were placed in 5 ml glass tubes containing 1 ml of (10% w/v) 
trichoroacetic acid, then vortexed well, followed by centrifugation for 10 minutes at 10,000g.  
The supernatants were transferred to fresh tubes and neutralized by addition of 1 M NaHCO3. The 
precipitates were removed by centrifugation and the supernatants were used directly for Xylulose 
5-Phosphate determination. 
 
Xylulose 5- phosphate was assayed spectrophotemetricaly by method of (Harvey D.J and 
Horning M.G 1976). 
 
Principle of the assay: 
 
(a)      Xu5-P + R5-P         TK                   G3-P + Sedoheptulose 7-P 
                                         TPP,Mg
2+ 
 
(b)     G3-P        TIM              DHAP 
 
(c)   DHAP + NADH + H
+         GDH       α- Glycerol Phosphate     + NAD
+    
 
The assay was carried out at 25°C in a final volume of 1 ml containing 250 mM glycylglycine 
buffer (pH 7.7), 50 mM ribose 5-phosphate 30 mM thiamine pyrophosphate, 4.3 mM NADH, 0.3 
M MgCl2, 4 µl from Glycerophosphate dehydrogenase/ triosephosphate isomerase (10 mg/ml) 
was freshly prepared, and 0.6 ml of cell  extract. The mixture was allowed to equilibrate at 25°C. 
The reaction was initiated by the addition of 10 µl of 5.0 unit/ml transketolase and the change in 
absorbance at 340nm was recorded. Readings were taken against a reagent blank where the 
samples were replaced with water.   114 
2.9.4 Measurement of adenine nucleotide contents 
Adenine nucleotides were measured by ion-pair reverse phase HPLC, as described by Sellevold et 
al (1986), using a 150 X 4.6 mm Nucleosil C18 column with a particle size of 5 μm and a pore 
size of 100Å. The mobile phase consisted of 215 mM KH2PO4, 2.3 mM tetrabutylammonium 
hydrogen sulphate (TBAHS), and 3.5 % (v/v) acetonitrile. The pH was adjusted to 6.25, with 10 
M KOH. The mobile phase was filtered through a 0.22 μm Millipore filter and degassed before 
use. 200 μl of ice-cold 0.21 M perchloric acid was added to the frozen myocytes and the mixture 
was vortexed. Following centrifugation at 13,000 g for 5 minutes at 4 ºC, perchlorate ion in 150 
μl of the supernatant was precipitated with 30-40 μl of 1M KOH, which was added in sufficient 
amounts to precipitate most of the perchlorate in the extract whilst maintaining an acidic pH 
(6.25). The precise amount was determined by the titration of an extract and the usual amount 
was 20-40 μl. Potassium perchlorate precipitates were removed by centrifuging at 13,000 g for 2 
minutes at 4 ºC, and 450  μl of the mobile phase was added to 50 μl of the supernatant. The 
samples diluted with the mobile phase were filtered through a 0.22 μM filter and 50 μl was 
injected onto the column which was pre-equilibriated with the mobile phase. Adenine nucleotides 
and creatine compounds were eluted isocratically at ambient temperature. The flow rate was 
1.0ml/min and each run lasted for 20 minutes.  The elution of the creatine compounds and the 
adenine nucleotides was detected by changes in the absorbance at 206 nm using a Waters tunable 
absorbance detector. The elution profile was stored and processed using Millennium 2010 
software.  The peaks for ATP, ADP, and AMP were identified by comparing the retention times 
with standards (Figure 2.3). In order to ensure that the standards had similar amounts of residual 
perchlorate as the samples, the former were prepared in 0.21 PCA, which was partially 
neutralised with the same amount of 1 M KOH as used in the preparation of the latter, and then 
diluted ten times with the mobile phase before injection onto the column.  The amounts of 
adenine nucleotides and creatine compounds were determined by the comparison of the peak   115 
areas and peak heights respectively with those of the standards. In order to establish whether this 
method is sufficiently sensitive accurately to measure the small amount of adenine nucleotides 
present in the myocyte samples, the standards were prepared in the range of concentrations 
similar to those seen in the myocyte samples (Figure2.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: ATP:ADP:AMP :Cr : CrP. 
A chromatogram of standard mixture of ATP,ADP,AMP, creatine, and phosphocreatine   116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: AMP standard curve.  AMP standard solution was analysed by HPLC 
as described in section 2.9.4 with the indicated concentrations. This result is from a 
single set of measurements.   117 
 
2.10 Measurement of protein concentration 
 
Protein concentration was determined by a bicinchoninic acid (BCA) method. This method is 
based on the concentration-dependent reduction of alkaline Cu(II) to Cu(I) by proteins, and the 
chromogenic reaction of BCA with Cu(I). 10 μl of the samples was incubated at 37  ºC for 30 
minutes with 200 μl of BCA, copper (II) sulphate pentahydrate 4% solution (50:1, v/v) in a 96 
well  microtitre plate. After incubation, the absorbance at 550 nm was determined using a 
Dynatech MR7000 spectrophotometer. BSA solutions (0.2-1mg/ml) were used as standards     118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5:  Protein standard curve. The standard curve shows net absorbance at 
550 nm versus the indicated protein concentrations for a single test assay. 
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2.11 Determination of non-esterified fatty acid concentration 
Non-esterified fatty acid concentration was assayed using a Wako NEFA C test kit. This assay is 
based on the oxidation of fatty acyl-CoA by acyl-CoA oxidase (ACOD) to 2,3-trans-enoyl-CoA. 
This reaction releases H2O2, which, in the presence of peroxidase and 4-aminoantipyrine, allows 
the conversion of 3-methyl-N-ethyl-N-(β-hydroxyethyl)-aniline (MEHA) to a coloured 
compound. 10 μl of the samples was incubated in a 96 well microtitre plate at 37 ºC for 10 
minutes with 67 μl of Reagent A (50 mM phosphate buffer [pH 6.9] containing 3 mM MgCl2, 0.3 
U/ml acyl-Coenzyme A synthetase, 3 U/ml ascorbate oxidase, 3 mg/ml ATP, 0.7 mg/ml 
coenzyme A, and 0.3 mg/ml 4-aminoantipyrine). 133 μl of Reagent B (1.2 mM MEHA, 6.6 U/ml 
ACOD and 7.5 U/ml peroxidase) was then added and the samples were incubated for a further 10 
minutes. The absorbance at 550 nm was determined with a Dynatech MR7000 
spectrophotometer. Oleate solutions (0.2-1mg/ml) were used as standards. 
2.12 Enzyme Assays 
2.12.1 AMPK activity assay 
Frozen myocytes were sonicated (3 x 7 seconds) in 0.3 ml of ice-cold sonication buffer 
containing 50 mM Tris/HCl( pH 7.5), 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 5 mM Na4P2O7, 
10% glycerol (v/v), 1% Triton X-100 (v/v), 1 mM DTT, 1mM phenylmethanesulfonyl fluoride 
(PMSF), 1 mM  benzamidine,  and  4  μg/ml  soybean  trypsin  inhibitor.  The  cell  lysate  was 
centrifuged at 13,000g for 10 minutes at 4°C and 60 µl of the supernatant was incubated at 4°C 
for 2 hours with either anti-AMPK antibody or pre-immune serum prebound to Protein G-
Sepharose  (Section 2.2.2). The volume of antibody/Protein G Sepharose used for 
immunoprecipitation was 20 µl for α2 AMPK. This volume was chosen because it was found to 
optimize immunoprecipitate AMPK from the 13,000xg supernatant (Figure 2. 9). After binding, 
the immunoprecipitates were collected by centrifugation at 5,200g for 1 minute at 4°C, and 
washed once with 200 µl of sonication buffer and twice with AMPK assay buffer (40mM Hepes   120 
(pH7.0), 80 mM NaCl, 0.8 mM EDTA, 8% glycerol (v/v), and 0.8 mM DTT) by centrifuging as 
above. The immunoprecipitates  were then incubated at 37°C with gentle shaking in a final 
volume of 50µl of AMPK assay buffer, which additionally contained 200 µM SAMS peptide 
(HMRSAMSGLHLVKRR), 200 µM [γ-
33P] ATP (100-500 dpm/pmol), 5 mM MgCl2, and 200 
µM AMP. The reaction was started by the addition of [γ-
33P] ATP. The assay which measures 
incorporation of 
33P to SAMS peptide (Davies et al 1989) is based on the sequence surrounding 
the AMPK phosphorylation site (Ser79) of ACC1, with a mutation of Ser77 to alanine to prevent 
phosphorylation by PKA and the addition of two arginines to allow recovery of SAMS peptide by 
ion exchange after the reaction. The reaction was stopped after 30 minutes by spotting the 
reaction mixture onto squares of P81 Whatman phosphocellulose ion exchange paper which were 
then immersed in 1% (v/v) orthophosphoric acid. The SAMS peptide phosphorylated with 
33P 
was separated from [γ-
33P] ATP by washing the papers twice in 1% orthophosphoric acid 
followed by two washes in  distilled H2O (10 minutes each). The papers were air-dried and 
transferred to scintillation vials, and 10 ml of Ecoscint A was added before radioactivity was 
determined by liquid scintillation counting. Because α-2 AMPK antibodies was raised in goats, 
activity immunoprecipitated with sheep/goat pre-immune serum prebound to Protein G-
Sepharose was used as a blank to account for the non-selective binding of AMPK with serum 
proteins and/or Protein G Sepharose, and was subtracted from the activity immunoprecipitated 
with anti-AMPK antibodies.AMPK showed a good linear correlation with amount of 13,000g 
protein in the range of the amount typically used (Figure 2.10). AMPK activity also increased 
linearly during the assay time (30 minutes) (Figure 2. 11).  
For heart samples, frozen, powdered heart was weighed and homogenised on ice using an Ultra 
Turrax tissue disintegrator in 1 ml per 100 mg of tissue homogenisation buffer containing 50 mM 
Tris/HCl (pH 7.8), 0.25 M mannitol, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 5mM Na4P2O7, 1 
mM DTT, 1 mM PMSF, 1 mM benzamidine, and 4 μg/ml soybean trypsin inhibitor. 13,000 g   121 
supernatant was obtained and AMPK was immunoprecipitated and assayed as above, except for 
the fact that the immunoprecipitate was washed with Homogenisation Buffer instead of 
Sonication Buffer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
Figure 2.6: Effect of altering antibody concentration on the 
Immunopreciptate of α2 AMPK activity.  α-2AMPK was immunoprecipitated with 
the  indicated volumes of Ab: Protein G. The assay was carried out in the presence of 
200μ AMP. Values are as dpm per minute for one myocyte preparation. 
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Figure 2.7: the relationship between AMPK activity and the amount of 
protein in the 13,000g supernatant. Cardiac myocytes were incubated for 1hr with 
KHB buffer. Cells were then lysed and centrifuged at 13000xg. The supernatant was 
then collected and different protein concentrations were prepared from the same 
myocyte preparation. α2 AMPK was immunoprecipitated from the supernatants and 
AMPK activity was assayed in the presence of 200 μM AMP as described in section 
(2.12.1)   123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
Figure 2.8: Time course of AMPK activity. α2 AMPK was immunoprecipitated 
from cardiac myocytes 13,000xg supernatant and assayed for AMPK activity  in the 
presence of 200 μM AMP. Values are mean ± SEM of 5 independent measurements of 
myocyte preparation.   124 
2.12.2 Phosphofructo-2-kinase 
For the determination of PFK-2 activity, cells suspensions were thawed in 50 µl of buffer 
containing 20 mM-Pi, 10 mM-  EDTA and 100 mM-KCl [pH 7]. The cell extracts were 
centrifuged at 10,000g. Each assay was conducted in a 1 ml final volume containing  0.95 ml of ( 
50 mM Hepes Buffer [ pH 7.1],  1 mM ATP 100 mM  KCl, 5 Mm MgCl2, 5 mM Fru-6-P,  3.5 
mM Glc-6-P, 0.1 mM AMP)  and 50 µl of cell extract. The reaction was terminated after 10 
minute incubation at 30°C, by the addition of 100 µl of 0.1 M NaOH, then cooled and 
centrifuged. The supernatant was taken for the measurement of Fructose 2,6-bisphosphate as 
described in Section 2.9.2. The activity was calculated from an extinction coefficient of 6.22x 10
3 
L.mol
-1.cm
-1  for NADH and as expressed as nmol/min/mg dry weight of cells.  For the time 
course, the reaction was terminated at 2, 4, 6 and 8 minutes (Figure 2.12). 
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Figure 2. 9:  PFK2 activity time course. Cardiac myocytes were incubated for 
1 hour at 37 °C in the presence of 5 mM glucose and 2 % BSA. Cell extracts were 
assayed for PFK2 activity for the indicated times as described in section (2. .9 .2). 
The results are expressed as mean ± SEM for 8 cell preparations.   126 
2.13 Western blotting 
Myocytes were lysed as desecribed in Section 2.12.1 and the proteins in 15-25 μl of the 13,000 g 
supernatant were separated by sodium dodecylsulphate polyacrylamide gel electrophoreses (SDS-
PAGE) under denaturing and reducing conditions on 4-12% Bis-Tris gels, and transferred to 
polyvinyldene difluoride (PVDF) membranes. Phospho-AMPK  α-Thr172, Phospho-AMPK  α-
Ser485/491, Phospho-PKB Thr308, Phospho-PKB Ser473, Phospho-ACC Ser79/227, total 
AMPKα, total PKB, and total ACC were detected by chemiluminescence (Fujifilm LAS-1000 
Image Reader) with horse redish peroxidase (HRP-) conjugated secondary antibody and 
chemiluminescent substrate (luminol). For these measurements, primary and secondary 
antibodies were used at a 1/1000 dilution in Tris Buffered Saline (TBS) (20 mM Tris/HCl pH7.6, 
137 mM NaCl) containing 5% (w/v) BSA and 0.1 % (v/v) Tween-20. The secondary antibody 
used for the detection of Ser485/491 was diluted in the same buffer which additionally contained 
0.01 % SDS. 5% (w/v) milk powder in TBS + 0.1% Tween-20 was used to block membranes 
except for those probed with anti-AMPK Ser485/491, which were blocked with 5% BSA in TBS 
+ 0.1% Tween-20. Band intensities were quantified with Fujifilm Multi Gauge software. After 
the measurements of Phospho-AMPK, ACC, or PKB, the membranes were stripped by incubating 
with 62.5 mM Tris/HCl buffer, pH 6.7, containing 0.8% (v/v) ß-mercaptoethanol and 2% (w/v) 
SDS at 50°C for 30 minutes, and then reprobed with total AMPK, ACC, or PKB antibodies.  
 
2.14 Liquid Scintillation counting 
The radioactivity of 
14C, 
3H, and 
33P was measured using a Perkin Elmer Tri-Carb 2900TR Liquid 
Scintillation Analyzer, which was equipped with software which made correction for chemical 
quenching and provided data as disintegrations per minute (dpm). 
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2.15 Statistical methods and representation of results 
 
All values are given as means ± S.E.M. for the numbers of independent myocyte preparations 
shown in the legends to figures and tables. 
Statistical significance was determined by Student’s t tests. For comparisons of data from 
perfused hearts and for myocyte adenine nucleotide contents an unpaired test was used. All other 
comparisons of data from myocytes were done by means of a paired test. Throughout P  ≤ 0.05 
was taken as the threshold of statistical significance. 
In some instances measurements of AMPK activity are given as absolute values but in many 
experiments AMPK activities were normalized by expression as percentages ± S.E.M. of the 
paired activity that was measured with 5 mM glucose alone (basal activity). Error bars shown on 
figure symbols for these 5 mM glucose basal values indicate the S.E.M. of the absolute values 
expressed as a percentage of the mean of the absolute values. For all other conditions individual 
values were first expressed as percentages of the paired basal value followed by calculation of 
means ± S.E.M. This form of data representation was particularly used for measurements of 
myocyte AMPK activity in order to facilitate easy comparison of effects in different experiments 
because AMPK activity measurements were made throughout the whole time frame of the project 
and showed some temporal ‘drift’ in their absolute values. This was possibly due to variations in 
animals or antibody reagents. Measurements of other quantities were usually performed within a 
much smaller time frame and did not suffer from this ‘drift’. From 106 independent preparations 
of myocytes incubated with 5 mM glucose alone theα2 AMPK activity assayed in the presence of 
200 µM AMP was 2.06 ± 0.17 pmol per min per mg of 13,000g supernatant protein. Although the 
mean absolute AMPK activities could be rather disparate between experiments performed at 
different times the ranges of AMPK activities within a given experiment generally were not large. 
For example the experiments recording the highest and lowest mean α-2 AMPK activities with 5   128 
mM glucose gave values of 4.44 ± 0.40 (n = 8) and 0.57 ± 0.04 (n = 9) pmol per min per mg of 
13,000g supernatant protein respectively. For comparison mean α-2 AMPK activities in rat hearts 
perfused for 1 hour with 5 mM glucose ranged from 1.8 to 4.2 pmol per min per mg of 13,000g 
supernatant protein (Figure 5 and Table 1 respectively of Clark et al., 2004).   
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Section:  1 
 3.1 Isolation and viability of Cardiac Myocytes 
In previous years, several methods have been developed for the isolation of cardiac myocytes. 
Many of the most successful methods involve perfusion and digestive enzymes, such as 
collagenase. The inability of isolated myocytes to maintain structural and metabolic integrity in 
the presence of Ca
2+ (Farmer et al., 1977; Vahouny et al., 1979) has been a major problem in the 
isolation of viable myocytes from heart tissue. This problem has been overcome by perfusing the 
heart tissue in Ca
2+ free buffer in the presence of EGTA, and digestion with a combination of 
collagenase and hyaluronidase. Myocytes are usually isolated under conditions of low Ca
2+ which 
assists their release from intercellular connections and the extracellular matrix (ECM). It has been 
reported that the gradual reintroduction of Ca
2+ to the myocytes via a series of washes can reduce 
the loss of viability caused by the Ca
2+  paradox. Cardiac myocytes isolated by the method 
described in section 2.5. Figure3 shows the cardiac myocytes visualized by light microscopy. 
Figure 3.2.  Myocyte viability was determined as described in section 2.6.  In this chapter, 
incubation conditions are described for each individual experiment where appropriate and stated 
in figure legends.  
To assess the metabolic performance of isolated myocytes, glucose oxidation by myocytes was 
determined. Linearity of the rates of glucose oxidation for at least 1 hour indicated that the cells 
are metabolically active and there is no significant loss of viability during this period (Figure 
3.3).  The value for the rate of glucose oxidation was roughly in the range of that reported by 
other investigators (Montini et al.; 1981), an oxidation rate with 5 mM glucose of approximately 
1.4  nmol/mg  protein. Burns and Reddy reported an  oxidation rate  with 5 mM glucose 
approximately 0.7 nmol/ min/mg protein. The rate of glucose oxidation (5 mM) obtained in the 
present study also was 0.7 nmol/ mg protein.    131 
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Figure 3 .1:  Isolated cardiac myocytes as visualized by light microscopy. The ratio 
of rod-shaped cells compared with rounded cells gives an indication of cell viability   132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Assessment of the viability of cardiac myocytes. Cardiac myocytes 
were incubated with 5  mM glucose and 2% BSA. The cell viability was assessed as 
described in section 2.6. The values are the mean ± SEM of 3 independent preparations.   133 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3:  Glucose oxidation by cardiac myocytes.  Cardiac myocytes were 
incubated for the indicated times in the presence of 5 mM [U-
14C]glucose. Glucose 
oxidation was estimated from 
14CO2 production as described in section 2.8. The values are 
means ± SEM of 4 independent myocyte preparations.   134 
3.1.1 Conclusions 
An isolation procedure which produced a good yield of uncontaminated, viable cardiac myocytes is 
essential for any biochemical investigation of myocardium at cellular level. The isolation procedure 
used in this study has been used successfully by previous members of the   Saggerson laboratory for 
a number of years and has been shown to produce cardiac myocytes which are viable both 
morphologically and biochemically.   
The linearity of glucose oxidation with time indicated that the cells viability was sustained. The 
combination of a good myocyte isolation procedure with reliable metabolites assays, allows reliable 
measurements of the metabolites to be made in cardiac myocytes. 
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 Section: 2 
3.2.1 Myocyte AMPK activity is decreased by increasing glucose 
concentration. 
A previous study by Itani et al. in 2003 found that, when rat skeletal muscles were incubated with 
increasing glucose concentrations AMPK activity and phosphorylation at α-Thr172 decreased in 
response to the increasing glucose concentration with no observed difference in the total AMPK 
protein levels. This decrease in AMPK activity was linked with a decrease in glucose transport. In 
addition, there were no changes in the concentration of adenine nucleotides or creatine-P during 
the incubation period (Itani et al.; 2003). It has been reported in   the yeast Saccharomyces 
cerevisiae Snf1 is regulated by glucose depletion, which triggers its phosphorylation at Thr210 
and concomitant increase in activity (Portillo et al.; 2005). Inactivation of AMPK by glucose has 
also been previously described in pancreatic β-cells and could be a pivotal regulatory event in 
glucose-induced lipogenesis (Salt et al.; 1998). In order to investigate this further, and examine 
whether or not this effect could be reproduced in cardiac myocyte, it was first necessary to isolate 
cells with good viability.  Cell viability was determined as described in section 2.6.  Second in 
this experiment, freshly isolated cardiac myocytes were subjected to several washings with 
washing buffer but no glucose in the last wash, in order to create a zero glucose baseline. Cardiac 
myocytes were then incubated for 1 hour in media containing 0, 2, 5, or 25 mM glucose.  Since it 
was impossible to remove all glucose from the incubation medium and myocytes prior to 
incubation, the 0 mM glucose incubation contained a small unknown amount of glucose. Finally 
after incubation, the cells were lysed and the AMPK was immunoprecipiated using anti-AMPK 
α2 polyclonal antibody. Immunoprecipitated AMPK was used in an in vitro 
33P AMPK kinase 
assay using SAMS peptide as a substrate, as described in section 2.12.1. Both α-1 and α-2 AMPK 
subunit are expressed by rat heart with the  α-2 complex being  responsible for 70-80% of kinase 
activity (Cheung   et al.; 2000). Measurement of AMPK activity was therefore confined to study 
of α-2 AMPK.    136 
  Figure 3.4 shows the effect of varying glucose concentration on AMPK α-2 activity. Glucose at 
2, 5, 25 significantly decreased   α-2 AMPK activity compared to the control (zero glucose) by 
70%, 52% and 18% respectively   when measured in the presence of 200 μΜ AMP (Suter  et al.; 
2006).  All AMPK  assay were performed in the presence of 200 µM AMP. Since the half- 
stimulation effect of AMP is less than 2 µM (Suter et al..; 2006) , this concentration of AMP will 
be essential to give maximal stimulation of the enzyme. Assay of AMPK with AMP present has 
the following advantages (i) it might be possible to assay the enzyme in the total absence of AMP 
because the possibility of breakdown of ATP to AMP either on storage or during the assay;(ii) the 
induction of AMP makes the assay more specific for AMPK and (iii) it increase the activity and 
thereby increases the   precision of the assay.      
The effect of glucose on AMPK need to be examined further to see whether glucose promotes an 
allosteric effect or dephosphorylation of such a site or other additional mechanisms might exist 
that leads to an inactivation of AMPK by glucose.  
3.2.2 The effect of glucose on α-2Thr172 phosphorylation 
AMPK is phosphorylated and activated by upstream kinases.  Thr-172 has been identified as the 
major site within the α catalytic subunits to be phosphorylated by these kinases (Hawley et al.; 
1996).  To determine whether phosphorylation of this residue was decreased  in response to 
increased  glucose concentration, immunoblotting experiments were carried out. Samples  of 
13,00g supernatants (60 ug of protein) were analysed by SDS-PAGE, transferred to PDVF and 
blotted with anti-phospho AMPK antibody. 
Figure 3.5 shows the result of immunoblotting  of myocytes incubated in the presence of 25 mM 
glucose significantly  decrease α-2 Thr172 phosphorylation compared to 0, 2, 5 mM glucose and  
AICAR  p<0.005. 
 Other sites have been identified on both α and β AMPK subunits that are phosphorylated by 
upstream AMPKKs  (Stein  et al.;  2000). The possibility  that additional, unidentified protein 
kinases may also regulate the activity of AMPK has also been suggested.   137 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: The effect of glucose concentration on myocyte α-2 AMPK activity. 
Myocytes were incubated for 1 hour with the indicated concentrations of glucose followed by 
freeze-stop, immunoprecipitation and assay of α-2 AMPK activity. The values are means ± 
S.E.M. from 7 independent myocyte preparations. A, B, C indicate P<0.05, <0.01, <0.005 
respectively compared against zero glucose (paired tests). The  significance  of the paired 
differences between 5 mM glucose and 2 and 25 mM glucose are shown directly on the figure.   138 
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Figure 3.5:  The effect of glucose concentration and AICAR on the 
phosphorylation of Threonine 172 in myocyte AMPK α-subunits.  Myocytes were 
incubated for 1 hour with the indicated additions.  (a)  Phospho-AMPK measurements were 
normalized against measurements of total AMPK α  -subunit protein and then expressed as 
percentages of the values in the presence of 25 mM glucose alone. The values are means ± 
S.E.M,  of the numbers of independent myocyte preparations shown in brackets.  A indicates 
P<0.005 compared against the 25 mM glucose value (paired tests). (b) Representitive blot.   139 
The experiment described in Figure 3.6 was performed in order to establish that the AMPK 
activity showed in Figure 3.4 was indicative of steady-state phosphorylation /dephosphorylation 
having being achieved. Figure 3.6 indicates that AMPK activity at 5, and 25 mM glucose was 
likely to have occurred after 1 hour of incubation and that then steady state persisted for at least a 
second   hour of incubation. There were no significant differences between AMPK activities at 
60, 90 or 120 min at either glucose concentration but all of these values were significantly 
different from zero time (P<0.0005, paired test). Additionally values at 30 min were significantly 
different (paired tests) from zero time (P<0.025 for 5 mM glucose and P<0.005 for 25 mM 
glucose). This is related to some experiment described later in which incubation was performed 
for 2 hours  
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Figure 3.6: The effect of incubation time on the ability of glucose to decrease and 
then  stabilize  myocyte  α-2 AMPK activity.  Immediately after isolation myocytes were 
washed in glucose-free medium followed by incubation for the indicated times with either 5 mM 
glucose (round symbols) or 25 mM glucose (square symbols). Incubation flasks were 
continuously gassed with O2/CO2 (95:5). The values are means ± S.E.M expressed as percentages 
of the zero time measurements and are from 4-5 independent myocyte preparations.  
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 3.2.3 The effect of glucose to decrease AMPK activity is not driven by 
changes in adenine nucleotide concentrations.  
 
In order to determine whether the glucose –induced inactivation of AMPK was due to a decrease 
in cellular AMP/ATP ratio, total adenine nucleotide content was measured. Cardiac myocytes 
incubated with 0, 5 and 25 mM glucose without and with 0.5 mM palmitate, were subjected to 
acid extraction as described in section 3.4.9 and adenine nucleotide contents were analysed using 
HPLC. Table 3.1 shows ADP and AMP at 5 and 25 mM glucose were significantly different 
from zero. Table 3.2  also shows 5 and 25 mM glucose in the presence of palmitate was 
significantly different from zero. Figure 3.7 shows the relative ATP: ADP: AMP content at 5 and 
25 Mm glucose were not significantly different from zero. Whereas cell incubated with 5 and  25 
mM glucose in the presence of palmitate shows significant difference on  the relative 
ATP:ADP:AMP content compared to the zero. .Therefore AMPK activity was determined in cells 
incubated with palmitate in order to see the effect of additional substrate on AMPK activity. 
 Figure 3.8 shows that glucose –dependent decrease in AMPK activity was still seen in the 
presence of palmitate and the percentage profile of this effect was very similar to that seen in the 
absence of palmitate (Figure  3.4).  It appears that the ability of glucose to decrease AMPK 
activity in cardiac myocytes is not due to increased ATP, and there may be a novel pathway 
linking glucose metabolism to the AMPK system in cardiac myocytes. Cells incubated in the 
absence of glucose and palmitate showed depletion in the total content of adenine nucleotides; 
and  it is possible  under this condition the activation of AMPK is due to an increase in the 
AMP/ATP ratio. This effect may become more significant if using myocytes incubated with no 
substrates are used and monitoring AMPK activity under basal conditions. Cells incubated in the 
absence of glucose and palmitate  showed significant changes in their AMP/ATP ratio versus the 
cells incubated with 5 mM and 25mM glucose (P< 0.05 and < 0 .02 respectively) (Tables 1&2). 
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Table 3.1/ 3.2 The effect of glucose concentration on myocyte adenine 
nucleotide contents. 
 
Myocytes were incubated for 1 hour with the indicated concentrations of glucose without (Table 
3.1) or with 0.5 mM sodium palmitate (Table 3.2), followed by freeze-stop and measurement of 
ATP, ADP and AMP contents. The values are means ± S.E.M. for the numbers of independent 
myocyte preparations shown in brackets. The ‘energy charge’ was calculated from (ATP + 
1/2ADP)/(total adenine nucleotides). 
A, B, N indicate P<0.01, <0.001, >0.05 respectively versus zero glucose (unpaired tests 
 
Table 3.1– Incubations with glucose alone. 
Adenine nucleotide contents 
(µmol per g wet wt. of cells) 
    zero glucose 
          [8] 
glucose = 5mM 
          [7]  
Glucose = 25 mM 
           [5] 
ATP  2.74 ± 0.42  8.29 ± 1.00
B  7.86 ± 0.61
B 
ADP  2.79 ± 0.27  2.79 ± 0.53
N  3.37 ± 0.43
N 
AMP  0.36 ± 0.08  0.39 ± 0.07
N  0.43 ± 0.10
N 
Total adenine nucleotides 
ΣATP + ADP + AMP)  5.89 ± 0.61  11.47 ± 1.60
A  11.70 ± 0.69
B 
Energy charge  0.693 ± 0.022  0.832 ± 0.029
A  0.816 ± 0.023
A 
  
Table 3.2 – Incubations with glucose plus palmitate. 
Adenine nucleotide contents 
(µmol per g wet wt. of cells) 
    zero glucose 
          [7] 
glucose = 5mM 
          [5]  
Glucose = 25 mM 
           [5] 
ATP  5.55 ± 0.70  5.62 ± 0.96
N  7.70 ± 1.11
N 
ADP  3.61 ± 0.41  2.93 ± 0.58
N  4.23 ± 0.79
N 
AMP  0.78 ± 0.13  0.57 ± 0.11
N  0.75 ± 0.18
N 
Total adenine nucleotides 
ΣATP + ADP + AMP)  9.95 ± 0.90  9.12 ± 1.60
N  12.47 ± 1.40
N 
Energy charge  0.738 ± 0.023  0.758 ± 0.027
N  0.782 ± 0.028
N   143 
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Figure 3.7:  The effects of glucose concentration and palmitate on the relative 
contents of ATP, ADP and AMP in myocytes. The measurements were obtained in the 
experiments shown in Table 3.1/3.2. These are expressed as percentages ± S.E.M. of the ATP 
content. A, B indicate P<0.05, <0.001 respectively versus zero glucose (unpaired tests). N.S. 
indicates P>0.5 versus zero glucose.(a) glucose alone (b)  glucose with palmitate  
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Figure 3.8: The effect of glucose concentration on myocyte α-2 AMPK activity in 
the presence of palmitate.  Myocytes were incubated for 1 hour with 0.5 mM sodium 
palmitate together with the indicated concentrations of glucose followed by freeze-stop, 
immunoprecipitation and assay of α-2 AMPK activity. The values are means ± S.E.M. from 7 
independent myocyte preparations.A, B, indicate P<0.01, <0.005 respectively compared against 
zero glucose (paired tests). The significance of the paired difference between 5 and 25 mM 
glucose is shown directly on the figure.   145 
It has been reported previously that increased activation and phosphorylation of AMPK occurs 
under conditions where cellular AMP/ATP is increased. However as was mentioned earlier, Itani 
et al;. 2003 found that in skeletal muscle decreased AMPK activity with increasing glucose was 
not accompanied by changes in the concentration of adenine nucleotides or creatine-P through out 
the incubation period.  Leptin  has  been  shown  to  activate  α-2 AMPK in skeletal muscle 
independent of the AMP: ATP ratio (Minokoshi et al.; 2002). Treatment of perfused rat hearts 
with insulin also decreased AMPK activity in aerobic hearts and prevented activation of AMPK 
during ischaemia without any detectable change in the AMP/ATP ratio (Beauloye et al.; 2001). 
Clark  et al.;  2004 found that perfustion of the rat hearts  with palmitate increased AMPK 
phosphorylation at α-2Thr172 without any change in the tissue AMP/ATP ratio. 
These results suggest that glucose decreases AMPK activity independently of adenine 
nucleotides. The mechanism by which glucose decreases AMPK activity and phosphorylation 
remains to be resolved.   146 
 
3.2.4 Inactivation of AMPK by glucose in the presence of AICAR 
AICAR is a cell-permeable precursor of 5-aminoimidazol-4-carboxamide ribonucleoside 
monophosphate (ZMP). ZMP mimics the activation of AMPK by AMP. AICAR has been shown 
to be taken up via nucleoside transport and metabolised to ZMP by a number of mammalian 
tissues, including hepatocytes (Vincent et al.; 1991; Corton et al.; 1995), adipocytes (Sullivan et 
al.; 1994), human erythrocytes (Zimmermam & Deeprose, 1978), fibroblasts (Thomas et al.; 
1981), skeletal muscle and heart tissue (Thomson et al.; 2009). Once synthesised within the cell, 
ZMP can be further phosphorylated to ZTP or metabolised to inosine monophosphate (IMP), 
which can be further metabolised to adenine and guanine or degraded to hypoxanthine or uric 
acid. 
In order to investigate whether, or not the effect of glucose on AMPK was also seen   under 
conditions where AMPK was activated by AICAR, cardiac myocytes were incubated with 3 mM 
glucose without AICAR and 3, 5, 10 and 25 mM glucose in the presence of AICAR.  
Cardiac myocytes incubated with AICAR AMPK activity significantly decreased as glucose 
concentration increased.  3 mM glucose in the present of AICR increased AMPK activity by 3.7 
fold while 5, 10 and 25 mM glucose increased AMPK activity by 2.0, 1.8 and 1.5 fold 
respectively compared to 3 mM glucose (Figure 3.9). 
  
Since AICAR mimics energy stress conditions these finding further indicated that the effect of 
glucose on AMPK activity could be separated from an effect that is mediated by change in 
adenine nucleotides. In addition that finding separated the effect of glucose from that of 
adrenaline.  Unpublished work by Dr. Tsuchiya in our laboratory has shown that AICAR 
abolished an adrenaline-dependent decrease in myocyte AMPK activity and phosphorylation. 
However it does not differentiate the effect of glucose from that of insulin. The ability of insulin 
to decrease myocyte AMPK activity is totally unaffected by AICAR (see section 3.2.6).   147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: The effect of glucose concentration on myocyte α-2 AMPK activity in 
the presence of AICAR. Myocytes were incubated for 1 hour without (filled symbol) or with 1 
mM AICAR (open symbols) together with the indicated concentrations of glucose followed by 
freeze-stop, immunoprecipitation and assay of α-2 AMPK activity. The values are means ± 
S.E.M. from 4 independent myocyte preparations. A, B indicate P<0.01, <0.005 respectively 
compared against 3 mM glucose with AICAR (paired tests).   148 
3.2.5 Conclusion 
AMPK activity decreases as glucose concentration increases in cardiac myocytes incubated for 1 
hour and the decrease on AMPK activity correlated with a decrease in the phosphorylation of α- 
Thr172.  Incubation with the  pharmacological agent AICAR had  no effect on the  ability  of 
glucose to decrease AMPK activity.  
 As already noted the classic view is that AMPK is activated by changes in the energy states of 
the cell, as reflected by the AMP/ATP ratio. An increase in AMP/ATP ratio can activate AMPK 
allosterically and inhibit its dephosphorylation by protein phosphatases. In the present study no 
change in adenine nucleotide contents was observed after 1 hour incubation with 5 or 25 mM 
glucose.  
AMPK activity was increased on the incubation without glucose. Therefore note that this is a 
totally abnormal state as total adenine nucleotides were decreased suggesting that the cells were 
so sick that they were catabolising their adenine nucleotides.  
Figure 3.10  shows that percentage effect of glucose  on AMPK activity in the presence and 
absence of palmitate were broadly similar. For comparison the percentage effect of glucose in the 
presence of AICAR is also shown.   
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Figure 3.10:  Summary of the effects of glucose concentration on myocyte α-2 
AMPK activity.  The values from the experiments shown in Figures 3.4, 3.8 and 3.9 are shown 
expressed as percentages of measurements with 5 mM glucose. The bars indicate S.E.M. 
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3.2.6  Interactions  between AMPK  activity,  insulin, adrenaline and 
glucose 
 Other work has shown that insulin and adrenaline can both increase glucose uptake by myocytes 
and can decrease AMPK activity/phosphorylation. Therefore  it was necessary to investigate 
whether the effect of glucose was totally independent of the effect of insulin (mediated through 
PKB) or the effect of adrenaline (via an unknown signalling pathway, which is independent of 
PKB) or whether there was some overlap of the glucose effect with either of these signalling 
pathways. In perfused hearts, insulin has been shown to decrease the basal AMPK activity as well 
as the activation of AMPK during ischemia. The mechanism of this inhibition is not fully 
understood (Beauloye et al.; 2001). The effect of insulin has been reported to be dependent on 
PI3K activity, but independent of changes in the AMP/ATP or Cr/CrP ratios (Beauloye et al.; 
2001). Previous studies have illustrated the involvement of PKB and the inhibitory effect of 
insulin on AMPK activity (Horman et al.; 2006). Kovacic et al. (2003) have shown that the effect 
of insulin on AMPK activity is mimicked by overexpressing constitutively active PKB, 
suggesting an involvement of the PI3K-PKB pathway (Kovacic et al.; 2003). The effect of insulin 
on AMPK activity was examined in cardiac myocytes  in order to establish whether there is any 
link in the mechanisms by which the sugar and the hormone decrease AMPK activity.  
 3.2.6.1 Effect of insulin on AMPK activity 
Figure 3.11 shows that 5 mM glucose decreased AMPK activity by 82% in both the absence and 
presence of insulin and insulin decreased AMPK activity by 31% and by 33% in the absence and 
presence of 5 mM glucose respectively. In Experiment B increasing glucose from 5 to 25 mM 
decreased AMPK activity by 45% and by 41% in the absence and presence of insulin respectively 
and insulin decreased AMPK activity by 44% and by 40% with 5 mM and 25 mM glucose 
respectively. 
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Figure 3.11: The effects of glucose and insulin to decrease myocyte α-2 AMPK 
activity are independent. The figure is a combination of two separate experiments (A & B). 
In both cases myocytes were incubated for 1 hour with the indicated concentrations of glucose 
without (open symbols) or with 10 nM insulin (filled symbols). The values are expressed as 
means ± S.E.M. of the measurements with 5 mM glucose alone. 6 independent myocyte 
preparations were used in Experiment A and 4 separate preparations were used in Experiment B. 
A, B indicate P<0.05, <0.025 respectively for effects of insulin (paired tests). Paired test P values 
for effects of glucose are shown directly on the figure.   152 
 
3.2.6.2 The effect of glucose concentration on the phosphorylation state 
of Serines 636/639 in myocyte insulin receptor substrate-1 (IRS-1) 
 
In general, reduced IRS activity  is associated with reduced tyrosine phosphorylation and/or 
increased serine phosphorylation. To determine levels of IRS1 phosphorylation of   Ser636/639, 
cells were incubated with zero or varying glucose concentrations. Figure 3.12 shows that IRS-1 
phosphorylation levels  at  2, 5, and 25 mM glucose  were not significantly different when 
compared to zero glucose.  These results suggested that IRS-1 was not involved in the signalling 
pathway whereas glucose decreases AMPK activity. 
The experiment shown in Figure 3.13 was performed as a control to accompany Figure 3.12; ie 
it shows that IRS-1 phosphorylation responded normally to insulin.  Interestingly AICAR in the 
presence of insulin slightly enhanced the phosphorylation of IRS1 Ser636/639 in response to 
insulin. A, B indicate P<0.025, <0.005 respectively for effects of insulin versus the appropriate 
control (paired tests). The P value shown directly on the figure indicates the significance of the 
effect of AICAR in the presence of insulin (paired test). AICAR had no significant effect on IRS-
1 phosphorylation in the absence of insulin. 
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Figure 3.12: the effect of glucose concentration on the phosphorylation state of 
Serines 636/639 in myocyte  insulin receptor substrate-1 (IRS-1).    Myocytes were 
incubated for 1 hour with the indicated concentrations of glucose. (a)Phospho-IRS-1 
measurements were normalized against measurements of total IRS-1 protein and then expressed 
as percentages of the values in the presence of 5 mM glucose. The values are means ± S.E.M. 
from 5 independent myocyte preparations. No significant effects of glucose were observed. (b) 
Representitive blot. 
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Figure 3.13: AICAR enhanced the effect of insulin on the phosphorylation state of 
Serines 636/639 in myocyte insulin receptor substrate-1 (IRS-1).  Myocytes were 
incubated for 1 hour with 5 mM glucose without (c) (open symbols) or with 1 mM AICAR(A) 
(filled symbols). Insulin was added as indicated  (ins) or (ins+A). Phospho-IRS-1(a) 
measurements were normalized against measurements of total IRS-1 protein and then expressed 
as percentages of the values in the absence of AICAR and insulin. The values are means ± S.E.M. 
from 5 independent myocyte preparations. (b) Representative blot. 
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3.2.6.3  Variation of glucose concentration had no effect upon the 
phosphorylation state of myocyte protein kinase B (PKB). 
 
 PKB is known to mediate a number of biological
 responses to insulin and growth factors in 
various tissues, its role in glucose
 uptake being one of the most extensively studied. PKB
 activity 
is  required for the insulin-induced activation of
  phosphodiesterase 3B (PDE3B),  and for the 
antilipolytic action
  of insulin  in adipocytes. Moreover  inhibition of PKB activity resulted  in
 
reduction in de novo lipid synthesis and in the ability of
  insulin to stimulate this process in 
lipogenic tissues. The regulation of the rate-limiting
 enzyme acetyl-CoA carboxylase (ACC) by 
insulin through
 dephosphorylation of AMPK phosphorylation site was dependent on the presence 
of active
 PKB. It is also required for positive effect of insulin on lipid storage in adipocytes.    
Next in this study the effect of glucose on myocyte PKB was examined in order to determine 
whether PKB could mediate the glucose effect on AMPK. 
Figure 3.14 shows that glucose at 0, 2, 5 and 25 mM glucose had no significant effect on PKB 
Thr 308 and Ser 473 phosphorylation. As expected insulin as a control significantly increased the 
phoshorylation of PKB at both Thr 308 and the Ser 473 sites (p<0.005). 
3.2.6.4 The effect of glucose and insulin on phosphorylation of AMPK α- 
subunit Ser485/491 
 
Recently, Horman et al. 2006 demonstrated that the AMPK α subunit is phosphorylated at Ser485 
(α1)  or  Ser491  (α2)  by  PKB  in vitro  or in response to insulin in perfused hearts.    The 
phosphorylation of α- Ser485/491 was shown to inhibit the phosphorylation of α- Thr172 and this 
was suggested to be the mechanism by which insulin inhibits AMPK (Horman et al., 2006). The 
effect  of  glucose  on  α-  Ser485/491 phosphorylation of AMPK was examined using a 
commercially available antibody. This antibody was previously used successfully to detect an 
increase in α- Ser485/491 phosphorylation by PKB (Soltys et al.; 2006).   156 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
Figure 3. 14:  Variation of glucose concentration had no effect upon the 
phosphorylation state of myocyte protein kinase B (PKB). (a) Myocytes were incubated 
for 1 hour with the indicated concentrations of glucose without (open symbols) or with 10 nM 
insulin (filled symbols). Phospho-PKB measurements were normalized against total PKB protein 
and then expressed as percentages of the values in the presence of 5 mM glucose alone. The 
values are means ± S.E.M. for 4 independent myocyte preparations. A indicates P<0.005 for the 
effects of insulin at 5 mM glucose (paired tests) (b) Representitive blot 
(a) 
(b)   157 
 
Figure 3.15 Cardiac myocytes incubated with 0, 2, 5 and 25 mM glucose showed no appreciable 
difference in Ser485/491 phosphorylation, whereas in cells incubated with insulin it increased the 
phosphorylation of Ser485/491 compared to the 0, 2, 5 and 25 mM glucose. This result confirms 
previous work (Horman et al.; 2006) in that insulin was able to increase the phosphorylation of 
AMPK  α-Ser485/491 at 5 mM glucose (result from 3 independent myocyte preparations). 
However,  in  a  single  preparation  glucose  alone  has  no  noticeable  effect  on  α-  Ser 485/491 
phosphorylation.   158 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15:  The effect of glucose on AMPK Ser485/491 phosphorylation. 
Phosphorylation of AMPK Ser485/491 was examined after incubating cardiac myocytes for 
1 hour with 0, 2, 5, 25 mM glucose or 5 mM glucose in the presence of 10nM insulin (ins).  
Cell lysates were used for Western blot analysis. Membranes were probed with AMPK Ser 
485/491 phospho and AMPK total antibody. The figures show results from four independent 
myocytes preparations.   159 
 
3.2.6.5 The effect of AICAR to enhance the effect of insulin on 
phosphorylation of PKB  
Figue 3.16 shows a significant increase in the phosphorylation of Thr 308 and Ser 473 in the 
presence of insulin compared to the control. Surprisingly AICAR  in the presence of insulin 
caused a  significant increase in PKB phosphorylation at Thr 308 and Ser 473 compared to when 
cells were incubated with insulin alone   (p<0.025, p<0.05 respectively). This result suggests that 
during hyperglycemic conditions glucose might play a part to antagonise PKB activity. Therefore 
the activation of AMPK might be beneficial during metabolic stress.    
 
3.2.6.6 The effect of insulin on AMPK activity on the presence of 
AICAR or oligomycin 
 In previous experiments, high glucose was shown to decrease AMPK activity in the presence of 
AICAR. It was additionally investigated whether the effect of insulin could be maintained under 
conditions  where AMPK was activated by other AMPK-activating stimuli;  i.e. AICAR  or 
oligomycin.  Cardiac myocytes were incubated with insulin in the presence of AICAR or 
oligomycin for 1 hour and then AMPK activity was examined under these conditions.  
Figure 3.17 shows AICAR and oligomycin significantly increased AMPK activity (p<0.01, p<0 
05). However the effect of insulin on AMPK activity was totally preserved in the presence of 
these agents; i.e. the percentage decreases in AMPK activity due to insulin were 44% without 
AICAR or oligomycin, 46% in the presence of AICAR and 48% in the presence of oligomyocin.    160 
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Figure 3.16: The effects of insulin on myocyte α-2 AMPK activity in the presence 
of AICAR or oligomycin.  Myocytes were incubated for 1 hour with 5 mM glucose without 
(open symbols) or with 10 nM insulin (filled symbols) together with other additions as indicated. 
The values are means ± S.E.M. of the measurements with 5 mM glucose alone and are from 5 
independent myocyte preparations.  A, B indicate P<0.01, <0.005 respectively for effects of 
insulin (paired tests). Paired test P values for effects of AICAR and oligomycin are shown 
directly on the figure.    161 
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Figure 3.17: AICAR enhanced the effect of insulin on the phosphorylation state of 
myocyte protein kinase B (PKB). (a)Myocytes were incubated for 1 hour with 5 mM glucose 
without (open symbols) or with 1 mM AICAR (filled symbols).10 nM  insulin was added as 
indicated. Phospho-PKB measurements were normalized against total PKB protein and then 
expressed as percentages of the values in the absence of insulin and AICAR. The values are 
means ±  S.E.M. for 5 independent myocyte preparations.  A, B indicate P<0.025, <0.005 
respectively for effects of insulin versus the appropriate control (paired tests). Paired P values 
shown directly on the figure indicate the significance of effects of AICAR in the presence of 
insulin. AICAR had no significant effect on PKB phosphorylation in the absence of insulin.(b) 
representititive blot   162 
3.2.7 The effect of an  inositol phosphoglycan  (IPG) preparation on 
AMPK activity 
It was previously reported that ceramide mediated the inhibition of AMPK by palmitate through 
the activation of PP2A (Yong et al.; 2007).  The action of extracellular agonists results in the 
activation of a variety of lipases. This causes the generation of lipid-derived second messengers, 
which comprise a growing list of molecules, including inositol (1,4,5)-trisphosphate, 
diacylglycerol, ceramide, lysophosphatidic acid, and others (Mato, 1990; Divecha & Irvine, 
1995). Inositol phosphoglycan (IPG) insulin second messenger, which has been reported to have 
potential effect to lower  blood glucose in  diabetic  rats  ( Ikhlass  & Gumma Patent no 
WO/2000/039135) and mimics the short-and long-term actions of insulin (Romero & Lamer, 
1993, Romero et al.; 1988), could perhaps mediate the effect of glucose on AMPK activity. In 
order to test this, cardiac myocytes were incubated with 5 and 25 mM glucose in the presence or 
absence of 10 μg/ml IPG (personal contact). Figure 3.18 shows that with myocytes incubated 
with 5 or 25 mM glucose IPG preparation significantly increased AMPK activity to the extent 
that the difference between AMPK activites at  5 and 25 mM glucose was a bolished . This 
possibly suggests that IPG preparation work in vivo as AMPK activator. If it is an AMPK 
activator in the liver this could leads to inhibition of gluconeogenesis and a lowering of blood 
glucose. However the effect of this preparation were not investigated further, including the 
possibility that it may have increased myocyte AMPK activity through increase cellular 
AMP/ATP ratio.  
3.2.8 The effect of glucose on AMPK activity was severely blunted in the 
presence of adrenaline.  
Figure 3.19 shows that, in the presence of adrenaline, variation of glucose concentration in the 
range 0 to 15 mM had no significant effect upon α-AMPK activity.  5 mM glucose was used in 
this experiment as a control because previous work in our laboratory has showed that adrenaline   163 
decreased AMPK activity at the same glucose concentration. The results provide the expected 
effect which is that adrenaline significantly decreased AMPK activity.  It has been reported that, 
in perfused hearts, adrenaline may antagonise the activation of α2 AMPK by palmitate (Clark et 
al..; 2004).  The stimulation of heart tissue with adrenaline is associated with a change in fuel 
selection,  adrenaline increases the rate of ATP production as the energy needs of the heart 
increases; it does this by increasing both glucose and fatty acid oxidation (Collins et al.; 1994).    164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: The effect of an IPG preparation on myocyte α-2 AMPK activity. 
Myocytes were incubated for 1 hour with the indicated concentrations of glucose without (open 
symbols) or with 10 μg/ml of IPG (filled symbols). The values are means ± S.E.M. from 6 
independent myocyte preparations expressed as percentages of the measurements in the presence 
of 5 mM glucose alone. A, B indicate P<0.05, <0.025 for effects of IPG versus the appropriate 
control (paired tests). 
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Figure 3.19:  Attenuation by adrenaline of the effect of glucose upon myocyte α-2 
AMPK activity.  Myocytes were incubated for 1 hour with the indicated concentrations of 
glucose without (filled symbol) or with 2 µM adrenaline (open symbols). The values are means ± 
S.E.M. expressed as percentages of the measurements with 5 mM glucose alone and are from 5 
independent myocyte preparations.A indicates P<0.01 for the effect of adrenaline at 5 mM 
glucose (paired test).   166 
3.2.9 Conclusion 
Glucose had no effet on phosphorylation of IRS-I Ser363/639, PKB Ser308, Thr473 and AMPK 
Ser485/491.  These  results  suggested that glucose decreases AMPK activity independently of 
insulin. The other finding that AICAR enhances the phosphorylation of PKB Ser308 and Thr473 
in the presence of insulin strengthens the hypothesis that AMPK could be a therapeutic target for 
type-2 diabetes.  
Interestingly an IPG preparation which, has been reported to decrease glucose levels in diabetic 
rats increased AMPK activity. The mechanism by which IPG preparation increased AMPK 
activity is unclear. 
Adrenaline has been reported to decrease cardiac myocyte AMPK activity by a mechanism which 
is not understood. In unpublished data from our laboratory showed that the effect of adrenaline on 
AMPK activity was completely blocked in the presence of AICAR. Insulin and glucose were 
found to decrease AMPK activity in the presence of AICAR. Therefore these results suggest that 
insulin, glucose and adrenaline decrease AMPK activity through distinct mechanisms.  
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Section: 3 
3.3 The effect of increasing glucose concentration on  AMPK 
phosphorylation targets in myocytes. 
 
3.3.1 Acetyl- CoA Carboxylase 
AMP-activated protein kinase (AMPK) is activated during muscle contraction in response to an 
increase in AMP. Once activated, AMPK has been proposed
  to phosphorylate a number of 
targets, resulting in increases in
 glucose transport, fatty acid oxidation, and gene transcription. It 
has been reported that using a phosphoserine
 antibody to ACC and a phosphothreonine antibody 
to AMPK, evidence
  was obtained for phosphorylation  and activation  of ACC in vitro
  in 
gastrocnemius muscle electrically stimulated at different frequencies,
 and in muscle from rats 
running on a treadmill. Significant
 negative linear correlations between phospho-ACC and ACC 
activity
 were observed. (Park et al.; 2002) In heart AMPK is able to phosphorylate ACCα and 
ACCβ,  resulting in an almost complete loss of ACC activity.  ACC in the heart exist in a 
heterodimeric structure, and that this structure is tightly associated with the α2 subunit of AMPK. 
(Saha  et al.; 2001). As ACC is a well established downstream target of AMPK in heart and other 
cell types, in the present study glucose decreased AMPK activity and this might has impact on 
ACC phosphorylation.  
Figure 3.20 shows that, relative to incubation at 5 mM glucose ACC Ser227 phosphorylation was 
significantly higher at zero and 2 mM glucose and was significantly lower at 25 mM glucose.  
The decrease in ACC phosphorylation between 5 and 25 mM glucose (without insulin) was very 
similar to the decrease in ACC phosphorylation when insulin was added to myocytes at 5 mM 
glucose. The effect of AICAR upon the phosphorylation of ACC at 5 mM glucose was also 
measured by way of comparison. 
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Figure 3.21 this experiment demonstrates that increasing glucose concentration decreased ACC 
phosphorylation in the presence of AICAR.  This experiment complements that in Figure 3.9 
which showed that AICAR did not abolish the effect of glucose to decrease AMPK activity. 
Figure 3. 22 shows that insulin significantly decreased the phosphorylation of ACC Ser277 by 
AICAR or oligomyocin.  These decreases on ACC Ser227 phosphorylation correlated with a 
decrease on AMPK activity. Therefore, it appears that glucose and insulin have genuine direct 
inhibitory effect on AMPK in cardiac myocytes. 
Figure 3.23 shows a positive linear correlation between changes in the phosphorylation of Serine 
227 in ACC and changes α -2 AMPK activity in cardiac myocytes. 
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Figure 3.20:  The effect of glucose concentration, insulin and AICAR on the 
phosphorylation of Serine 227 in myocyte acetyl-CoA carboxylase (ACC). (a)Myocytes 
were incubated for 1 hour  with the indicated additions. Phospho-ACC measurements were 
normalized against measurements of total ACC protein and then expressed as percentages of the 
values in the presence of 5 mM glucose alone. The values are means ± S.E.M. of the numbers of 
independent myocyte preparations shown in brackets. A, B, C indicate P<0.025, <0.01, <0.005 
respectively compared against the 5 mM glucose value (paired tests).(b) Representitive blot. 
 
 
 
 
 
 
 
 
 
Figure 3.21:  Effect of glucose on ACCS Ser227 phosphorylation in the presence of 
AICAR.  Cardiac myocytes were incubated  at the indicated glucose concentrations  with or 
without 1mM AICAR (+) or  with 10 nM insulin (INS). Cells were lysed and analysed by western 
blotting using anti-phospho-Ser227 and total ACC antibody.   170 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22: Effects of insulin on the phosphorylation of Serine 227 in myocyte 
acetyl-CoA carboxylase (ACC) in the presence of AICAR or oligomycin. Myocytes 
were incubated for 1 hour with 5 mM glucose without (open symbols) or with 10 nM insulin 
(filled symbols) together with other additions as indicated. Phospho-ACC measurements were 
normalized against measurements of total ACC protein. Values are means ± S.E.M. of the 
measurements with 5 mM glucose alone and are from the same 5 independent myocyte 
preparations used in the experiment shown in Figure 3.18.A, B, C indicate P<0.05, <0.025, 
<0.005 respectively for effects of insulin (paired tests). Paired test P values for effects of AICAR 
and oligomycin are shown directly on the figure.   171 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23: A positive linear correlation between the phosphorylation of Serine 
227 in acetyl-CoA carboxylase and α -2 AMPK activity in myocytes. The Values are 
taken from Figures 3.17 and 3.22. The bars indicate S.E.M. Where these are not shown, they lie 
within the symbol. The gradient of the regression line ± its standard error was 0.922 ± 0.168 
which is not significantly different from a gradient of 1.0 (P<0.3).  
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3.3.2 The effect of glucose on PFK2 activity and the content of Fructose 
2, 6-bisphosphate in cardiac myocyte  
 
PFK-2 is an enzyme responsible for synthesis of fructose 2, 6-bisphosphate which is a powerful 
activator of PFK-1 in the glycolytic pathway (Toyoda et al., 2004). It has been reported to be 
phosphorylated and activated by AMPK (Hue et al.; 2000). Heart PFK-2 was phosphorylated on 
Ser466 and activated by AMPK in vitro. In perfused rat hearts, anaerobic conditions or inhibitors 
of oxidative phosphorylation (oligomycin and antimycin) caused  induced AMPK activation, 
which correlated with PFK-2 activation and with an increase in fructose 2,  6-bisphosphate 
concentration. Moreover, in cultured cells transfected with heart PFK-2, oligomycin treatment 
resulted in a parallel activation of endogenous AMPK and PFK-2. In these cells, the activation of 
PFK-2 was due to the phosphorylation of Ser466. A dominant-negative construct of AMPK 
abolished the activation of endogenous and cotransfected AMPK, and prevented both the 
activation and phosphorylation of transfected PFK-2 by oligomycin (Hue et al.; 2000). 
 PFK-2 activity was tested in this study. The main purpose was to see what effect of varying 
glucose concentration had on myocyte PFK-2 activity on the basis that heart PFK-2 is activated 
on being phosphorylated by AMPK. Whilst glucose decreases AMPK activity the expectation 
was that increasing glucose concentration might decrease PFK-2 activity.PFK-2 activity was 
measured as described in section 1.12.2.  However Figure 3.24 shows a significant increase  in 
PFK-2 activity at 2, 5, and 25 mM glucose compared to zero glucose (p <.025, < 0.005, < 0.005 
respectively). In parallel to this experiment the level of fructose 2, 6-bisphosphate was measured 
in cardiac myocytes.Figure 3.25  shows fructose  2,6-bisphosphate level was  significantly  
increased at all glucose concentrations compared to cell incubated with zero glucose.  
Previous work with perfused hearts (Clark et  al.;  2004) showed that palmitate caused a 
significant increase in AMPK activity. On that basis we reasoned that heart PFK-2 activity might 
be increased by palmitate.   Figure 3.26 shows that in heart perfused with palmitate under 
conditions which are known to activate AMPK, there was a slight but non–significant decrease in   173 
PFK-2 activity. Similary the levels of F2,6BP were not significantly decreased in the presence  of 
palmitate ( Figure 3.27).  
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Figure 3.24: The effect of glucose concentration on myocyte phosphofructokinase -
2 (PFK-2) activity. Myocytes were incubated for 1 hour with the indicated concentrations of 
glucose followed by freeze-stop and assay of PFK-2 activity. The values are means ± S.E.M. 
from 9 independent myocyte preparations. A, B indicate P<0.025, <0.005 respectively versus 
zero glucose (paired tests). 
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Figure 3.25: The effect of glucose concentration on the myocyte content of fructose 
2,6-bisphosphate. Myocytes were incubated for 1 hours with the indicated concentrations of 
glucose followed by freeze-stop and the measurement of fructose 2,6-bisphosphate content. The 
values are means ± S.E.M. from 5 independent myocyte preparations. A indicates P<0.0005 
versus zero glucose (paired tests). 
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Figure 3.26:    Phosphofructokinase-2 (PFK-2) activities in perfused rat hearts. 
Hearts were perfused for 1 hours with 5 mM glucose without (open symbol) or with 0.5 mM 
sodium palmitate (filled symbol) followed by freeze-stop and assay of PFK-2 activity. The values 
are means ± S.E.M. from 9 hearts. As indicated, palmitate did not significantly affect PFK-2 
activity (unpaired test).   177 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.27:  Fructose 2,6-bisphosphate content of perfused rat hearts 
Hearts were perfused for 1 hours with 5 mM glucose without (open symbol) or with 0.5 mM 
sodium palmitate (filled symbol) followed by freeze-stop and assay of fructose 2,6-bisphosphate. 
The values are means ± S.E.M. from 5 hearts. As indicated, palmitate did not significantly affect 
fructose 2,6-bisphosphate content (unpaired test). 
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To investigate the effect of palmitate on Fru 2,6bisphosphate level in cardiac myocytes, first 
AMPK activity was investigated under this condition. Figure  3.28  shows  that  palmitate 
significantly increased AMPK activity compared to the control.  To examine whether the 
increased on AMPK activity by palmitate had an effect on the level of fructose 2,6-bisphosphate 
level  in cardiac myocyte, fructose 2,6-bisphosphate level was examined   under similar 
conditions.  
Figure 3.29 shows that the levels of F 2,6BP at 15, 30 or 60 minutes were significantly decreased 
in cells incubated with palmitate compared to the control. This result suggestes that  in the 
presence of fatty acid the level of allosteric inhibitors of FPK-2 might increase, and these could 
have negated any activating effect of AMPK. 
  Hue and co-workers have observed in isolated working rat heart that glycolysis was stimulated 
to different extents by increasing the concentration of glucose, by increasing the workload or 
addition of insulin (Hue and   Rousseau, 1993). Under all the condition tested, an increase in 
fructose 2, 6-bisphosphate content was observed. Similar results were observed in hepatic cells 
when liver was perfused with 40 mM glucose. The mechanism of the stimulation of hepatic 
glycolysis by glucose is unclear (Kabashima et al,; 2002). In this circumstance, elevated glucose 
levels might cause a covalent modification of PFK-2/FBPase-2, by a mechanism which overrides 
any effect resulting from glucose-induced suppression of AMPK, thus leading to the activation of 
glycolysis. There is substantial evidence to suggest that glucose increases the fructose 2, 6-
bisphosphate level. The most convincing lines of evidence come from a demonstration carried out 
in pancreatic and MIN6 cell line. Glucose may have an impact on the fructose 2, 6- bisphosphate 
content by covalent modification of PFK-2/FBPase or through changes in metabolite 
concentration that act as activators or inhibitors of either the kinase or bisphosphatase (Catherine 
et al.; 2008).   179 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28:  The effects of palmitate on myocyte α-2 AMPK activity. 
Myocytes were incubated for 1 hour with 5 mM glucose without or with 0.5 mM palmitate as 
indicated. The values are means ± S.E.M. expressed as percentages of the measurements with 5 
mM glucose alone and are from 5 independent myocyte preparations P<0.05, Paired test. 
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Figure 3.29: The effect of palmitate on the myocyte content of fructose 2,6-
bisphosphate. Myocytes were incubated for the indicated times with 5 mM glucose 
without (open symbols) or with 0.5 mM sodium palmitate (filled symbols) followed by 
freeze-stop and assay of fructose 2,6-bisphosphate. The values are means ± S.E.M. from 
7 independent myocyte preparations. 
A, B, indicate P<0.025, <0.005 respectively for effects of palmitate (paired tests 
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3.3.3 eNOS phosphorylation 
A potential downstream target of  AMPK signalling is the nitric oxide pathway. Ischemic 
activation of AMPK is accompanied by an increase in eNOS phosphorylation and activation in 
the heart rate (Chen et al.; 2000).  Nitric oxide (NO) can enhance ADP-ribosylation of  a 37-KDa 
cytosolic protein, later identified as GAPDH (Dimmeler & Brune, 1992), a key enzyme involved 
in the glycolytic pathway. A similar action of NO has been documented in neuronal cells (Zhang 
& Snyder, 1992). Other researchers found that as eNOS increases glucose transport there is an 
indirect stimulatory action of NO on PFK-2 in neurons (Almeida et al.; 2004). Although the 
mechanisms are still poorly defined, convincing evidence has been provided that eNOS   plays an 
important role in the regulation of myocardial substrate metabolism (Depre C et al.;  1989). 
Previous studies have outlined the involvement of eNOS in glucose metabolism by a stimulation 
of glucose uptake (Young et al.; 2004) mediated by AMPK. In this study cardiac myocyte eNOS 
Ser 1177 phosphorylation was investigated under different conditions. 
Figure 3.30 shows that no effect of glucose concentration, insulin or AICAR on eNOS Ser1177 
phosphorylation could be detected. Unfortuntely eNOS appeared to be expressed at low levels in 
the myocytes and this low level of expression may have precluded the detection of effects. This 
result is in agreement with the results of other groups (Schulz, et al.; 2004) 
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Figure 3.30:  Effect of glucose, insulin and AICAR on eNOS Ser1177 
phosphorylation. Phosphorylation of eNOS Ser1177 was examined after incubation of cardiac 
myocytes for 1 hour with 10 nM  insulin, (INS) 1 mM AICAR (A), 0, 5 , or 25  mM glucose. Cell 
lysates were analysed by western blotting using (a) anti-phospho-e –NOS antibody and  (b) an 
antibody against total e-NOS. The results are from 3 independent myocyte preparations. The 
above is representative blot. 
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3.3.4 Conclusion 
 In this study, ACC227 phosphorylation was decreased as glucose concentration was increased.  
The extended N-termial sequence of ACCβ has been proposed to regulate the association of the 
enzyme with the mitochondrial outer membrane (He et al.; 1996). A later study has shown ACCβ 
to be localised on the mitochondrial outer membrane in avariety of cell type (Abu- Eliheiga et al.; 
2000). Whether the phosphorylation state of the enzyme can regulate membrane association is not 
known. A protein regulator able to activate ACC has been isolated from rat liver (Quayle  et al.; 
1993). This activation is not due to a change in ACC phosphorylation and appears to be due to a 
specific protein-protein interaction. It is therefore possible that if such a regulator exists in heart 
tissue, phosphorylation of ACCβ may regulate this association. The activity of ACC may be 
influenced by the cytosolic concentration of citrate. Citrate may activate ACC allosterically or 
increase provision of the acetyl-CoA substrate via ATP-citrate lyase (Saha   et al.; 2002). Purified 
rat ACCβ is phosphorylated and inactivated in vitro by PKA and AMPK (Dyck et al.; 1999) 
PFK-2 
 Cardiac ischemia or anoxia increase glycolysis by activation of PFK-2 and increases glucose 
transport. This effect is mediated by AMPK. AMPK phosphorylates heart PFK-2 on Ser 466 
which leads  to its activation.  Therefore, heart PFK-2 is a novel substrate of AMPK  and its 
activation is involved in the  Pasteur effect (Marsin et al.; 2000).  Hue and co-workers showed   
that activation of PFK-2 did not require PKB, but was mediated by another protein kinase located 
downstream of PDK1, this kinase was termed WISK (Hue et al.; 2000). Likewise the effect of 
glucose to activate PFK-2 cannnot require PKB because I have showed that PKB phosphorylation 
is unaffected by varying glucose concentration (Figure 3.14). Since the activation of PFK-2 
activity in response to increasing glucose persisted through freeze-stop and lysis of the cell it 
seems reasonable to believe that this is due to some covalent modification of PFK-2 (an allosteric 
effect should not survive this treatment). However at this stage we cannot differentiate between 
the possibility that glucose alter the activity of a protein kinase which modifies PFK-2 or that   184 
glucose is altering of a protein phosphatase for which PFK-2 is a target. At present there is little 
kown about the protein phosphatases which dephosphorylate heart PFK-2 (personal 
communication from Rider to Saggerson). The protein kinases which can phosphorylate heart 
PFK-2 have been reviewed by Rider et al.; 2004 and include the conventional Protein kinase C, 
WISK, AMPK, Ca CAMK,  protein kinase,  p70S6 kinase and p90 rsk.  AMPK, protein kinase A 
and PKB can be ruled out as possible mediators of the glucose effect on PFK-2. Further work is 
needed to define which kinase or phosphotase mediates the effect of glucose.  
eNOS 
During myocardial ischemia, the phosphorylation of eNOS at serine residue 1177 close to the 
carboxyl-terminal is a critical requirement for eNOS activation and has been reported to be 
mediated by AMPK. (Chen    et al.; 1999). The activity of eNOS is also influenced by 
phosphorylation at threonine residue (eNOS Thr495). Phosphorylation at this site inhibits NO 
synthesis, whereas dephosphorylation can promote NO synthesis (Mount et al.; 2007). In mice 
metformin significantly increased the phosphorylation of eNOS Ser1177 phosphorylation over 
the basal level for a period of 24 h. Metformin did not alter eNOS Thr495 phosphorylation at any 
investigated time point. It has been reported that Metformin also failed to increase NOS Ser117 
phosphorylation  when  administered  to  AMPKα2  dn  Tg  mice.  Similarly, eNOS  Thr495 
phosphorylation remained unchanged in AMPKα2 dn Tg mice administered metformin.(Andrina 
et al.; 2008). From the above studies eNOS phosphorylation is more detectable after at least two 
hours. In the present study the cells were incubated only for 1 hour. This might be the reason why 
changes in phosphorylation were undetecable even in the presence of AICAR. eNOS is  relatively 
poorly expressed  in cardiac myocytes, and this might affect ability to detected change in its 
phosphorylation.   185 
Section: 4 
3.4 Is the effect of variation of glucose concentration to decrease AMPK 
activity mediated by a product of glucose metabolism? 
 
3.4.1 The effect of glucose on myocyte glycogen content  
 
AMPK β subunits contain a conserved domain that causes association with glycogen. Although 
glycogen availability is known to affect AMPK regulation in vivo, the molecular mechanism for 
this has not been clear. It has been reported that AMPK is inhibited by glycogen, particularly 
preparations  with a high branching content. Oligosaccharide  with single  α1-6  branch  is  an 
allosteric inhibitor that also inhibits AMPK phosphorylation by upstream kinases. Removal of the 
outer chains of glycogen using phosphorylase, thus exposing the outer branches, renders 
inhibition of AMPK more potent. Inhibition by all carbohydrates tested was dependent on the 
glycogen-binding domain and was abolished by mutation of residues required for carbohydrate 
binding (Hardie et al.; 2008). 
Myocardial glycogen content reflects the balance between glycogen synthase and glycogen 
phosphorylase fluxes.  Both of these enzymes are controlled in a complex manner via 
phosphorylation and key allosteric mediators, including AMP, ATP, inorganic phosphate and 
glucose-6-phosphate (Neely et al .; 1974; Saha  et al.; 2002). In previous studies using heart 
tissue extracts, AICAR had no effect on glycogen synthase and glycogen phosphorylase. Other 
investigators using skeletal muscle have found contrary evidence, that AICAR activates glycogen 
phosphorylase and stimulates glycogenolysis (Young et al.; 1996). In this study to test whether 
the increase in stored glycogen is associated with decreased AMPK activity, cells were incubated 
in 0, 5, and 25 mM glucose for an hour then treated as described in section  2.9.1  and  the 
extracted glycogen was hydrolysed and assayed   by the method described in section    2.9.1. 
Figure 3.31 shows that the glycogen content in cells was not significantly altered within the 
glucose concentration range of 5 to 25 mM within which AMPK activity is normally halved.    186 
Hence the decrease   in AMPK activity on going from normal glycemic conditions (5mM) to 
severe hyperglycemia (25mM) cannot be attributed a to a change  in glycogen content. The 
essentially zero glycogen content in cells incubated with zero glucose shows how starved those 
cells are this complements the significant decrease in total adenine nucleotides under this 
condition. (Table3.1)    187 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.31:  The effect of glucose concentration on myocyte glycogen content. 
Myocytes were incubated with the indicated concentrations of glucose for 1 hour followed by 
extraction and measurement of the glycogen content. The values are means ± S.E.M. from 6 
independent myocyte preparations.  N  .S. indicates that there was no significant difference 
between the glycogen contents at 5 and 25 mM glucose (P<0.15, paired test).   188 
 
3.4.2 The effect of glucose on AMPK activity may be one of mediated by 
its metabolites  
Glucose metabolism occurs in three stages - glucose uptake, glycolysis and glucose oxidation. 
Glucose uptake in the heart occurs via facilitated transport by the glucose transporters, Glut-1 and 
Glut-4 (Brownsey et al., 1997). The inhibitory effect of glucose on AMPK activity could be due 
to either a direct action of the sugar  itself or due to one of the products generated by its 
metabolism. To distinguish between  direct and an  indirect effect of glucose, the effect of a non-
metabolizable analogue of glucose on AMPK activity was examined.Figure 3.32 shows glucose 
enter the cell through its transporters in the heart GLUT1 and GLUT4. Glucose in cardiac 
myocyte is phosphorylated by hexokinase to glucose 6-phosphate which is metabolised further.  
Figure 3.33 shows that the glucose analogue, 3-O-methy-D-glucose failed to decrease AMPK 
activity below the level seen with zero glucose.  Therefore it seemed more likely that a glucose 
metabolite might be responsible of the effect of glucose on AMPK activity. The next approache 
was to try to establish which metabolite or pathway might be responsible for this effect. 
3.4.3 Glycolysis 
Upon entering the cell, glucose can be metabolised along three different pathways, glycolysis, the 
pentose phosphate pathway and the hexosamine biosynthetic pathway as it is shown in Figure 
3.34. This prompted us to examine which pathway might be responsible for decreasing  AMPK 
activity. Therefore some metabolites  of the glycolytic pathway were tested. Firstly cardiac 
myocytes were exposed to 2-deoxyglucose (2-DOG). Besides possibly mimicking an effect of 
free glucose, 2-DOG can be phosphorylated by hexokinase to yield 2-DOG 6-phosphate which is 
not metabolized further in glycolysis but which might possible mimic a regulatory effect of 
glucose 6-phosphate. However like 3-O-methyglucose, 2-DOG was failed to decrease AMPK 
activity below the level seen with zero glucose (Figure 3.33). As a second approach cardiac   189 
myocytes  were incubated with the glycolytic products lactate and pyruvate as the indicated 
concentrations.  
 Figure 3.35 shows a significant increased in AMPK activity in cells incubated in the presence of 
3 mM pyruvate when compared with the control cells (p<0.005). However pyruvate did not 
mimic the effect of glucose to decrease AMPK activity. The effect of pyruvate on AMPK activity 
is unexpected.  It should be noted that the concentration of pyruvate which was used in this 
experiment was supra-physiological. 
In order to determine whether lactate could affect AMPK activity in cardiac myocytes, cells were 
incubated with various lactate concentrations and α-2 AMPK activity was measured. Figure 3.36 
shows that there was no significant difference in AMPK activity in cells incubated with lactate 
concentrations in the range of 0.5 - 2 mM, in comparison to the control cells. However, the 
activity of AMPK was significantly increased at the slightly supra-physiological concentration of 
5 mM lactate in comparison to the control (p<0.005).  
During metabolic stress – such as ischemia – the heart quickly adapts to the restricted oxygen and 
nutrient supply, and undergoes a dramatic switch from aerobic to anaerobic metabolism. Pyruvate 
produced from glycolysis is converted to lactate. There is a growing body of evidence which 
suggests that AMPK is considered to be an important mediator in the control of glucose and fatty 
acid metabolism during metabolic stress. From the above results, one could conclude that AMPK 
activation  occurs at high lactate concentrations which could act in parallel to the ischemic 
condition. Additionaly,   these findings suggest that pyruvate and lactate are not the candidates as 
mediators of the effect of glucose to decrease AMPK activity. 
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Figure 3.32  shows 3-O-methylglucose is not phosphorylated by hexokinase 
whereas 2-deoxyglucose is phosphorylated to 2-deoxyglucose 6-phosphate. Neither 
sugar is further metabolized.   191 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.33: 3-O-methylglucose (3-O-MeG) and 2-deoxyglucose (2-DOG) did not 
mimic the effect of glucose to decrease myocyte α-2 AMPK activity. 
Myocytes were incubated for 1 hour with the indicated additions. The values are means ± S.E.M. 
expressed as percentages of the paired 5 mM glucose values. The numbers of independent 
myocyte preparations were: 5 mM glucose, 12; with no sugar, 5; with 5 mM 3-O-MeG, 5; with 5 
mM 2-DOG, 7.A, B, indicate P<0.01, <0.005 respectively versus the 5 mM glucose value (paired 
tests). 
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Figure 3.34 Hypothetical mechanism of glucose sensing in cardiac myocyte in response 
to an alteration in glucose level. Accumlation of glycolytic intermediates result in an 
increased flux through the pentose phosphate pathway via glucose 6-phosphate 
dehydrogenase and the hexosamine biosynthethic pathway via glutamine fructose-6-
phosphate amidotransferase, resulting in accumulation in xylulose 5-phosphate and UDP N-
acetyl glucosamine, respectively. These metabolites affect the activity of various enzymes 
and transcription factors for phosphorylation and/or glycosylation events.   193 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.35: the effect of pyruvate on myocyte α-2 AMPK activity. 
Myocytes were incubated for 1 hour with 5 mM glucose without (open symbol) or with 3 mM 
sodium pyruvate (filled symbol). The values are means ± S.E.M. expressed as percentages of the 
zero pyruvate measurements and are from 8 independent myocyte preparations.A indicates 
P<0.0005 for the effect of pyruvate (paired test). 
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Figure 3.36: The effect of L-lactate on myocyte α-2 AMPK activity. 
Myocytes were incubated for 1 hour with 5 mM glucose alone (filled symbol) or with the 
indicated concentrations of sodium L-lactate (open symbols). The values are means ± S.E.M. 
expressed as percentages of the zero lactate measurements and are from 10 independent myocyte 
preparations. A indicates P<0.005 for the effect of 5 mM lactate (paired test). 
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3.4.4 The hexosamine biosynthetic pathway 
Once glucose is phosphorylated to glucose 6-phosphate, it is converted to fructose 6-phosphate in 
the next step of glycolysis. Fructose 6-phosphate can be converted into UDP-N-
acetylglucosamine (UDPGlcNac) by glutamine fructose 6-phosphate-amidotransferase (GFAT), 
the first and rate-limiting enzyme on the hexosamine biosynthetic pathway. UDPGlcNac serves 
as the substrate for the O-GlcNacylation of protein by the enzyme O-GlcNac transferase (OGT). 
O-GlcNacylation has been shown to compete for the phosphorylation sites of some signalling 
proteins and transcription factors leading to modification of activity of these proteins (McClain 
DA 2002).  In order to test the effect of inhibition of GFAT by azaserine on AMPK activity, 
cardiac  myocytes  were  incubated  with  5  mM  glucose  in  the  presence  or  absence  of  30  μM 
azaserine; an inhibitor of GFAT. 
 Figure 3.37 shows (a) AMPK activity was not significantly difference in cells incubated in the 
presence of azaserine compared to the control. (b) Azaserine failed to alter the phosphorylation of 
AMPK at α-Thr172. Also no change was observed on the total AMPK protein with azaserine.  
This result suggests that the effect of glucose on AMPK activity was unlikely to be mediated by 
an intermediate formed post the GFAT reaction of the hexosamine pathway. 
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Figure 3.37: Azaserine had no effect on myocyte α-2 AMPK activity. 
(a)Myocytes were incubated for 1 hour with 5 mM glucose(C) without (open symbol) or with 30 
μM azaserine (filled symbol)(AZ). The values are means ± S.E.M. expressed as percentages of 
the measurements without azaserine and are from 6 independent myocyte preparations. N.S. 
indicates that azaserine had no significant effect (P<0.3, paired test). (b) The phoshorylation of 
AMPK α-Thr172 and total AMPK were examined. Cells were lysed and analysed by western 
blotting using anti-phospho- AMPK α-Thr172 and total AMPK antibody (Representative blot). 
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3.4.5 The pentose phosphate pathway 
Goodwin and co workers (2001), using perfused working rat hearts, showed that flux through the 
oxidative arm of PPP is very low compared with metabolisation of glucose via glycolytic 
pathway. However Goodwin et al.; 2001 made the conclusion based on the measurement of the 
detritiation of [5-
3H]glucose that there as  as much as 20% of the glucose can be taken up by the 
heart may have some interconversion within  non- oxidative arm of the PPP.  
To investigate possibility of the involvement of the pentose phosphate pathway metabolites on 
AMPK activity, cardiac myocytes were incubated in 5 mM glucose in the presence or absence of  
0.1and 0.5 μM xylulose or .05 and 0.2  mM ribose or  0.5 and 1 mM xylitol, which is known to be 
converted to xylulose 5-phosphate within cells. 
Figure3.38 shows no significant difference in AMPK activity between the control cells incubated 
with ribose or xylulose at the treated concentrations.  These results suggest that the possibility 
that  the concentrations of these sugars which were used in these experiments were too low. 
Additionally these sugars might not penetrate into the cells.  
Figure 3.39 shows that 1 mM xylitol significantly decreased AMPK activity (p<0.005) compared 
to the control.  In addition when cells lysate were probed against phospho- AMPK α-Thr 172 and 
phospho– ACC Ser277 it was difficult to quantify the bands so as to detect the difference between 
control and treated cells. No change in the AMPK total protein was observed.  
 In addition, we examined whether increased glucose could lead to an increase in the level of 
xylulose-5-phosphate. Xylulose 5-phosphate levels were measured by the method described in 
section 2.9.3.  Figure 3.40 shows that xylulose 5-phosphate levels were significantly increased in 
cardiac myocytes incubated with 2, 5 and 25mM glucose versus cells incubated with 0 mM 
glucose (p< 0.05, <   0.005, < 0.005 respectively). 
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Figure 3.38: D-ribose and D-xylulose had no effect on myocyte α-2 AMPK 
activity. Myocytes were incubated for 1 hour with 5 mM glucose alone without (filled symbol) 
or with 5 mM glucose together with the indicated concentrations of D-ribose or D-xylulose. The 
values are means ± S.E.M. expressed as percentages of the measurements with 5 mM glucose 
alone and are from 5 (ribose) or 4 (xylulose) independent myocyte preparations. No significant 
effects of ribose or xylulose were observed (paired tests). 
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Figure 3.39: The effect of xylitol on myocyte α-2 AMPK activity. (a) Myocytes were 
incubated for 1 hour with 5 mM glucose and the indicated concentrations of xylitol. The values 
are means ± S.E.M. expressed as percentages of the zero xylitol measurements and are from 7 
independent myocyte preparations. A indicates P<0.0005 compared against zero xylitol (paired 
test).  (b)  Representative  blot  of  AMPK  phosphorylation  at  α-Thr172 and AMPK total.  The 
phosphorylation  of  AMPK  α-Thr172 and total AMPK were examined. Cells were lysed and 
analysed by western blotting using anti-phospho- AMPK α-Thr172 and total AMPK antibody 
(Representative blot).   200 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.40:  The effect of glucose concentration on the myocyte content of 
xylulose 5-phosphate. Myocytes were incubated for 1 hour with the indicated concentrations 
of glucose followed by freeze-stop and measurement of xylulose 5-phosphate content. The values 
are means ± S.E.M. from 9 independent myocyte preparations.A, B, C indicate P<0.05, <0.005 
<0.0005 versus zero glucose (paired tests).   201 
3.4.5.1  Effect of  phenazine methosulphate  (PMS)  and  dehydroepi-
androsterone (DHA) on AMPK activity 
 
Two complementary approaches were employed to investigate  a possible contribution of the 
pentose phosphate pathway to  AMPK inhibition by glucose in cardiac myocytes. The first 
approach is the inhibition of glucose-6-phosphate dehydrogenase (G6PD), which functions as the 
first  and  rate-limiting enzyme in the pentose phosphate pathway, and is responsible for the 
generation of NADPH in a reaction coupled with the de novo production of cellular ribose. It has 
been reported that, in adult cardiac myocytes, G6PD activity rapidly increases in response to 
cellular oxidative stress, and with the translocation of G6PD to the cell membrane, which can 
lead to PPP acceleration (Mohit et al.; 2003). The inhibition of G6PD results in a decreased PPP 
rate which can lead to the depletion of reduced glutathione (GSH) levels, and may subsequently 
cause cardiomyocyte contractile dysfunction.  
AMPK activity was examined under conditions when the oxidative arm of the PPP was either 
inhibited or activated. Firstly cardiac myocytes were incubated in 5 mM glucose in the presence 
or absence of 30 μM and 60 μM dehydroepi-androsterone (DHA), a non-competitive inhibitor of 
G6PD, for 1 hour. Figure 3.41 shows that in  cells incubated with of 30 or 60 μM DHA AMPK 
activity significantly increased by 2- to -3  fold compared  with the untreated cells (p <0.025, < 
0.005,  respectively). 
A second approach was to activate this pathway using the artificial electron acceptor phenazine 
methosulphate (PMS). Cardiac myocytes were incubated in 5mM glucose in the presence of 30 or 
50 mM PMS. Figure 3.42 shows PMS at 30, 50 μM significantly decreased AMPK activity by 
28%  and  65% respectively compared to the control (p<.0.005.<0.0005  respectively).  
Furthermore xylulose 5-phosphate was assayed to see the   effect of PMS and DHA on its level. 
Figure 3.43 shows that PMS significantly increased xylulose 5-phosphate level compared to the 
control (p< 0.005) whereas DHA significantly decreased xylulose 5- phosphate to a level that was 
hardly detectable.   202 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.41: The effect of dehydroepiandrosterone (DHA) on myocyte α-2 AMPK 
activity.  Myocytes were incubated for 1 hour with 5 mM glucose and the indicated 
concentrations of DHA. The values are means ± S.E.M. expressed as percentages of the 
measurements without DHA and are from 6 independent myocyte preparations. A, B indicate 
P<0.025, <0.005 respectively compared against zero DHA (paired tests). 
   203 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.42:  Tthe  effect  of  phenazine  methosulphate  (PMS)  on  myocyte  α-2 
AMPK activity. Myocytes were incubated for 1 hour with 5 mM glucose and the indicated 
concentrations of PMS. The values are means ± S.E.M. expressed as percentages of the 
measurements without PMS and are from 6 independent myocyte preparations. A, B indicate 
P<0.005, P<0.0005 respectively compared against zero PMS (paired tests). 
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Figure 3.43:  The effects of phenazine methosulphate (PMS) and  dehydroepi-
androsterone (DHA) on the myocyte content of xylulose 5-phosphate. Myocytes were 
incubated for 1 hour with 5 mM glucose alone (basal) or with 5 mM glucose plus either 30 µM 
PMS or 30 µM DHA followed by freeze-stop and measurement of the xylulose 5-phosphate 
content. The values are means ± S.E.M. for 8 independent myocyte preparations. In 3 
experiments the xylulose 5-phosphate content with DHA was below the limits of the assay and 
was recorded as zero. The mean content of xylulose 5-phosphate in the presence of DHA was 1.7 
± 0.5 nmol per g wet wt. of cells. A indicates P<0.0005 for effects of PMS and DHA (paired 
differences).   205 
 The relationship between α-2 AMPK activity and xylulose 5-phosphate content in 
myocytes is shown  in Figure 3.44.   This finding would not be at variance with notion 
that xylulose 5-phosphate might be part of a process of feedback regulation of AMPK, 
possibly through activation of PP2A. Further experiments were then conducted with a 
view to explore a possible link between PPP flux, xylulose 5-phosphate content and 
myocytes AMPK activity.   206 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.44: The relationship between the α-2 AMPK activity and the xylulose 5-
phosphate content in myocytes. Values for α2 AMPK activity and for xylulose 5-phosphate 
content from several different experiments were normalized by expression of these as percentages 
± S.E.M. of the measurements made from cells incubated with 5 mM glucose alone where the 
absolute values were: AMPK activity, 1.71 ± 0.19 pmol per min per mg of 13,000g supernatant 
protein (n = 56); xylulose 5-phosphate content, 157 ± 14 nmol per g wet wt. of cells (n = 17). 
Data for AMPK activity were taken from Figures 3.4, 3.11, 3.18,  3.38, 3.33, 3.35, 3.39, 3.41, and 
3.42.  Data for xylulose 5-phosphate were taken from Figures 29 and 39. The minimum number 
of independent measurements of AMPK activity at any data point was 6 and the minimum 
number of independent measurements of xylulose 5-phosphate at any data point was 8.Filled 
circles: varied glucose concentrations between zero and 25 mM. Open square: 5 mM glucose + 
30 µM DHA. Open circle: 5 mM glucose + 30 µM PMS. Where S.E.M. bars are not visible they 
lie within the symbol.    207 
3.4.6 The combined effect of PMS and insulin on AMPK activity 
Previous studies have shown that insulin inhibits AMPK activity and α-Thr172 phosphorylation. 
In the present studies PMS significantly decreased AMPK activity as is shown in  Figure 3.34.  
As the result of these two findings, an experiment was performed to see the extent to which PMS 
and insulin were or were not additive in their effect on AMPK activity. Insulin decreases AMPK 
activity through PKB whereas PMS might be working through activation of PP2A by Xu5P. 
Figure 3.45 shows that there was additively in combined effects of PMS and insulin on AMPK 
activity at 5 mM glucose. At 25 mM glucose although both PMS and insulin had significant 
effect on AMPK ativity   but they had no additively of effect in combination. As a speculation 25 
mM glucose plus either PMS or insulin gives an approximate rock-bottom AMPK activity which 
is about 40% of that seen with 5 mM glucose alone. Presumably actions of cellular AMPKKs 
work to always ensure a certain phosphorylation/activity level of the AMPK. 
     208 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.45: The combined effects of glucose concentration, insulin and phenazine 
methosulphate (PMS) on myocyte α-2 AMPK activity. Myocytes were incubated for 1 
hour with either 5 mM or 25 mM glucose together with 10 mM insulin or 30 µM PMS as 
indicated. The values are means ± S.E.M. expressed as percentages of the measurements with 5 
mM glucose alone. 8 independent  myocyte preparations were used at 5 mM glucose and 5 
preparations at 25 mM glucose. A, B indicate P<0.005, <0.0005 respectively for effects of insulin 
or PMS compared with the appropriate basal state (paired tests). The paired test P values shown 
directly on the figure indicate the significance of the effect of PMS in the presence of insulin. At 
5 mM glucose effects of insulin and PMS were partially additive, i.e. PMS decreased AMPK 
activity by 49% and by 38% in the absence and presence of insulin respectively. Significant 
additive effects of PMS and insulin were not seen with 25 mM glucose.    209 
3.4.7 Thiamine attenuates the effect of glucose on AMPK 
 
 High doses of thiamine might metabolize xylulose 5-phosphate rapidly and therefore not allow it 
to accumulate to a level suffient to activate PP2A. Cardiac myocytes were incubated with 5 and 
25 mM glucose in the presence or absence of 1mM thiamine. Figure 3.46 shows that when the 
cells were incubated for 1 hour with 5 mM glucose, thiamine significantly increased AMPK 
activity by 47% compared to the control (p< 0 .025). In cells incubated for 2 hour in 5 or 25 mM 
glucose, thiamine significantly increased AMPK activity by 55% and 100% (p< 0.005 <0.005 
respectively) compared to the control. The level of phosphorylation of the AMPK at Thr172 and 
ACC Ser277 were also accessed by Western blotting analysis. Figure 3.47 shows that thiamine in 
the presence of 5 mM glucose significantly increased the phosphorylation of AMPK α-Thr172 
compared to the control (p<0.05).  However, thiamine in the presence of 25 mM glucose also 
showed  increased  on  the  phosphorylation  of  AMPK  αThr172,  but  this  increase  was  not 
statistically significant, yet a noticeable increase of phosphorylation of AMPK at 25 mM glucose 
can be seen on the blot (Figure 3.47). 
 Figure 3.48 shows that thiamine at 5 and 25 mM glucose increased the phosphorylation ACC at 
Se277 significantly compared to the control (p < 0.025, <0.005 respectively).  
These results suggest that thiamine may pay a role in the regulation of AMPK activity and its 
downstream target ACC. The mechanism by which thiamine increases AMPKactivity is unclear.  
The possible explanations are (i) that thiamine might decrease xylulose 5-phosphate content and 
(ii) that thiamine might increase the cellular AMP/ATP ratio,   210 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.46: The effect of thiamine on myocyte α-2 AMPK activity. Myocytes were 
incubated for 1 or 2 hours with the indicated concentrations of glucose without (open symbols) or 
with 1 mM thiamine (filled symbols). The values are means ± S.E.M. expressed as percentages of 
the 5 mM glucose measurements in the absence of thiamine and are from 6 and 13 independent 
myocyte preparations for 1 and 2 hour incubations respectively. 
A, B, C indicate P<0.025, <0.005, <0.0005 respectively for effects of thiamine (paired tests).   211 
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Figure 3.47: the effect of thiamine on the the phosphorylation of Threonine 172 in 
myocyte AMPK α-subunits. (a) Myocytes were incubated for 2 hours with the indicated 
concentrations of glucose without (open symbols) or with 1 mM thiamine (filled symbols). 
Phospho-AMPK measurements were normalized against measurements of total AMPK α-subunit 
protein. The values are means ± S.E.M. from 4 independent preparations of myocytes. A, 
indicates a significant (P<0.05) effect of thiamine (paired test). (b) Representative blot.   212 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.48: the effect of thiamine on the phosphorylation of Serine 227 in 
myocyte acetyl-CoA carboxylase (ACC). Myocytes were incubated for 2 hours with the 
indicated concentrations of glucose without (open symbols) or with 1 mM thiamine (filled 
symbols). Phospho-ACC measurements were normalized against measurements of total ACC 
protein and then expressed as percentages of the values with of 5 mM glucose in the absence of 
thiamine. The values are means ± S.E.M. from 5 independent myocyte preparations. 
A, B indicate P<0.025, <0.005 respectively versus measurements with 5 mM glucose alone 
(paired tests). 
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3.4.8 Conclusion 
 
 The above experiments investigated the possibility that glucose or one of its metabolites played a 
role in driving the AMPK phosphorylation/dephosphorylation system in cardiac myocytes 
towards inactivation of the kinase. Experiments with 3-O-methylglucose and 2-deoxyglucose 
suggested that neither glucose itself nor glucose 6-phosphate were likely to be the ‘active 
principle’ in this regard. Likewise pyruvate and lactate the terminal products of glycolysis caused 
no inactivation of AMPK. The lack of any significant effect of azaserine upon AMPK activity 
also suggested that AMPK activity was unlikely to be affected by an intermediate of the 
hexosamine pathway. Interestingly AMPK activity was decreased in myocytes incubated with 
xylitol, a metabolite which in principle can be converted to the PPP intermediate xylulose 5-
phosphate an allosteric activator of PP2A. Incubation of cells with ribose which would also be 
expected to increase the cellular pentose phosphate pool (R5P, Ru5P and Xu5P) failed to 
decrease AMPK activity.  Thiamine and DHA increased AMPK activity whereas PMS had 
contrary effects.  Xylulose 5-phosphate contents increased as both glucose concentrations were 
increased and in the presence of PMS Wherease DHA decreased xylulose 5-phosphate content. 
The curve shown in Figure 3.43 is only a rough fit to the 6 data points. However it does provide a 
rough estimate of the xylulose 5-phosphate content which matches half maximal inactivation of 
AMPK activity. This was approximately 30 nmol per g wet weight of the cells. Interestingly, 
Mishimura and Uyeda  (1995)  reported  that  10  μM  xylulose  5-phosphate gave half maximal 
activation of a preparation of PP2A from rat liver. 
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3.9 Assessment of pentose phosphate pathway 
Since PMS and DHA were shown respectively to increase and to decrease myocyte Xu5P content 
the effects of these agents on the oxidation of 5 mM glucose were measured with the aim of 
determining whether PMS and DHA might have specific effects upon pentose phosphate pathway 
(PPP) flux quantitated as CO2 formation by the oxidative arm of the pathway. Effects of thiamine 
with 5 mM glucose and effects of PMS at the supra-physiological concentration of 20 mM 
glucose were also investigated. 
CO2 is released from the hexose C-1 position at the 6-phosphogluconate dehydrogenase step in 
the oxidative arm of the PPP (Figure 1.6).  If the entire F6P product of the PPP is then swept into 
glycolytic flux all of the PPP CO2 is derived from C-1 of the original glucose. By contrast if all of 
the F6P product of the PPP is recycled to G6P and re-enters the PPP at the glucose 6-phosphate 
dehydrogenase step the resulting PPP CO2 is derived from C-1, C-2 and C-3 of the original 
glucose in equal proportions. No PPP CO2 is derived from C-4, C-5 and C-6 of glucose. In the 
glycolysis pathway glucose C-1 and C-6 both become the C-3 carbons of pyruvate and finally 
give rise to CO2 in equal proportions in the citric acid cycle. On this basis glycolysis in isolation 
yields a C-1/C-6 ratio of 1.0 in the metabolites (pyruvate + lactate) and a C-1/C-6 ratio of 1.0 in 
citric acid cycle CO2. By contrast when the PPP makes a contribution to glucose metabolic flux 
the C-1/C-6 ratio found in (pyruvate + lactate) is less than 1.0. Following from this it has been 
argued that the presence of PPP flux should give rise to a C-1/C-6 ratio of greater than 1.0 in CO2 
and that the size of this ratio provides an index of the relative contributions of the oxidative PPP 
and glycolysis to glucose catabolism. A related approach has been to take the difference between 
the yields of 
14CO2 from [1-
14C]glucose and [6-
14C]glucose (C-1 minus C-6) as an estimate of 
metabolic flux in the oxidative arm of the PPP (Hothersall et al, 1979; Muirhead & Hothersall, 
1995). This approach was used by Sochor et al. (1984) who observed a positive C-1 minus C-6 
value (i.e. a C-1/C-6 ratio of greater than 1.0) in 
14CO2 when rat heart slices were incubated with 
20 mM 
14C-labelled glucose.   215 
 
Burns & Reddy (1977) observed a C-1/C-6 ratio for 
14CO2 of 0.97 when rat cardiac myocytes 
were incubated with 5 mM glucose. This ratio was increased to appreciably greater than 1 when 
competing substrates (pyruvate, lactate, acetate or octanoate) were additionally present. These 
authors concluded that there can be an appreciable contribution of the oxidative arm of the PPP to 
glucose catabolism under conditions where mitochondrial oxidation of glucose-derived carbon is 
suppressed by these other substrates. However two studies with isolated working hearts are at 
variance with this conclusion. Pfeiffer et al. (1986) using an indirect approach which employed 
14CO2 washout kinetics could not detect oxidative PPP flux. Goodwin et al. (2001) measured the 
steady state C-1/C-6 ratios for 
14CO2 and for 
14C-labelled (pyruvate + lactate) and found that both 
were not significantly different from 1. These authors therefore suggested that normally cardiac 
oxidative PPP flux, though not necessarily absent, was small compared with overall glucose 
oxidation. 
Table  3.3  shows that incubation of cardiac myocytes with C-1 and C-6 
14C-labelled 5 mM 
glucose resulted in 
14CO2 yields per g wet wt. per hour which were broadly similar to those found 
with heart slices by Sochor et al. (1984). However the C-1/C-6 ratio was not significantly 
different from 1.0. Interestingly the difference between the yields from C-2 and C-6 labelled 
glucose was significantly greater than zero. Previously Muirhead & Hothersall (1995) have 
proposed that a positive value for (C-2 yield minus C-6 yield) is indicative of recycling of 
fructose 6-phosphate products back into the oxidative arm of the PPP. In an attempt to create 
conditions where the C-1/C-6 ratio was greater than 1 myocytes were incubated with 5 mM 
labelled glucose in the presence of physiological concentrations of palmitate or lactate as 
competing substrates. However, as shown in Table 3.4 this approach did not lead to a C-1/C-6 
ratio of greater than 1. This would appear to contradict the findings of Burns & Reddy (1977). A 
possible explanation is that the concentrations of competing substrates used in the present 
experiments were lower than those used by Burns & Reddy (1977). From these experiments I   216 
concluded that a value for the (C-1 yield minus C-6 yield) could not be obtained which gave any 
sensible index of xidative PPP flux under the chosen experimental conditions. Katz & Wood 
(1962) have previously discussed the limited quantitative value of the measurement of the C-1/C-
6 ratio of 
14CO2 in the absence of additional measures of glucose utilization.  
Following these inconclusive studies I then adopted a different approach to making an estimate of 
PPP oxidative flux. This approach was based upon the following assumptions. First, in the 
cardiac myocyte conversion of [U-
14C]glucose to 
14CO2 (the C-U yield) essentially is only due to 
6-phosphogluconate dehydrogenase in the oxidative arm of the PPP, pyruvate decarboxylation by 
pyruvate dehydrogenase (PDH) and the two decarboxylation reactions of the TCA cycle. Second, 
the yield of 
14CO2 from [3,4-
14C]glucose (C-3/4 yield) provides a measure of the PDH flux. Third, 
essentially all acetyl-CoA formed by PDH in cardiac myocytes is committed to the TCA cycle. 
This is a reasonable assumption because fatty acid biosynthesis in these cells is negligible (Awan 
& Saggerson, 1993). Therefore the value [3 x C-3/4 yield] provides a measure of 
14CO2 
production by PDH and the TCA cycle combined. By difference, 
14CO2 formation in the PPP then 
can be calculated as the C-U yield minus the [3 x C-3/4 yield]. This is referred to as the U/3,4-
glucose method. It is stressed that this method offers only an approximation to the true PPP 
oxidative flux because of the following, and probably other, considerations. First, the assumption 
that the oxidative PPP, PDH and the TCA cycle are the only significant sources of glucose-
derived CO2 may not be totally correct. Second, C-3 from glucose can appear as CO2 in the 
oxidative arm of the PPP if fructose 6-phosphate derived from transketolase or transaldolase in 
the non-oxidative arm of the PPP is recycled back into the oxidative PPP rather than entering 
glycolysis. Third, transketolase and transaldolase activities put original glucose C-3 into the C-2 
position of fructose 6-phosphate. This could decrease the apparent yield of CO2 at PDH, but at the 
same time would increase the yield of that carbon as TCA CO2 (by contrast the original C-4 of 
glucose remains as the C-4 of fructose 6-phosphate via the PPP or it appears in the C-1 position   217 
of the glyceraldehyde 3-phosphate product of the PPP and the PPP causes no shift in the position 
of this carbon within pyruvate). 
 
Figures 3.49, 3.51 and 3.53 show that in myocytes incubated with 5 mM glucose alone PPP CO2 
formation was barely detectable by the U/3,4-glucose method. Overall in the series of 
experiments covered by Figures 3..49, 3.51 & 3.53 using 21 different myocyte preparations 
estimates of PPP CO2 production were 1.5 ± 1.6 µg atoms of carbon per hour per g wet wt. of 
cells compared with a CO2 production from [U-
14C]glucose of 26.9 ± 3.4 µg atoms of carbon per 
hour per g wet wt. of cells; i.e. the PPP contributed 5.7% of total glucose oxidation. However the 
S.E.M. for the PPP CO2 value was large compared to the mean because 8 out of the 21 calculated 
values for PPP CO2 production were negative. The fairest interpretation of these data is that PPP 
flux from 5 mM glucose cannot be regarded as significantly different from zero. An effect of 
PMS to increase oxidative PPP flux has previously been shown in mammary gland slices 
(McLean, 1959) in adipose tissue or in adipocytes (Saggerson & Greenbaum, 1970; Katz & Wals, 
1971; Kather et al., 1972), in liver slices (Greenbaum et al., 1971) and in heart slices (Sochor et 
al., 1984). Figure 3.49 shows that 30 µM PMS increased total glucose oxidation by 1.9-fold 
whilst increasing CO2 formation by PDH plus the TCA cycle by only 1.4-fold. Use of the U/3,4-
glucose approximation indicated that 57% of the increase in total glucose oxidation was due to 
oxidative PPP flux which was increased approximately 19-fold to a value of 14.2 ± 4.1 µg atoms 
per hour per g wet wt. of cells, a value which is significantly greater than zero (P<0.005, paired 
test). Figure 3.50 shows the effects of 30 µM PMS in myocytes incubated with 20 mM glucose. 
14CO2 formation from [U-
14C]glucose and from [3,4-
14C]glucose was increased 2.4-fold and 2.1-
fold respectively compared to cells incubated with 5 mM glucose (Figure3.49) . Figure 3.51 
shows the effect of 30 µM DHA in myocytes incubated with 5 mM glucose. Total glucose 
oxidation was significantly decreased by 33% whereas the 9% decrease in 
14CO2 formation from 
[3,4-
14C]glucose was not statistically significant. It should be noted that estimates of PPP CO2   218 
formation at 5 mM glucose in the absence and presence of DHA differed significantly by 4.8 ± 
1.7 µg atoms of carbon per hour per g wet wt. of cells (P<0.005 by paired test) and that this value 
might be a truer estimate of oxidative PPP flux with 5 mM glucose alone. 
Figure 3.52 shows the effects of 30 µM PMS and 30 µM DHA on the yields of 
14CO2 from C-1 
and C-6-labelled 5 mM glucose. Neither agent had any significant effect on the yield of glucose 
C-6 in CO2. However PMS significantly increased the C-1 yield 1.8-fold and DHA decreased the 
same by 38%. Although these data cannot be used quantitatively they qualitatively support the 
notions that PMS and DHA respectively increase and decrease oxidative PPP flux. 
With 5 mM glucose in the presence of 30 µM PMS the C-1 yield was 6.8 µg atoms of carbon per 
hour per g wet wt. of cells Figure 3.52. This can be compared with an estimated PPP CO2 
production under the same conditions of 14.2 µg atoms of carbon per hour per g wet wt. of cells 
(Figure 3.49A). Clearly a significant proportion of the PPP CO2 in the presence of PMS must 
derive from C-2 and C-3 of glucose after recycling of fructose 6-phosphate units rather than 
entirely from C-1 of glucose. 
Figure 3.53 shows that 1 mM thiamine had no significant effects upon total oxidation of 5 mM 
glucose or upon 
14CO2 formation from [3,4-
14C]glucose and therefore had no effect upon the 
estimated low value for PPP CO2 formation. This was not unexpected as thiamine is a potential 
precursor for thiamine pyrophosphate (TPP) which is the coenzyme for transketolase, an enzyme 
of the non-oxidative rather than the oxidative arm of the PPP.  
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Table 3.3: The yields of 
14CO2 by myocytes incubated with C-1, C-2 or C-6 
14C-
labelled 5 mM glucose. 
 
Table 3.3 Myocytes were incubated for 1 hour with C-1, C-2 or C-6 
14C-labelled 5 mM 
glucose followed by collection and measurement of 
14CO2. The values are means ± S.E.M. from 
12 independent myocyte preparations. 
A indicates significantly different from zero (P<0.005 by paired test). N.S. indicates not 
significantly different from zero (P>0.2).  
 
 
Glucose label 
14CO2 yield (µg atoms per hour per g wet wt. of cells) 
C-1  2.98 ± 0.41 
C-6  3.10 ± 0.41 
C-2  3.61 ± 0.46 
   
C-1 minus C-6  – 0.12 ± 0.17
N.S. 
C-2 minus C-6  + 0.51 ± 0.13
A 
   
C-1/C-6 ratio  1.01 ± 0.06 
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Table 3.4: The yields of 
14CO2 by myocytes incubated with C-1 or C-6 
14C-labelled 
5 mM glucose in the presence of palmitate or lactate. 
 
Table 3.4 Myocytes were incubated for 1 hour with C-1 or C-6 
14C-labelled 5 mM glucose 
together with either 0.25 mM sodium palmitate or 1 mM sodium lactate followed by collection 
and measurement of 
14CO2. The values are means ± S.E.M. from 4 independent myocyte 
preparations.  
 
Glucose label 
 
additional substrate 
14CO2 yield (µg atoms per hour per g wet 
wt. of cells) 
C-1  Palmitate  3.13 ± 0.61 
C-6  Palmitate  4.07 ± 0.93 
C-1  Lactate  3.50 ± 0.93 
C-6  Lactate  4.23 ± 1.59 
     
C-1/C-6 ratio  Palmitate  0.82 ± 0.10 
C-1/C-6 ratio  Lactate  0.96 ± 0.19 
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Figure 3.49: the effect of phenazine methosulphate (PMS) on myocyte pentose 
phosphate pathway (PPP) CO2  formation from 5 mM glucose.  Myocytes were 
incubated for 1 hour with 5 mM glucose labelled with either [U-
14C]glucose or [3,4-
14C]glucose 
without (open symbols) or with 30 µM PMS (filled symbols). PPP CO2 formation was estimated 
by the U/3,4-glucose method. The values are means ± S.E.M. from 12 independent myocyte 
preparations. A, B, C indicate P<0.01, <0.005 <0.0005 respectively for effects of PMS (paired 
tests). 
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Figure 3.50: the effect of phenazine methosulphate (PMS) on myocyte pentose 
phosphate pathway (PPP) CO2  formation from 20 mM glucose.  Myocytes were 
incubated for 1 hour with 20 mM glucose labelled with either [U-
14C]glucose or [3,4-
14C]glucose 
without (open symbols) or with 30 µM PMS (filled symbols). PPP CO2 formation was estimated 
by the U/3,4-glucose method. The values are means ± S.E.M. from 5 independent myocyte 
preparations. A, B indicate P<0.005, <0.0005 respectively for effects of PMS (paired tests). 
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Figure 3.51:  the effect of  dehydroepi-androsterone DHA on myocyte pentose 
phosphate pathway (PPP) CO2  formation from 5 mM glucose.  Myocytes were 
incubated for 1 hour with 5 mM glucose labelled with either [U-
14C]glucose or [3,4-
14C]glucose 
without (open symbols) or with 30 µM DHA (filled symbols). PPP CO2 formation was estimated 
by the U/3,4-glucose method. The values are means ± S.E.M. from 10 independent myocyte 
preparations. 
N.S., A, B,  indicate P>0.05, P<0.005 ??<0.0005 respectively for effects of DHA (paired tests). 
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Figure 3.52: the effects of phenazine methosulphate (PMS) and  dehydroepi-
androsterone DHA on the yields of CO2 by myocytes incubated with C-1 or C-6 
14C-
labelled 5 mM glucose. Myocytes were incubated for 1 hour with labelled 5 mM glucose 
without (open symbols) or with PMS or DHA (filled symbols). The values are means ± S.E.M. 
from 4 and 7 independent myocyte preparations incubated with PMS and DHA respectively. 
A, B indicate P<0.025, P<0.005 respectively for effects of PMS or DHA (paired tests).  
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Figure 3.53: Thiamine had no effect on CO2 formation from 5 mM glucose by 
myocytes.  Myocytes were incubated for 1 hour with 5 mM glucose labelled with either [U-
14C]glucose or [3,4-
14C]glucose without (open symbols) or with 1 mM thiamine (filled symbols). 
PPP CO2 formation was estimated by the U/3,4-glucose method. The values are means ± S.E.M. 
from 5 independent myocyte preparations. 
N.S. indicates that thiamine had no statistically significant effects on CO2 formation (P>0.05 by 
paired tests).  
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3.91 Conclusions  
I n this study the estimates of the oxidative PPP flux rate gave positive values and the mean rate 
of formation of CO2 by the PPP of 9.6 ± 1.3 µg atoms of carbon per hour per g wet wt. of cells 
was clearly different from zero (P<0.005, paired test). Addition of PMS increased total glucose 
oxidation and CO2 formation by PDH plus the TCA cycle by 2.7-fold and 1.3-fold respectively. 
Additionally PMS had the dramatic effect of increasing oxidative PPP flux by 10.6-fold. 84% of 
the increase in total glucose oxidation with PMS was attributable to PPP activity. These resuls e 
strongly suggest that PMS can increase oxidative PPP flux. They also reveal that the oxidative 
arm of the cardiac myocyte PPP has an enormous reserve capacity.Whereas the mean estimated 
value for PPP CO2 production with DHA was negative (– 2.57 ± 1.82 µg atoms of carbon per 
hour per g wet wt. of cells). 
This reveals an inaccuracy in the use of the U/3,4-glucose method, but possibly suggests where 
the real zero value for oxidative PPP flux should be since the myocyte xylulose 5-phosphate 
content was almost zero in the presence of 30 µM DHA 
The observation that thiamine increased AMPK activity (Figure 3.46) suggested the possibility 
that thiamine would decrease xylulose 5-phosphate content. This could occur provided both (i) a 
significant proportion of myocyte transketolase normally was in an inactive apo-enzyme form and 
(ii) transketolase holo-enzyme activity normally was insufficient to equilibrate its reactants 
thereby rendering the non-oxidative  arm of the PPP irreversible. Under those conditions the 
pentulose phosphate pool (ribulose 5-phosphate and xylulose 5-phosphate) would not be able to 
be replenished from glycolytic intermediates. The very low content of xylulose 5-phosphate when 
glucose 6-phosphate dehydrogenase is inhibited by DHA (Figure 3.43)  would support this 
notion. Investigation of the effect of thiamine on myocyte xylulose 5-phosphate content should be 
the subject of further studies.    
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4.0 General Discussion 
Fatty acids and glucose both play multiple functions in cardiac myocytes extending far beyond 
their clear use as an energy source. An alternative is to take a less restricted view of metabolism, 
beyond its stereotypical function as a provider of ATP. Alterations in metabolic flux within cells 
create essential signals for heart adaptation to each situation. An increasing number of nutrients 
and hormones are being shown to regulate the AMPK signalling   pathway (Xu and Kahn 2006).  
The work contained in this thesis has allowed a greater understanding of the interaction between 
glucose, AMPK and the insulin signalling pathway. Once glucose has been transported to the cell 
and metabolised, it fulfils multiple functions. The original discovery in this study was that, when 
glucose concentration increases in cardiac myocytes, a significant decrease of α2 AMPK activity. 
This is associated with a tendency towards a decrease in α-Thr 172 phosphorylation.This work is 
supported by other work carried out in skeletal muscle which has found a similar outcome(Itani al 
et.; 2003). 
 
 Glucose decreased AMPK activity independently of change in the AMP: ATP ratio. No change 
in total cardiac adenine nucleotide concentration occurred after incubation with  5 or 25 mM 
glucose in the presence or absence of palmitate. The level of ATP in myocytes obtained in this 
study 6-8 nmol/mg protein was rather low and the ADP is  rather high compared to that found by 
other groups (see e.g. Ladilov et al.; 2003). This might first suggest a technical problem during 
the analysis of the samples. In order to obtain a clearly visible peak by HPLC, concentrated 
samples were prepared by extracting the cells with a minimal volume of 0.21 M PCA. It was 
found difficult to obtain a concentrated neutralised extract in sufficient amount with a higher 
concentration of PCA because of increased precipitation of KClO4. However, this concentration 
of PCA is lower than the concentrations commonly used to extract cells, and a previous  study 
measuring the  adenine nucleotides using the same method as used in this study reported   229 
incomplete extraction of ATP by 0.21 M PCA (Sellevold et al.; 1986). In the unpublished data in 
our lab adenine nucleotides in the perfused hearts measured in the extract prepared by 0.21M 
PCA were also approximately half of the values obtained by other groups.  Thus the low amount 
of adenine nucleotides seen in myocytes in this study probably reflects an incomplete extraction 
of adenine nucleotide.  
AMPK activity was increased in the incubations without glucose. Therefore note that this is a 
totally abnormal state as total adenine nucleotides were decreased suggesting that the cells were 
so sick that they were catabolised their adenine nucleotides. Figure 3.10 shows a plot of the 
effects of glucose at 0, 2, 5, and 25 mM glucose in the presence or absence of palmitate and 
AICAR, this graph provides evidence that the effect of glucose on AMPK activity could not be 
adenine nucleotide dependent.  
Insulin  has previously been reported to inhibit cardiac AMPK via the PI3-PKB pathway 
(Beauloye  et al.;  2001). The phosphatidylinositol-3-kinase inhibitor wortmannin is able to 
overcome the insulin-stimulated decrease in AMPK activity (Beauloye et al.; 2001). However, 
the observation in this study was that PKB was not activated in the absence of insulin and the 
effect of glucose on AMPK was not mediated by this signalling pathway. The inhibitory effect of 
insulin is reportedly due to PKB phosphorylation of Ser 485/491 of the α-AMPK α subunit, 
which prevents the phosphorylation of Thr172 by LKB1 and possibly by other AMPKKs 
(Horman et al.; 2006; Soltys et al.; 2006). Recently, this site was also reportedly phosphorylated 
by PKA in vitro (Hurley et al.; 2006). However, Ser458/491 phosphorylation was not increased 
in cardiac myocytes incubated with varying glucose concentrations; this provided evidence that 
the phosphorylation of AMPK Ser 485/491 is not responsible for the effect of glucose on AMPK 
activity. Insulin levels decreased overall AMPK activity in hearts perfused with 5 mM glucose 
(Beauloye et al.; 2001) and there appears to be no insulin effect on kinase activity in hearts 
perfused with 0.4 or 1.2 mM palmitate (Sakamoto et al.; 2000). The present study contradicts this   230 
study as it was shown that palmitate had no effect on AMPK inhibition by insulin in cardiac 
myocytes. AMPK activity was also decreased in newborn rabbit hearts perfused with fatty acids 
(Makinde  et al.;  1997) and in adult rat hearts by a ten-fold at higher  insulin concentration 
(Gamble J & Lopaschuk GD, 1997). The ability of palmitate to override insulin dependent 
increased in malony-CoA and the inhibition of AMPK is also interesting regarding the role of 
fatty acids in the development of insulin resistance.  The elevation of plasma fatty acid 
concentrations because insulin resistance in human skeletal muscle, an effect associated with 
decreased IRS-associated PI3 kinase activity (Dresner A et al.; 1999).  
The role of inositol phosphoglycan molecules as insulin mediators has been postulated mainly on 
the ability of IPG preparation to mimic the short- and long-term effect of this hormone; which 
includes modulation of the activity level of many enzymes involved in lipid metabolism, glucose 
utilisation, phosphorylation and dephosphorylation of cellular proteins, protein synthesis and gene 
expression and the stimulation of cell growth (Romero & Larner, 1993; Gaulton & Pratt, 1994). 
Interestingly in cardiac myocytes incubated with 5 or 25 mM glucose in the presence or absence 
of an IPG preparation AMPK activity was significantly increased at both glucose concentrations 
by 37% and 82% respectively.  
The effect of glucose on AMPK activity was examined in this study to see if it had effects on 
well-established downstream targets of AMPK such as ACC, eNOS and PFK-2. In this study 
ACC Ser227 phosphorylation was decreased as glucose concentration increased. In heart AMPK 
is able to phosphorylate ACCα and ACCβ , resulting in an almost complete loss of ACC activity. 
ACC in the heart exist in a heterodimeric structure, and some heart ACC associated with the α2 
subunit of AMPK. (Sarah et al.; 2001, Lopaschuk et al.; 1999). The activity of ACC may be 
influenced by the cytosolic concentration of citrate. Citrate may activate ACC allosterically or 
increase provision of the acetyl-CoA substrate via ATP-citrate lyase. In skeletal muscle the 
increase in malonyl-CoA in response to glucose and glucose plus insulin are associated with an   231 
increase in tissue citrate plus malate (Saha  et al.; 1997). Purified rat ACCβ is phosphorylated and 
inactivated in vitro by PKA and AMPK (Dyck et al.; 1999) 
The activation of AMPK in cardiac myocytes increased glucose transport and that this was 
associated with eNOS phosphorylation at Se1177 (li J et al.;  2004). In the present study, 
phosphorylation eNOS was detected in cardiac myocytes at a very low level even in the presence 
of AICAR at insulin and all glucose concentrations. 
In mice metformin significantly increased the phosphorylation of eNOS Ser1177 phosphorylation 
over the basal level for a period of 24h (Andrina  et al.; 2008). Metformin did not alter eNOS 
Thr495 phosphorylation at any time point investigated. It has been reported that metformin also 
failed to  increase  NOS  Ser117  phosphorylation  when  administered  to  AMPKα2  dn  Tg  mice 
(Andrina  et al.; 2008).    Similarly, eNOSThr495 phosphorylation remained unchanged in 
AMPKα2 dn Tg mice administered metformin.(John  et al.; 2008). From the above studies eNOS 
phosphorylation is more detectable after at least two hours, in the present experiments cells were 
incubated only for 1 hour. This might be the reason that phosphorylation was undetectable even 
in the presence of AICAR.   Another explanation   of this discrepancy was that cardiac myocytes 
are the only cells in the heart that contain GLUT4 (Young  et al.; 1997), which accounts for much 
of the glucose transport in the heart tissue. However, in vascular endothelial cells, eNOS is 
known to be activated by AICAR (Idly et al.; 2002); endothelial cells are known predominantly 
to express the α-1or α-2 isoform of AMPK (Morrow et al.; 2003). It has been reported that 
AICAR activates the α-1 or α-2  isoform and binds to eNOS in the heart muscle, suggesting that 
AICAR activation of the endothelial cell AMPK and eNOS may play an important role in the 
stimulation of cardiomyocyte glucose transport through a paracrine mechanism. However, 
additional immunoprecipitation experiments demonstrated that eNOS was also associated with α2 
AMPK, the more predominant isoform in cardiac myocytes, which is virtually absent from 
endothelial cells (Morrow et al.; 2003). Although the cardiac myocyte expression of eNOS is 
generally low, there is heterogeneity within the heart, with greater eNOS expression in the   232 
specialized endocrinal cells lining of the cardiac chambers (Mungue et al.; 2003) and pericardial 
cardiomyocytes (Brahmajohi & Campell, 1999). Taken together, these findings suggest that both 
autocrine and paracrine mechanisms may be involved to some extent in the interaction between 
the AMPK, eNOS and the glucose transport pathways in heart muscle. 
 In the heart, AMPK activation leads to the phosphorylation and activation of PFK-2 (Marsin et 
al.; 2000). Elevated glucose levels cause a decrease in AMPK activity, which would subsequently 
be expected to decrease PFK-2 activity and thereby the cell content of fructose 2, 6-bisphosphate. 
However, in this study, elevated glucose levels caused an increase in PFK-2 activity. In this 
circumstance, elevated glucose levels might cause a covalent modification of PFK-2FBPase-2, by 
a mechanism which overrides any effect resulting from glucose-induced suppression of AMPK, 
thus leading to the activation of glycolysis. There is substantial evidence to suggest that glucose 
increases the fructose 2, 6-bisphosphate level. The most convincing lines of evidence come from 
a demonstration carried out in pancreatic MIN6 cell line. Glucose may have an impact on the 
fructose 2, 6-  bisphosphate content by covalent modification of PFK-2/FBPase or through 
changes in metabolite concentration that act as activators or inhibitors of either the kinase or 
bisphosphatase (Catherine et al, 2008).  
This study provides evidence in support of the hypothesis that glucose metabolites play a role to 
decrease AMPK activity in cardiac myocytes. Glycolysis metabolites, glycogen and azserine the 
inhibitor of GFAT had failed to decrease AMPK  activity.  As a potential mechanism I  then 
focused on the pentose phosphate pathway. Both arms of the pentose phosphate pathway can 
potentially produce xylulose 5-phosphate which has been shown to induce the expression of 
several genes in the liver and may modify other signalling pathways, (Doiron B et al.; 1996). 
Cardiac myocytes incubated with xylitol (which is converted to xylulose 5-phosphate) decreased 
AMPK activity significantly (p< 0.0005). In addition  the level of xyluose 5-phosphate was   233 
elevated  as the glucose concentration  was  increased.  Supporting this finding, xylulose 5-
phosphate and AMPK activity in cardiac myocytes show negative correlation.  
 In this study, AMPK inhibition by glucose was diminished upon G6PD inhibition by the non-
competitive inhibitor, dehydroepiandrosterone (DHA). It has been reported that DHA increases 
Ca
+ levels; however, it appears that changing intercellular Ca
2+ does not alter AMPK activity in 
cardiac myocytes (unpublished data in our laborotary). The activation of the pentose phosphate 
pathway by the artificial electron acceptor PMS resulted in a  dramatic decrease in AMPK 
activity. The pentose phosphate pathway was significantly decreased in the presence of DHA. By 
contrast, PMS and the increasing glucose concentration significantly increased PPP activity. The 
accumulating evidence suggests that the pentose phosphate pathway is a crucial regulator of the 
glucose effect on AMPK activity.  
Thiamine reverses the effect of glucose on AMPK activity. This might be through   decrease of 
xylulose 5- phosphate level by accelerating the trasketolase reaction. This may lead to xylulose 5-
phospate to be metabolized rapidily and does not accumulate to levels sufficient to activate 
protein phosphatase 2A.  
The mechanism by which Xu 5-P activates protein phosphatase (PP2A) is currently unknown. It 
has been reported that, in the liver, xylulose-5-phosphate regulates the bifunctional enzyme 
through PP2A. (Nishimura et al; 1995.). This group suggested the   possibility is that, since Xu 5-
P activates the dephosphorylation of only Fru-6-P, 2-kinase: Fru-2, 6-Pase as a substrate, the 
pentose-P may bind to the bifunctional enzyme, and the complex could be a better substrate than 
the free enzyme for the protein phosphatase. Another possibility is that Xu 5-P may bind to the P 
subunit and dissociate P from the heterotrimer, resulting in activation (Nishimura et al; 1995.). 
Xu 5-P in rat liver represents one of only two examples of metabolite (or small M  compound) 
activation of PP2A. The other is the activation of a heterotrimeric form of PP2A of rat T9 glioma 
cells by ceramide (Dobrowsky and Hunnun, 1992) (Dobrowsky et al.; 1993). However, a more   234 
recent report (Law and Rossle 1995) indicates that the PP2A catalytic subunit also is activated by 
ceramide. Therefore this ceramide effect is probably unspecific. This is by contrast to the Xu 5-P-
activated PP2A, because activation by Xu 5-P shows substrate unspecific, thus reflecting the 
differences in the activation mechanism. Since PP2A is not only the most abundant form of 
protein phosphatase, especially in cytoplasm, but also shows broad substrate specificities, it is 
possible that other PP2As may be regulated by specific metabolites. 
4.1 Conclusion 
A hypothetical involvement of AMPK in an amplification loop which links cholesterol or fatty 
acid synthesis with the PPP in a lipogenic tissue such as the liver is shown in (Figure 4.1).  This 
amplification loop might be envisaged to function in various situations such as the following. 
An increased supply of the substrates for ACC and HMG-CoA reductase (e.g. acetyl-CoA or 
HMG-CoA) should increase fatty acid/cholesterol synthesis resulting in increased NADPH 
utilization and hence increased oxidative PPP flux. If this resulted in an increase in the Xu5P 
content it is envisaged that activation of PP2A would followed by a decrease in AMPK α-Thr172 
phosphorylation and activity. In turn this would result in decreased phosphorylation down-
regulation of ACC and HMG-CoA reductase leading to further enhancement of these enzymes’ 
activities. 
An increase in NEFA supply to the liver, leading to an increase in the cellular content of fatty 
acyl-CoA, an allosteric inhibitor of ACC, and hence reduce fatty acid synthesis. The resulting 
decrease in NADPH utilization would lead to a decrease in oxidative PPP flux and possibly a 
decrease in the content of Xu5P. In this instance operation of the ‘Xu5P/PP2A/AMPK axis’ 
described above would lead to activation of AMPK leading to phosphorylation down-regulation 
of ACC and HMG-CoA reductase activities. Presumably a similar outcome might occur if either 
fatty acid synthesis or cholesterol synthesis were inhibited pharmacologically. This could 
possibly provide an explanation for the activation of AMPK by statin drugs (Sun et al.; 2006).   235 
A direct activation of AMPK either through an increase in the cellular AMP/ATP or in response 
to a stimulatory neuroendocrine agent would lead to a decrease in the activities of ACC and 
HMG-CoA reductase, leading to decreased NADPH utilization, decreased oxidative PPP flux and 
operation of the ‘Xu5P/PP2A/AMPK axis’ leading to increased phosphorylation/activation of 
AMPK and further decreases in the activities of ACC and HMG-CoA reductase. Alternatively, 
direct inactivation of AMPK either through a decrease in the cellular AMP/ATP or in response to 
an inhibitory neuroendocrine agent (e.g. insulin) would result in operation of the amplification 
loop to further decrease the activities of ACC and HMG-CoA reductase. 
Presumably these hypothetical amplification effects must reach some upper limit dictated by 
factors such as the response range of PP2A to Xu5P and the range of 
phosphorylation/dephosphorylation changes occurring in AMPK, ACC and HMG-CoA reductase. 
The obvious uncertainties in this hypothesis are (i) the extent to which Xu5P content is altered by 
oxidative PPP flux and (ii) the important question of whether it is feasible to expect the 
phosphorylation/dephosphorylation of ACC and HMG-CoA reductase to be linked in this way.    236 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.1:  The hypothetical involvement of AMPK in an amplification loop linking 
cholesterol or fatty acid synthesis with the pentose phosphate pathway in a lipogenic tissue such 
as the liver. See the text for discussion of this hypothesis. 
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 Finally  this study has contributed to the ever-increasing knowledge regarding the effect of 
glucose on AMPK activity. However, in this model, AMPK activation in response to a limited 
glucose supply presumably has a survival value, because it would both increase ATP generation 
and decrease the use of ATP for such processes as cholesterol, triglyceride, and possibly protein 
synthesis as it mention early (Hardie   et al.; 1997).  
Conversely, the decrease in AMPK activity induced by glucose through the pentose phosphate 
pathway would perhaps direct fatty acids into storage as triglycerides at the expense of oxidation. 
Hypothetically, it could also allow an up-regulation of other synthetic processes that are inhibited 
by AMPK. 
 What is less clear is exactly how this scenario could play out in vivo, where blood flow and 
hormonal (among other) factors might attenuate the effects of hyper- and hypoglycemia on the 
activity of AMPK. This question could be relevant to such clinical problems as glucose toxicity 
and the effects of acute hypoglycemia. Finally, AMPK-mediated glucose metabolism could 
hypothetically act in any cells type. 
 
4.3 Future work 
In order to further understand the mechanisms by which AMPK interacts with various nutrients, 
more studies are needed. 
Principally important is the question of how other factors play a role in modulating AMPK 
activity. 
1.  Measurements of AMPK activity in heart tissue in response to different substrates after 
treatment with varying thiamine concentrations. 
2.  Measurements of xylulose5-phosphate and AMPK activity after perfusion of the hearts 
with varying glucose concentrations. 
3.   Measurements of the activity of essential enzymes in the pentose phosphate pathway.   238 
4.  Measurements of AMPK activity in the presence of thiamine and hormones. 
5.  Measurements of pentose phosphate pathway metabolites and flux rates in the presence of 
AMPK activators. 
6.  Measurements of AMPK activity in the presence of insulin’s second messenger e.g. (IPG) 
under certain pathological conditions.   239 
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